**CURRICULUM VITAE**

**Kathleen Maletic Neuzil, MD, MPH, FIDSA, FACP**

The Myron M. Levine, MD, DTPH, Professor in Vaccinology

Director, Center for Vaccine Development and Global Health

Chief, Division of Geographic Medicine, Department of Medicine

University of Maryland School of Medicine

**Date** February 13, 2024

**Contact Information**

Business Address:Center for Vaccine Development and Global Health

University of Maryland School of Medicine
685 W. Baltimore St.

 Room 480-G

 Baltimore, MD 21201

Business Phone Number: (410) 706-4946

Fax: (410) 706-6205

Email: kneuzil@som.umaryland.edu

**Education**

1983 B.S., Zoology, University of Maryland, College Park, MD, (Summa cum laude)

1987 M.D., Johns Hopkins University School of Medicine, Baltimore, MD (AOA)

1998 M.P.H., Vanderbilt University School of Medicine, Nashville, TN

**Post Graduate Education and Training**

1987-1990 Intern and Resident, Internal Medicine, Vanderbilt University School of Medicine

1990-1991 Hugh J. Morgan Chief Resident, Internal Medicine, Vanderbilt University School of Medicine

1991-1994 Fellow, Division of Infectious Diseases, Vanderbilt University School of Medicine

**Certifications**

1991 American Board of Internal Medicine, Internal Medicine,

Recertification 2005 - 2016

1994 American Board of Internal Medicine, Infectious Diseases,

Recertification 2005 -2016

**Medical Licensures**

1998-2016 Washington State

2015 Active, Maryland

**Employment History**

**Academic Appointments**

1994-1998 Assistant Professor, Division of Infectious Diseases, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN

1998-2003 Assistant Professor of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA

2003-2005 Associate Professor of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA

2005-2011 Clinical Associate Professor of Medicine, Division of Allergy and Infectious Diseases, University of Washington School of Medicine, Seattle, WA

2009-2011 Clinical Associate Professor, Department of Global Health, University of Washington, Seattle, WA

2011-2015 Clinical Professor, Departments of Medicine and Global Health, University of Washington, Seattle, WA

2015-2019 Professor, Departments of Medicine and Pediatrics, UMSOM

2019-present Professor, Departments of Medicine and Pediatrics, UMSOM Tenured

**Other Employment**

2005-2008 Senior Technical Advisor, Vaccines, and Clinical Director, Rotavirus Vaccine Program, PATH, Seattle, WA

2008-2012 Director, Influenza Vaccine Project, Vaccine Development Global Program, PATH, Seattle, WA.

2012-2015 Director, Vaccine Access and Delivery Global Program, PATH, Seattle, WA

**Professional Society Membership**

1992-present Fellow, American College of Physicians

1992-present Fellow, Infectious Diseases Society of America

2012-present Member, International Society for Infectious Diseases

2015-present Member, American Society of Tropical Medicine and Hygiene

**Honors and Awards**

1983 Phi Beta Kappa

1987 Alpha Omega Alpha Honor Medical Society

1990 Clinical Teaching Award, Vanderbilt University School of Medicine

1991 Clinical Teaching Award, Vanderbilt University School of Medicine

1991 National Clinical Vignette Competition Winner, American College of Physicians

1993 & 1994 Trainee Investigator Award for Excellence in Scientific Research, Association of American Physicians, American Society for Clinical Investigation, American Federation for Clinical Research Foundation

1998 Chiron Award for Epidemiology of Infectious Diseases, International Society of Infectious Diseases

2004 VA Certificate of Merit for Leading VISN 20 Smallpox Vaccination Program

2005 Honor Award Certificate, Public Health Epidemiology and Laboratory Research (for work on influenza), CDC, National Center for Infectious Diseases

2007 PATH Vision Award in the Advancing Global Health Category for the Japanese Encephalitis Project

2009 PATH Vision Award in the Healthy Partnering Category for the Rotavirus Vaccine Program Clinical Trials

2009 PATH Vision Award in the Advancing Global Health Category for the Cervical Cancer Prevention Project

2010 Joseph E. Smadel lectureship, IDSA Annual Meeting, Vancouver, CA

2013 PATH Vision Award in the Healthy Partnering Category for the Vaccine Implementation Technical Assistance Consortium (VITAC) Team

2014 PATH Vision Award in the Advancing Global Health Category for the Japanese Encephalitis (JE) Vaccine Prequalification Team

2014 Named “One of 50 Most influential persons in Vaccines”, Vaccine Nation, <http://www.vaccinenation.org/2014/09/03/influential-people-vaccines-2014>

2016 Vanderbilt University School of Medicine Distinguished Alumna Award

2017 The Chairman’s Special Achievement Faculty Award, Department of Medicine, University of Maryland School of Medicine

2018 Teaching Commendation in Host Defenses and Diseases, UMSOM Class of 2020

2018 Daily Record Maryland’s Top 100 Women Award

2019 The Chairman’s Special Achievement Faculty Award, Department of Medicine, University of Maryland School of Medicine

2019 National Academy of Medicine

2019 The Myron M. Levine, MD, DTPH, Professor in Vaccinology (Endowed Professorship), University of Maryland School of Medicine

2020 Baltimore Sun’s 25 Women to Watch

2020 Fierce Pharma “The 22 Most Influential People in the Fight Against COVID-19”

2020 Baltimore Sun Marylander of the Year Awardee for Unprecedented Leadership on COVID-19 Vaccines Research and Treatment

2021 Sonia Skarlatos Public Service Award from the American Society of Gene & Cell Therapy

2021 University of Maryland School of Medicine Department of Medicine Chairman’s Special Achievement Award

2021 Annual Boy Scouts of Central Maryland Health Services Leadership Award for Outstanding Service

2021 University of Maryland Baltimore Exemplary Service During Pandemic Award

2022 University of Maryland College Park Alumni Excellence in Research Award

2023 University of Maryland Baltimore Researcher of the Year award.

**Administrative Service**

**Institutional Service**

**Past Service**

1996-1998 Assistant Chief, Medical Service, Department of Veterans Affairs Medical Center, Nashville, TN

1997-1998 Acting Chief, Medical Service, Department of Veterans Affairs Medical Center, Nashville, TN

1998-2000 Program Director, Internal Medicine, Swedish Medical Center, Seattle, WA

1999-2004 Member, Internal Medicine Resident Selection Committee

2000-2001 Chair, Scientific Review Committee, VA Puget Sound Research and Development

2000-2003 Member, Dean's Committee on Issues of Women Faculty

2000-2004 Member, Appointment and Promotions Committee, Dept of Medicine

2000-2005 Chair, Infection Control Committee, VA Puget Sound Health Care System

2001-2002 Member, Scientific Review Committee, VA Puget Sound Research and Development

2001-2002 Co-moderator, 2001 and 2002 Junior Faculty Development Seminar

2003-2004 Member, UW Faculty Senate

2003-2005 Associate Director, Clinical Research Unit, VA Puget Sound

**Service at University of Maryland School of Medicine**

2015-present Member, Executive Committee of the School of Medicine

2015-2018 Director, Center for Vaccine Development, UMSOM

2015-2018 Deputy Director, Institute for Global Health, UMSOM

2016-present Chief, Division of Geographic Medicine, Department of Medicine, UMSOM

2016-2017 Co-Chair, Research Strategic Planning Committee

2016-2017 Member, Dermatology Chair Search Committee

2016-2020 Member, Diversity Advisory Committee

2016-2018 Member, Institute for Global Health Executive Committee

2017-2019 Member, Search Committee for Malaria Faculty Position

2017-2020 Member, Search Committee for Dept of Micro Influenza Scientist Faculty Position

2018-present Director, Center for Vaccine Development and Global Health, UMSOM

2019-present Chair, Dean’s Culture Transformation Advisory Committee

2019 Chair, Dean’s Festival of Science on Global Health Research

2020–present UMD COVID-19 Research Advisory Task Force

**National Service**

1997-2014 Member, Executive Committee, VA Cooperative Study 438: Evaluation of a Live Attenuated Influenza Vaccine

2000-present Member, National Physician Advisory Board, ACP Adult Immunization Initiative

2000-2006 ACP Representative to Immunization Action Coalition Advisory Board

2000-2006 ACP Liaison Representative to Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention

2001-2002 Member, Institute of Medicine Committee to Review the CDC Program on the Safety and Efficacy of Anthrax Vaccine

2002-2003 Member, Test-Writing Committee for Infectious Diseases, ABIM

2003-2005 Member, Subspecialty Board on Infectious Diseases, ABIM

2004-2008 Member, National and Global Public Health Committee, IDSA

2005-2008 Chair, Vaccines in Pregnancy Working Group Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention

2005-2008 Chair, Pandemic Influenza Task Force, Infectious Disease Society of America (IDSA)

2006-2010 Member, Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention

2008-2010 Chair, Influenza Vaccine Working Group, Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention

2008-2012 Member, Pandemic Influenza Task Force, Infectious Disease Society of America (IDSA). Chair 2011-2012

2008, 2009, Co-Chair, IDSA Seasonal and Pandemic Influenza Conference,

2010 & 2011 Washington, DC

2009 Collaborator, Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. *Red Book: 2009 Report of the committee on Infectious Diseases*. 28th ed. Elk Grove Village, IL: American Academy of Pediatrics

2011-2018 IDSA Liaison Representative to Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention

2011-present IDSA Liaison Representative to Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention

2012-2015 Member, IDSA Nominations Committee

2013-present Member, Program Committee, Annual Conference on Vaccine Research, National Foundation for Infectious Diseases

2016-2021 Reviews Editor, *Vaccine*

2016-present Editorial Board, *NPJ Vaccines*

2017-present Board member, National Foundation of Infectious Disease, Awards Committee and Finance Committee. Awards Committee Chair

2018-present Member, Safety Monitoring Committee, A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the ID93 GLA-SE Tuberculosis Vaccine in Healthy Adult Subjects

2019-present Member, IDSA Annual Meeting Program Committee

2019-present Review Panel Participant, NIH NIAID Special Emphasis Panel

2019-present Safety Oversight Protocol 16-0111, SMC Data Review Committee

2020-present VRC Scientific Advisory Panel, NIH

2020-present WHO Department of Immunization, Vaccine & RSV Biologicals Technical Advisory Group

2020-present Co-Director of COVID-19 Prevention Network

2022 – 2023 Vice President, Board of Directors for the National Foundation for Infectious Diseases (NFID)

**International Service**

2004-present Faculty, Advanced Course of Vaccinology (ADVAC), Annecy, France

2006-2010 Member, WHO Steering Committee on Diarrheal Disease Research

2007 Co-Chair, WHO Meeting, “Rotavirus Vaccines in the Developing World: Evaluating Clinical Trial Data and Guiding Future Research,” Atlanta, GA, November 27-29

2008 Meeting Rapporteur, WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection, Vilamoura, Portugal, September 14

2008-2014 Member, Scientific Advisory Board, Introduction of an oral live human rotavirus (Rotarix) vaccine in Matlab, Bangladesh

2008-2009 Member, WHO Ad hoc Group of Experts on Rotavirus

2009-2011 Member, Data Safety Monitoring Board, A Phase 2 Study to Assess the Safety and Immunogenicity of an A (H1N1) 2009 Influenza Virus-like Particle (VLP) Vaccine in Mexican Adults

2009, 2013 Member, Scientific Organizing Committee, WHO Global Vaccine Research Forum

2011-2016 Member, Working Group for Safety of Vaccines in Pregnant Women, Global Advisory Committee for Vaccine Safety, WHO, December 2

2011 Member, Expert Committee on Influenza Vaccines for Children and Pregnant Women, European CDC

2011-2014 Member, Data Safety and Monitoring Board, CAPITA (Community-Acquired Pneumonia Immunization Trial in Adults trial, Prevnar-13), Pfizer

2012-present Member, ROTA Council

2014 Member, Program Committee, International Rotavirus Symposium, Delhi, India

2014-2015 Member, Data Safety Monitoring Board, Phase I clinical trial of the cAd3-EBO-Z Ebola vaccine in Mali, University of Maryland Center for Vaccine Development and NIH

2015-2017 Chair, Scientific Steering Committee, CDC Ebola vaccine trial in Sierra Leone

2015-2016 Member, Advisory Board, WHO committee on vaccine composition for tropics and sub-tropics

2015-2016 Chair, Working Group, WHO preferred product characteristics for next generation influenza vaccines

2015-2017 Member, Technical Advisory Committee on Maternal Influenza immunization project, WHO/PATH

2016 Member, Scientific Organizing Committee, Global Vaccine and Immunization Research Forum (GVIRF), Johannesburg, South Africa, March 15-17

2016 Member, Working Group to Determine Outcome Definitions for Severe Influenza in the Context of Vaccine Clinical Trials, WHO

2016 Co-Chair, Scientific Organizing Committee, 10th African Rotavirus Symposium, Bamako, Mali, June 1-2

2016-2017 Member, Scientific Advisory Board, Enteric Vaccine Initiative, PATH

2016 Member, Steering Committee, Full Public Health Value of Preventive Vaccines, Foundation Mérieux

2016-2021 Scientific Advisory Board member, Coalition for Epidemic Preparedness Innovations (CEPI), WHO

2017 Member, Scientific Advisory Board, XIX International Symposium on Respiratory Viral Infections, June 22-25.

2017 Member, Scientific Organizing Committee, Vaccine Congress, San Diego, CA, September 16-19.

2018 Member, Scientific Organizing Committee, Global Vaccine, and Immunization Research Forum (GVIRF), Bangkok, Thailand, March 20-22.

2018 Member, Scientific Organizing Committee, Vaccine Congress, Budapest, -Hungary, September 16-19.

2018-present Member, WHO Strategic Advisory Group of Experts on Immunization, World Health Organization

2019 Member, Scientific Organizing Committee, Global Vaccine, and Immunization Research Forum (GVIRF), Seoul, South Korea, March 10-12, 2020.

2020 Member, Scientific Advisory Committee, 15th International Conference on Diarrheal Disease & Nutrition (ASCODD), Dhaka, Bangladesh, January 28-29, 2020.

2021 Committee Member, Scientific Organizing Committee, 2021 International Conference on Typhoid & Other Invasive Salmonelloses, March 16-18, 2021.

2021-present Member, Advisory Group for the Global Typhoid Genomics Consortium,

2021-present Member, BactiVac Network Advisory Board.

2021-present Senior Advisor to the Global Virus Network (GVN)

**Teaching Service**

**Undergraduate and Graduate Student Teaching**

**University of Washington School of Public Health**

2005-2011 Lecturer, Influenza

Zoonotic Infections (526)

15 public health students, 2 contact hours/year

2005-2013 Lecturer, Influenza, and rotavirus vaccines

 Vaccines – various topics (527)

30 students per class, 1.5 contact hours/year

2007-2015 Lecturer, Influenza (every other year)

Epidemiology of Infectious Disease in Resource-Limited Countries (532)

15 public health students per class, 2 contact hours/year

2008 Lecturer, Influenza

Epidemiology of infectious Disease (520)

20 public health students, 1.5 contact hours/year

2010 Lecturer, Seasonal and pandemic influenza

Emerging Infections of International Public Health Importance (EPI 520)

20 public health students, 1.5 contact hours/year

2010, 2011 Lecturer, Project management: Case study influenza vaccine development

Global Health Project Life cycle – Managing for success (GH 590)

30 global health students per class, 4 contact hours/year

(Presented and evaluated student presentations)

2012-2014 Lecturer, Vaccines for low resource populations

Contemporary Issues in Global Health (GH 402/502)

60 public health students, 1.5 contact hours/year

2012, 2014 Lecturer, Meningitis vaccine

Controlling Infections with Vaccines (GH 580)

15 global health students, 2 contact hours/year

**University of Maryland School of Medicine**

2017 Lecturer, Domestic and international vaccine policy

 Vaccinology Course (PREV 627)

 8 postdoctoral students, 1 contact hour/year

2017 Lecturer, Rotavirus vaccines

 Vaccinology Course (PREV 627)

 8 postdoctoral students, 1 contact hour/year

2017-2020 Lecturer, Rotavirus, vaccines and vaccine introduction

 Principals of Virology (GPLS 704)

 20 graduate students, 1.5 contact hours/year

**Medical Student Teaching**

**University of Washington School of Medicine**

2005-2014 Lecturer, Vaccines

Infectious Diseases Conjoint Course for second year medical students (550)

100 second year medical students, 2 contact hours/year

2005-2015 Lecturer, Rotavirus and meningococcal vaccines for low resource settings

Tropical Medicine (561)

50 medical students, 2 contact hours/year

**University of Maryland School of Medicine**

2015 Lecturer, Overview of Vaccinology

 Immunology and Microbiology Course

 Second year medical students, 1 contact hour/year 2016 Lecturer, Overview of Vaccinology

 Immunology and Microbiology Course

 Second year medical students, 1 contact hour/year

2016-2017 Lecturer, Pneumonia

Small group HDID Session for second year medical students

2 contact hours/year

2016-2018 Lecturer

Infectious Disease Interest Group

First year and second year medical students, 1 contact hour/year

2017 Lecturer, Respiratory Infections

 Small group HDID Session for second year medical students

 2 contact hours/year

2017 Lecturer, Rotavirus Vaccine Development

 Principles of Virology

 MD-PhD students, 1.5 contact hours/year

2017 Lecturer

 Medical Scientist Training Program – Physician Scientist Career Seminar

 MD-PhD students, 1 contact hour/year

2019 Lecturer, Success in science and global health: persistence, partnerships, passion

UMB School of Medicine’s Summer Research Program’s Summer Series

MD-PhD students, 1 contact hour/year

2019 Lecturer, Rotavirus, Vaccines and Vaccine Introduction

 Principles of Virology

 MD-PhD students, 1.5 hours/year

**Resident and Fellow Teaching**

**University of Washington School of Public Health**

2010, 2014 Lecturer, Careers in the non-profit sector

Infectious Diseases Fellows Conference

15 Infectious Diseases fellows, 1 contact hour/year

**University of Maryland School of Medicine**

2016 Lecturer

 Medicine Grand Rounds

 30 residents, 1 contact hour/year

2016 Lecturer, Reaching every child with rotavirus vaccines

Pediatric Grand Rounds for the Global Health Track

30 pediatric residents, 1 contact hour/year

2017 Lecturer, Updates in Vaccines

 Infectious Diseases Fellow Friday Conference

 14 ID fellows, 1 contact hour/year

**Significant Mentoring Activities**

2009-2013 Dissertation committee, Dr. Kristen Lewis, Walden University; PhD—Public Health, Epidemiology; Degree conferred in Feb. 2013,

Dissertation: Lewis, K. (2012). [*Optimizing the measurement of severe rotavirus gastroenteritis among children under 2 years of age in Africa and Asia*](http://search.proquest.com.ezp.waldenulibrary.org/docview/1151096728/13B644299C63A9389F1/1?accountid=14872)*.* Available from ProQuest Digital Dissertations database (AAT 3517551).

2010-2014 Primary mentor for Dr. Justin Ortiz, Pulmonary and Critical Care Fellow and MPH candidate (degree conferred 2014). Dr Ortiz has received the following grants for which I was the primary mentor:

Development of Novel Tools to Estimate the Burden of Influenza-Associated Critical Illness Robert Wood Johnson Harold Amos Medical Faculty Development Program (Grant 67423). 7/1/10 - 6/30/14, $375,000

Assessment of Indoor Air Pollution as a Risk Factor for Influenza in Senegalese Children Thrasher Research Fund Early Career Award (Grant NR-0099). 10/1/09 - 9/30/11, $25,000

2016-present Primary mentor for Dr. Meagan Fitzpatrick, Postdoctoral Fellow and T32 Vaccinology Training grant fellow.

Dr. Fitzpatrick received the NIH K01 grant for which I am the primary mentor. The grant is in the amount of $649,319. Project period 12/1/18- 11/30/23. Project title: Mathematical modeling to optimize rotavirus vaccination in sub-Saharan Africa.

2020-present Primary mentor for Dr. Meagan Deming, Infectious Diseases and T32 Vaccinology Training Grant Fellow, 2019-2021. Dr. Deming received Grant: NIH-NIAID, #K08AI170950 in the amount of $635,171 for which I am the primary mentor. Project title: Characterization of seasonal CoV immunity and operationalization of a novel controlled human infection model for the beta coronavirus OC 43.

Project period:05/23 – 04/27.

2017 Dissertation committee, Hoi Ting Yeung, The Chinese University of Hong Kong Faculty of Medicine Department of Medicine & Therapeutics; PhD candidate – Medical Sciences; Dissertation: Yeung, Hoi Ting (2017).Identifying and Lowering Barriers to Optimise Interventions and Pneumonia and Diarrhea in Children.Dissertation not yet available.

2019-2021 Primary Mentor for Dr. Megan Birkhold, Surgery Resident, T32 Gastroenterology Fellow.

Project: Intestinal perforations and other complications of typhoid fever in low resource settings.

Project period: July 2019-June 2021.

2019-present Mentor for Dr. Amed Ouattara, Research Fellow.

Grant: Mentored Research Scientist Career Development Award, 1 K01HL140285 – 01A1, in the amount of $658,178.

Project: Designing a diversity-covering multiantigen multi-strain malaria vaccine.

Project period: 08/01/19 - 07/31/24.

2019-present Mentor for Dr. Rekha Rapaka, Assistant Professor of Medicine.

 Grant: NIH-NIAID, K08AI143923 in the amount of $798,166.

Project: Human Cellular Immune Programming Against Invasive Salmonella.

Project period:08/05/2019-07/31/2023*.*

2022-present Primary Mentor for Dr. Leah Sukri, Surgery Resident.

Project: A prospective study on typhoid intestinal perforations in Niger.

Project period:07/22 – 06/24.

2022–present Primary Mentor for Dr. Laura Hobbs, Surgery Resident.

Project: Complications due to shigella and typhoid infections.

Project period:07/23 – 06/25.

**Grant Support**

**Active Grants:**

03/01/19-04/30/24  (PI: 5%)

*Effect of a novel typhoid conjugate vaccine in Africa:  a multicenter study in Ghana and the Democratic Republic of the Congo (THECA) (“the research”)*

Total Direct Costs:      $400,000

04/15/19-04/30/24  (Protocol PI: 3%)

*“Vaccine and Treatment Evaluation Units (VTEU) Protocol Development and Implementation, Natural History Challenge Study for Influenza, Task Area B-C, 18-0010.B1C1.0120”*

NIAID Vaccine Treatment and Evaluation Unit, FY. 2018.B1C1.0120

Total Direct Costs:      $1,036,546

09/16/19-09/15/26  (Contact PI: 20%)

*“Collaborative Influenza Vaccine Innovation Centers (CIVICs) Component C: Clinical Core”*

National Institute of Allergy and Infectious Disease (NIAID), 75N93019C00055

Total Direct Costs:      $12,616,499

12/05/19-11/30/26  (Co- PI, Multi-PI Award: 20%) Contact PI: David Stephens, Emory

*“Leadership Group for Infectious Diseases Clinical Research Consortium (IDCRC)”*

NIH, NIAID, 1UM1AI148684-01

Total Direct Costs:      $2,372,307

12/11/19-11/30/26 (Co-Investigator: 10%)

*“Implementing Vaccine Treatment and Evaluation Unit (VTEU) Clinical Site Protocols”*

NIH, NIAID, UM1AI148689

Total Direct Costs:      $2,797,634

11/01/21–10/31/25 (PI)

                                 “Accelerating Access to Typhoid Conjugate Vaccines” (TyVAC 2.0)

                               Sponsor: Bill and Melinda Gates Foundation

                               Total Award Amount: $17,255,627

05/01/22–03/31/24 (PI)

“Advanced Development of a Multivalent Vaccine Candidate for Filovirus and Lassa Fever”

Sponsor: National Institute of Allergy and Infectious Disease (NIAID), HHSN272201700082C

                               Total Award Amount: $2,656,112

05/01/23–04/30/25 (PI)

“A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of DCFHP-Alum, A Spike-Functionalized Ferritin Nanoparticle Vaccine Targeting COVID-19, Co-formulated with Aluminum Hydroxide Adjuvant, in Health Adults in the United States”

Sponsor: Vaccine Company, Inc.

Total Award Amount: $1,783,329

06/01/23–04/30/28   (PI)

“Development of a multivalent variant-proof mucosal SARS-CoV-2 vaccine”

Sponsor: National Institute of Health (NIH).

Total Award Amount: $3,635,043

**Completed Grants at University of Maryland:**

2015 (PI)

 “*To develop a preferred product for universal influenza vaccine”*

World Health Organization

Total Direct Costs: $24,100

2015-2016 (PI)

 *“Analysis of influenza vaccine trials in Bangladesh and Senegal”*

Subcontract from PATH

 Total Direct Costs: $52,775

2016 (PI)

 *“10th African Rotavirus Symposium, Bamako, Mali”*

 The Bill and Melinda Gates Foundation

 Total Direct Costs: $150,000

2017 (Site PI)

 “*Vaccination modeling and cost-effectiveness analyses”*

Yale University

 Total Direct Costs: $15,159

2017 (Site PI)

*“Effectiveness and cost effectiveness of vaccine programs for pertussis in Israel”*

Yale University

Total Direct Costs: $67,911

2018-2023  (Contact PI: 1%)

*“Fellowship Training Program in Vaccinology” T32 Grant*

National Institute of Allergy and Infectious Disease (NIAID), T32AI007524

Total Direct Costs:      $1,594,640

2018-2023  (Contact PI: 1%)

*“Fellowship Training Program in Vaccinology” T32 Grant*

National Institute of Allergy and Infectious Disease (NIAID), T32AI007524

Total Direct Costs:      $1,594,640

2020 (Contact PI)

*“Improving Vaccine Education Among Low Income Pregnant Women”*

National Foundation for Infectious Diseases (NFID)

Total Direct Costs: $94,832

2014-2021 (PI)

*“Impact of rotavirus vaccine introduction on diarrhea in Africa study”* The Bill and Melinda Gates Foundation, OPP1116751

 Total Direct Costs: $506,495

 Total Award: $4,800,000

2016-2020 (PI)

*“A Phase I Randomized, Double-Blind, Controlled Trial in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Inactivated Influenza A/H5N8 Virus Vaccine Administered Intramuscularly Given With or Without AS03 or MF59 Adjuvants: Assessment of Immunological Responses and Lymphocyte Interplay”*

NIAID Vaccine Treatment and Evaluation Unit, 15-0066

 Total Direct Costs: $2,092,160

2017-2021 (Protocol PI: 2%)

*“Vaccine and Treatment Evaluation Units (VTEU) Protocol Development and Implementation Task Area B-C Phase II Vaccine Trial for Influenza Task Order Task Area B-C (Clinical Trials of H7N9 Vaccines)”*

NIAID Vaccine Treatment and Evaluation Unit, FY. 2017.B2C12.0080

Total Direct Costs: $3,029,005

2020-2021 (Co- PI, Multi-PI Award: 10%) Contact PI: David Stephens, Emory

*“Leadership Group for Infectious Diseases Clinical Research Consortium (IDCRC) COVID Supplement”*

NIH, NIAID, 3UM1Al148684-01S1

Total Direct Costs: $927,353

2016- 2022    (PI: 20%)

*“Accelerating Availability and Access to Typhoid Conjugate Vaccines”*

                              The Bill and Melinda Gates Foundation, OPP1151153

                              Total Award:               $43,635,066

2017- 2023 (Protocol PI: 3%)

“A Phase II Trial to Evaluate the Safety, Immunogenicity, and Efficacy of a Single Dose of Tdap on Infant Immune Responses in Pregnant Women in a Low-Middle Income Country”

                                NIAID Vaccine Treatment and Evaluation Unit, 16-0024

Total Direct Costs:      $3,807,592

**PATH Grants (Note: Several grants could not transfer when Dr. Neuzil moved to the University of Maryland, Baltimore School of Medicine Center for Vaccine Development in July 2015, so the end date may extend beyond that date)**

2010-2015 (Co-Inv, 10%) PI: Chris Victor

“*Understanding the performance of rotavirus vaccines in developing countries”*

Bill and Melinda Gates Foundation

Annual Direct Costs: $1,920,000

Total Direct Costs: $9,600,000

*This proposal has funded several clinical trials, effectiveness studies and work on correlates of protection to understand the immunogenicity and to evaluate interventions to improve the immunogenicity of current rotavirus vaccines through innovative schedules, booster doses and studying the effects of breastfeeding or probiotics*

2011-2015 (Co-Inv, 10%) PI: Chris Victor

*“Senegal Influenza Vaccine Effectiveness Study in a Tropical Developing Country”*

Center for Disease Control

Annual Direct Costs: $1,110,000

Total Direct Costs: $4,440,000

*This grant funded the 4th year of a large, cluster-randomized trial of influenza vaccine among children in Senegal (see below), as well as two additional trials of adjuvanted influenza vaccine and live-attenuated vaccines in this rural population in Senegal.*

2013-2015 (PI, 15%)

*“Accelerating introduction of rotavirus vaccines in India”*

Bill and Melinda Gates Foundation

Annual Direct Costs: $372,000

Total Direct Costs: $1,860,000

2013-2016 (PI, 20%)

*“Maternal influenza immunization: Building an immunization platform in conjunction with antenatal care in low and middle income countries”*

World Health Organization

Annual Direct Costs: $486,667

Total Direct Costs: $1,460,000

2014-2015 (PI, 15%)

*“Advancing maternal immunization against pertussis”*

Bill and Melinda Gates Foundation

Total Direct Costs: $251,149

2014-2017 (Co-Inv, 10%) PI: Anthony Marfin

*“Japanese Encephalitis (JE) vaccine introduction and sustainability project”*

Bill and Melinda Gates Foundation

Annual Direct Costs: $5,400,000

Total Direct Costs: $16,200,000

*This multifaceted project involves technical assistance on manufacturing and pharmacovigilance to the Chinese manufacturer, clinical trials to assess the need for booster doses of JE vaccine and the effect of co-administration with measles-rubella vaccine, and work with countries to assist them with vaccine introduction planning.*

2015-2017 (PI, 10%)

*“Meningitis Sustainability Project”*

Bill and Melinda Gates Foundation

Annual Direct Costs: $2,450,000

Total Direct Costs: $4,900,000

2015-2019 (Co-Inv, 10%) PI: Carla Botting

*“Optimizing the public health impact of ppRTS,S malaria vaccine in malaria-endemic countries”*

Bill and Melinda Gates Foundation

Annual Direct Costs: $7,500,000

Total Direct Costs: $30,000,000

*With phase 3 studies of the RTS, S malaria vaccine completed, this grant will fund regulatory and policy activities, and, after anticipated approvals by regulatory agencies, phase IV safety and effectiveness studies, including possible demonstration projects in select countries.*

**Past PATH Funding**

2003-2010 Clinical Director

*“Accelerated Development and Introduction Plan for Rotavirus Vaccines”*

GAVI Alliance

Annual Direct Costs: $6,428,572

Total Direct Costs: $45,000,000

*I led the clinical development plan and the partnerships on four clinical trials throughout Africa and Asia to establish the evidence base for the policy decision on rotavirus vaccines.*

2006-2008 (PI)

*“Subaward, Intradermal versus intramuscular influenza vaccine in immunocompetent elders”*

United States Agency for International Development (USAID)

Annual Direct Costs: $124,500

Total Direct Costs: $249,000

2006-2011 (PI)

*“The Immunogenicity and Reactogenicity of Alternative Schedules of HPV Vaccine in 11-13 Year Old Girls in Vietnam”*

Bill & Melinda Gates Foundation

2008-2011 (Co-Inv) PI: Chris Victor

*“Senegal Influenza Vaccine Effectiveness Study in a Tropical Developing Country”*

Center for Disease Control

Annual Direct Costs: $1,330,000

Total Direct Costs: $3,990,000

*This grant funded a three-year large, cluster-randomized trial of influenza vaccine among children ages 6 months through 10 years in Senegal to assess total and indirect effects.*

2008-2015 (Project director 2008-2012, 50%, PI 2012-2015, 20%)

*“Advancing seasonal and pandemic influenza vaccines project”*

Bill & Melinda Gates Foundation

Annual Direct Costs: $5,542,858

Total Direct Costs: $38,800,000

2009-2013 (PI)

*“Enhancing influenza vaccine development in Vietnam”*

U.S. Biomedical Advanced Research and Development Authority (BARDA)

Total Annual Costs: $1,975,000

Total Direct Costs: $7,900,000

2014 (PI, 5%)

*“Influenza Vaccine Probe Pilot”*

World Health Organization

Total Direct Costs: $136,500

**Research Activities, University of Washington**

1999-2005 (PI Seattle site)

*“Trial of varicella-zoster vaccine for the prevention of herpes zoster and its complications”*

Department of Veterans Affairs Cooperative Study #403

Total Annual Costs: $140,334

Total Direct Costs: $842,000

2000-2001 (PI)

*“The effect of influenza on school and family life”*

GlaxoWellcome Worldwide Epidemiology, Unrestricted educational grant

Total Direct Costs: $69,091

2000-2001 (PI)

*“The burden of influenza illness in the veteran population”*

GlaxoWellcome Worldwide Epidemiology, Unrestricted educational grant

Total Direct Costs: $72,657

2000-2002 (PI)

*“RSV-associated morbidity in adults aged greater than 50 years”*

Aventis-Pasteur, unrestricted educational grant

Total Annual Costs: $17,272

Total Direct Costs: $34,545

2001-2002 (PI)

*“Diagnosing influenza in a highly immunized, high-risk veteran population”*

Department of Veterans Affairs Epidemiology Pilot Project

Total Direct Costs: $25,000

2002-2005 (Co-Inv) PI: Lisa Jackson

*“Vaccine Safety Datalink Project”*

Centers for Disease Control and Prevention

2002-2005 (Co-Inv) PI: Janet Englund

*“Improving the delivery of influenza vaccine to young children”*

Aventis-Pasteur

2002-2005 (PI Seattle site)

*“Comparative randomized study of safety and immunogenicity of a non-adjuvanted RSV vaccine versus an RSV vaccine adjuvanted with aluminum phosphate when administered with a licensed influenza vaccine in high-risk adults aged > 65 years of age”*

Aventis-Pasteur

Total Annual Costs: $46,667

Total Direct Costs: $140,000

2004-2005 (PI)

*“Risk of stroke following clinically evident herpes zoster reactivation”*

UW Royalty Research Fund

Total Direct Costs: $25,000

2004-2005 (PI Seattle site)

*“SchoolMist A Phase IV Study to Evaluate the Effectiveness of FluMist (Influenza Vaccine, Live Intranasal) Vaccine in a School-Based Intervention Program”*

MedImmune

Total Direct Costs: $366,400

2005-2007 (PI)

*“Intradermal vs intramuscular influenza vaccine in immunocompetent elders”*

VA Merit Review

Total Annual Costs: $124,500

Total Direct Costs: $249,000

(Award declined secondary to job change; grant resubmitted and awarded through USAID to PATH, see above)

**Publications**

##### Peer-reviewed original investigations

1. Graham BS, Henderson GS, Tang YW, Lu X, **Neuzil KM**, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol. 1993 Aug 15;151(4):2032-40. PMID: 8345194.
2. **Neuzil KM**, Gruber WC, Chytil F, Stahlman MT, Engelhardt B, Graham BS. Serum vitamin A levels in respiratory syncytial virus infection. J Pediatr. 1994 Mar;124(3):433-6. doi: 10.1016/s0022-3476(94)70369-8. PMID: 8120715.
3. **Neuzil KM**, Mitchell HC, Loyd JE, Lagerstrom CF, Hammon JW Jr, Graham BS. Extrapulmonary thoracic disease caused by Blastomyces dermatitidis. Chest. 1994 Dec;106(6):1885-7. doi: 10.1378/chest.106.6.1885. PMID: 7988217.
4. **Neuzil KM**, Wang E, Haas DW, Blaser MJ. Persistence of Campylobacter fetus bacteremia associated with absence of opsonizing antibodies. J Clin Microbiol. 1994 Jul;32(7):1718-20. doi: 10.1128/jcm.32.7.1718-1720.1994. PMID: 7929763; PMCID: PMC263773.
5. **Neuzil KM**, Gruber WC, Chytil F, Stahlman MT, Graham BS. Safety and pharmacokinetics of vitamin A therapy for infants with respiratory syncytial virus infections. Antimicrob Agents Chemother. 1995 May;39(5):1191-3. doi: 10.1128/AAC.39.5.1191. PMID: 7625814; PMCID: PMC162709.
6. **Neuzil KM**, Tang YW, Graham BS. Protective Role of TNF-alpha in respiratory syncytial virus infection in vitro and in vivo. Am J Med Sci. 1996 May;311(5):201-4. doi: 10.1097/00000441-199605000-00001. PMID: 8615393.
7. **Neuzil KM**, Gruber WC, Graham BS. Vitamin A therapy for respiratory syncytial virus infection. Pediatr Infect Dis J. 1997 Jan;16(1):84-5. doi: 10.1097/00006454-199701000-00024. PMID: 9002114.
8. **Neuzil KM**, Johnson JE, Tang YW, Prieels JP, Slaoui M, Gar N, Graham BS. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine. 1997 Apr;15(5):525-32. doi: 10.1016/s0264-410x(97)00218-1. PMID: 9160520.
9. Tang YW, **Neuzil KM**, Fischer JE, Robinson FW, Parker RA, Graham BS. Determinants and kinetics of cytokine expression patterns in lungs of vaccinated mice challenged with respiratory syncytial virus. Vaccine. 1997 Apr-May;15(6-7):597-602. doi: 10.1016/s0264-410x(96)00214-9. PMID: 9178456.
10. Standaert SM, Clough LA, Schaffner W, Adams JS, **Neuzil KM**. Neurologic manifestations of human monocytic ehrlichiosis. Infect Dis Clin Prac 1998; 7: 358-362.
11. **Neuzil KM**, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol. 1998 Dec 1;148(11):1094-102. doi: 10.1093/oxfordjournals.aje.a009587. PMID: 9850132.
12. **Neuzil KM**, Reed GW, Mitchel EF Jr, Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA. 1999 Mar 10;281(10):901-7. doi: 10.1001/jama.281.10.901. PMID: 10078486.
13. **Neuzil KM**, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med. 2000 Jan 27;342(4):225-31. doi: 10.1056/NEJM200001273420401. PMID: 10648763.
14. Boyce TG, Hsu HH, Sannella EC, Coleman-Dockery SD, Baylis E, Zhu Y, Barchfeld G, DiFrancesco A, Paranandi M, Culley B, **Neuzil KM**, Wright PF. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine. 2000 Sep 15;19(2-3):217-26. doi: 10.1016/s0264-410x(00)00171-7. PMID: 10930676.
15. **Neuzil KM**, Wright PF, Mitchel EF Jr, Griffin MR. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr. 2000 Dec;137(6):856-64. doi: 10.1067/mpd.2000.110445. PMID: 11113844.
16. **Neuzil KM**, Edwards KM, Reed GW. Seroepidemiology of pertussis in senior adults. Clin Infect Dis. 2001 Mar 1;32(5):847-8. doi: 10.1086/319230. PMID: 11229862.
17. **Neuzil KM**, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J. 2001 Aug;20(8):733-40. doi: 10.1097/00006454-200108000-00004. PMID: 11734733.
18. **Neuzil KM**, Zhu Y, Griffin MR, Edwards KM, Thompson JM, Tollefson SJ, Wright PF. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis. 2002 Jan 15;185(2):147-52. doi: 10.1086/338363. Epub 2001 Dec 17. PMID: 11807687.
19. Griffin MR, Coffey CS, **Neuzil KM**, Mitchel EF Jr, Wright PF, Edwards KM. Winter viruses: influenza- and respiratory syncytial virus-related morbidity in chronic lung disease. Arch Intern Med. 2002 Jun 10;162(11):1229-36. doi: 10.1001/archinte.162.11.1229. PMID: 12038940.
20. **Neuzil KM**, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med. 2002 Oct;156(10):986-91. doi: 10.1001/archpedi.156.10.986. PMID: 12361443.
21. **Neuzil KM**, O'Connor TZ, Gorse GJ, Nichol KL. Recognizing influenza in older patients with chronic obstructive pulmonary disease who have received influenza vaccine. Clin Infect Dis. 2003 Jan 15;36(2):169-74. doi: 10.1086/345668. Epub 2003 Jan 8. PMID: 12522748.
22. Gorse GJ, O'Connor TZ, Young SL, Mendelman PM, Bradley SF, Nichol KL, Strickland JH Jr, Paulson DM, Rice KL, Foster RA, Fulambarker AM, Shigeoka JW, Kuschner WG, Goodman RP, **Neuzil KM**, Wittes J, Boardman KD, Peduzzi PN. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine. 2003 May 16;21(17-18):2133-44. doi: 10.1016/s0264-410x(02)00748-x. PMID: 12706704.
23. Jackson LA, **Neuzil KM**, Yu O, Benson P, Barlow WE, Adams AL, Hanson CA, Mahoney LD, Shay DK, Thompson WW; Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med. 2003 May 1;348(18):1747-55. doi: 10.1056/NEJMoa022678. PMID: 12724480.
24. **Neuzil KM**, Maynard C, Griffin MR, Heagerty P. Winter respiratory viruses and health care use: a population-based study in the northwest United States. Clin Infect Dis. 2003 Jul 15;37(2):201-7. doi: 10.1086/375604. Epub 2003 Jul 7. PMID: 12856212.
25. **Neuzil KM**, Coffey CS, Mitchel EF Jr, Griffin MR. Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. J Acquir Immune Defic Syndr. 2003 Nov 1;34(3):304-7. doi: 10.1097/00126334-200311010-00008. PMID: 14600576.
26. Hartert TV, **Neuzil KM**, Shintani AK, Mitchel EF Jr, Snowden MS, Wood LB, Dittus RS, Griffin MR. Maternal morbidity and perinatal outcomes among pregnant women with respiratory hospitalizations during influenza season. Am J Obstet Gynecol. 2003 Dec;189(6):1705-12. doi: 10.1016/s0002-9378(03)00857-3. PMID: 14710102.
27. Chi RC, **Neuzil KM**. The association of sociodemographic factors and patient attitudes on influenza vaccination rates in older persons. Am J Med Sci. 2004 Mar;327(3):113-7. doi: 10.1097/00000441-200403000-00001. PMID: 15090748.
28. Jackson ML, **Neuzil KM**, Thompson WW, Shay DK, Yu O, Hanson CA, Jackson LA. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004 Dec 1;39(11):1642-50. doi: 10.1086/425615. Epub 2004 Nov 8. PMID: 15578365; PMCID: PMC7108010.
29. Meltzer MI, **Neuzil KM**, Griffin MR, Fukuda K. An economic analysis of annual influenza vaccination of children. Vaccine. 2005 Jan 11;23(8):1004-14. doi: 10.1016/j.vaccine.2004.07.040. PMID: 15620473.
30. Jackson LA, Benson P, **Neuzil KM**, Grandjean M, Marino JL. Burden of community-onset Escherichia coli bacteremia in seniors. J Infect Dis. 2005 May 1;191(9):1523-9. doi: 10.1086/429344. Epub 2005 Mar 22. PMID: 15809912.
31. Englund JA, Walter E, Fairchok M, Monto A, **Neuzil KM**. A comparison of two influenza vaccine schedules in 6-23-month-old children. Pediatrics 2005; 115: 1039-1047.
32. Oxman MN, Levine MJ, Johnson GR, **Neuzil KM** (22 out of 45 authors). A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. N Engl J Med. 2005 Jun 2;352(22):2271-84. doi: 10.1056/NEJMoa051016. PMID: 15930418.
33. Jackson LA, **Neuzil KM**, Whitney CG, Starkovich P, Dunstan M, Yu O, Nelson JC, Feikin DR, Shay DK, Baggs J, Carste B, Nahm MH, Carlone G. Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2005 May 25;23(28):3697-703. doi: 10.1016/j.vaccine.2005.02.017. PMID: 15882530.
34. Jackson LA, Nelson JC, Whitney CG, **Neuzil KM**, Benson P, Malais D, Baggs J, Mullooly J, Black S, Shay D. Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the Vaccine Safety Datalink population. Vaccine 2006 Jan 12;24(2):151-6. doi: 10.1016/j.vaccine.2005.07.066. Epub 2005 Aug 10. PMID: 16122845.
35. Chi RC, Jackson LA, **Neuzil KM**. Characteristics and outcomes of older adults with community acquired pneumococcal bacteremia. J Am Geriatr Soc. 2006 Jan;54(1):115-20. doi: 10.1111/j.1532-5415.2005.00528.x. PMID: 16420207.
36. Abramson J, **Neuzil KM**, Tamblyn S. Annual Universal Influenza Vaccination: Ready or Not? Clin Infect Dis. 2006 Jan 1;42(1):132-5. doi: 10.1086/498514. Epub 2005 Nov 23. PMID: 16323103.
37. Chi RC, Reiber GE, **Neuzil KM**. Influenza and pneumococcal vaccination in older veterans: results from the behavioral risk factor surveillance system. J Am Geriatr Soc. 2006 Feb;54(2):217-23. doi: 10.1111/j.1532-5415.2005.00577.x. PMID: 16460371
38. Jackson LA, Nelson JC, Benson P, **Neuzil KM**, Reid RJ, Psaty BM, Heckbert SR, Larson EB, Weiss NS. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol. 2006 Apr;35(2):345-52. doi: 10.1093/ije/dyi275. Epub 2005 Dec 20. PMID: 16368724.
39. Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, **Neuzil KM**. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics. 2006 Sep;118(3):e579-85. doi: 10.1542/peds.2006-0201. PMID: 16950949.
40. Walter EB, **Neuzil KM**, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? Pediatrics. 2006 Sep;118(3):e570-8. doi: 10.1542/peds.2006-0198. PMID: 16950948.
41. Gorse GJ, O'connor TZ, Young SL, Habib MP, Wittes J, **Neuzil KM**, Nichol KL. Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination. Chest. 2006 Oct;130(4):1109-16. doi: 10.1378/chest.130.4.1109. PMID: 17035445.
42. **Neuzil KM**, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, Dunn J, DeStefano F, Shay D. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis. 2006 Oct 15;194(8):1032-9. doi: 10.1086/507309. Epub 2006 Sep 11. PMID: 16991077.
43. Jackson LA, **Neuzil KM**, Baggs J, Davis RL, Black S, Yamasaki KM, Belongia E, Zangwill KM, Mullooly J, Nordin J, Marcy SM, DeStefano F. Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: a Vaccine Safety Datalink study. Pediatrics. 2006 Nov;118(5):2032-7. doi: 10.1542/peds.2006-1422. PMID: 17079576.
44. King JC Jr, Stoddard JJ, Gaglani MJ, Moore KA, Magder L, McClure E, Rubin JD, Englund JA, **Neuzil K**. Effectiveness of school-based influenza vaccination. N Engl J Med. 2006 Dec 14;355(24):2523-32. doi: 10.1056/NEJMoa055414. PMID: 17167135.
45. Jackson LA, **Neuzil KM**, Nahm MH, Whitney CG, Yu O, Nelson JC, Starkovich PT, Dunstan M, Carste B, Shay DK, Baggs J, Carlone GM. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2007 May 16;25(20):4029-37. doi: 10.1016/j.vaccine.2007.02.062. Epub 2007 Mar 12. PMID: 17391816.
46. Chi RC, **Neuzil KM**, Lipsky BA, Reiber GE. Where high-risk adults receive influenza vaccine during a shortage. Arch Intern Med. 2007 Nov 26;167(21):2366-8. doi: 10.1001/archinte.167.21.2366. PMID: 18039997.
47. Gatchalian S, Yao Y, Zhou B, Zhang L, Yoksan S, Kelly K, **Neuzil KM**, Yaïch M, Jacobson J. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants. Vaccine. 2008 Apr 24;26(18):2234-41. doi: 10.1016/j.vaccine.2008.02.042. Epub 2008 Mar 18. PMID: 18394765.
48. Jackson ML, Nelson JC, Weiss NS, **Neuzil KM**, Barlow W, Jackson LA. Influenza vaccination and risk of community-acquired pneumonia in immunocompetent elderly people: a population-based, nested case-control study. Lancet. 2008 Aug 2;372(9636):398-405. doi: 10.1016/S0140-6736(08)61160-5. PMID: 18675690.
49. Falsey AR, Walsh EE, Capellan J, Gravenstein S, Zambon M, Yau E, Gorse GJ, Edelman R, Hayden FG, McElhaney JE, **Neuzil KM**, Nichol KL, Simões EA, Wright PF, Sales VM. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis. 2008 Nov 1;198(9):1317-26. doi: 10.1086/592168. PMID: 18855558.
50. Zaman K, Sack DA, Yunus M, Arifeen SE, Podder G, Azim T, Luby S, Breiman RF, **Neuzil K**, Datta SK, Delem A, Suryakiran PV, Bock HL; Bangladeshi Rotavirus Vaccine study group. Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. Vaccine. 2009 Feb 25;27(9):1333-9. doi: 10.1016/j.vaccine.2008.12.059. Epub 2009 Jan 20. PMID: 19162114.
51. Mirzayeva R, Steele AD, Parashar UD, Zaman K, **Neuzil KM**, Nelson EA. Evaluation of rotavirus vaccines in Asia--are there lessons to be learnt? Vaccine. 2009 Nov 20;27 Suppl 5:F120-9. doi: 10.1016/j.vaccine.2009.09.039. PMID: 19931711.
52. Harper SA, Bradley JS, Englund JA, File TM, Gravenstein S, Hayden FG, McGeer AJ, **Neuzil KM**, Pavia AT, Tapper ML, Uyeki TM, Zimmerman RK; Expert Panel of the Infectious Diseases Society of America. Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2009 Apr 15;48(8):1003-32. doi: 10.1086/598513. PMID: 19281331; PMCID: PMC7107965.
53. Bright RA, **Neuzil KM**, Pervikov Y, Palkonyay L. WHO meeting on the role of neuraminidase in inducing protective immunity against influenza infection, Vilamoura, Portugal, September 14, 2008. Vaccine. 2009 Oct 23;27(45):6366-9. doi: 10.1016/j.vaccine.2009.02.084. PMID: 19840675.
54. Steele AD, Patel M, Parashar UD, Victor JC, Aguado T, **Neuzil KM**. Rotavirus vaccines for infants in developing countries in Africa and Asia: considerations from a world health organization-sponsored consultation. J Infect Dis. 2009 Nov 1;200 Suppl 1:S63-9. doi: 10.1086/605042. PMID: 19817616.
55. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, Han HH, **Neuzil KM**. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med. 2010 Jan 28;362(4):289-98. doi: 10.1056/NEJMoa0904797. PMID: 20107214.
56. Chi RC, Reiber GE, Lipsky BA, Boyko EJ, **Neuzil KM**. Influenza vaccination rates of children in households with high-risk adults. Public Health Rep. 2010 Mar-Apr;125(2):192-8. doi: 10.1177/003335491012500207. PMID: 20297745; PMCID: PMC2821846.
57. Tate JE, Patel MM, Steele AD, Gentsch JR, Payne DC, Cortese MM, Nakagomi O, Cunliffe NA, Jiang B, **Neuzil KM**, de Oliveira LH, Glass RI, Parashar UD. Global impact of rotavirus vaccines. Expert Rev Vaccines. 2010 Apr;9(4):395-407. doi: 10.1586/erv.10.17. Erratum in: Expert Rev Vaccines. 2010 Jul;9(7):804. PMID: 20370550.
58. Ortiz JR, **Neuzil KM**, Victor JC, Wald A, Aitken ML, Goss CH. Influenza-associated cystic fibrosis pulmonary exacerbations. Chest. 2010 Apr;137(4):852-60. doi: 10.1378/chest.09-1374. Epub 2009 Dec 4. PMID: 19965953; PMCID: PMC2851556.
59. Chi  RC, Rock MT, **Neuzil KM**. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. Clin Infect Dis. 2010 May 15;50(10):1331-8. doi: 10.1086/652144. PMID: 20377407.
60. Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, Levin MJ, Schmader KE, Gelb LD, Keay S, **Neuzil K**, Greenberg RN, Griffin MR, Davis LE, Morrison VA, Annunziato PW; Shingles Prevention Study Group. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Ann Intern Med. 2010 May 4;152(9):545-54. doi: 10.7326/0003-4819-152-9-201005040-00004. PMID: 20439572.
61. Walter EB, Rajagopal S, Zhu Y, **Neuzil KM**, Fairchok MP, Englund JA. Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally? Vaccine. 2010 Jun 17;28(27):4376-83. doi: 10.1016/j.vaccine.2010.04.058. Epub 2010 May 4. PMID: 20447477.
62. Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR, Binka FN, Steele AD, Laserson KF, Ansah NA, Levine MM, Lewis K, Coia ML, Attah-Poku M, Ojwando J, Rivers SB, Victor JC, Nyambane G, Hodgson A, Schödel F, Ciarlet M, **Neuzil KM**. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Aug 21;376(9741):606-14. doi: 10.1016/S0140-6736(10)60889-6. Epub 2010 Aug 6. PMID: 20692030.
63. Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ, Podder G, Vu DT, Le TP, Luby SP, Le HT, Coia ML, Lewis K, Rivers SB, Sack DA, Schödel F, Steele AD, **Neuzil KM**, Ciarlet M. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010 Aug 21;376(9741):615-23. doi: 10.1016/S0140-6736(10)60755-6. Epub 2010 Aug 6. PMID: 20692031.
64. Schmader KE, Johnson GR, Saddier P, Ciarleglio M, Wang WW, Zhang JH, Chan IS, Yeh SS, Levin MJ, Harbecke RM, Oxman MN; Shingles Prevention Study Group (including **Neuzil KM**). Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc. 2010 Sep;58(9):1634-41. doi: 10.1111/j.1532-5415.2010.03021.x. PMID: 20863322; PMCID: PMC2946120.
65. Waitumbi JN, Kuypers J, Anyona SB, Koros JN, Polhemus ME, Gerlach J, Steele M, Englund JA, **Neuzil KM**, Domingo GJ. Outpatient upper respiratory tract viral infections in children with malaria symptoms in Western Kenya. Am J Trop Med Hyg. 2010 Nov;83(5):1010-3. doi: 10.4269/ajtmh.2010.10-0174. PMID: 21036828; PMCID: PMC2963960.
66. Ortiz JR, **Neuzil KM**, Victor JC, Aitken ML, Goss CH. Predictors of influenza vaccination in the Cystic Fibrosis Foundation patient registry, 2006 through 2007. Chest. 2010 Dec;138(6):1448-55. doi: 10.1378/chest.10-0356. Epub 2010 May 21. PMID: 20495106; PMCID: PMC2998208.
67. **Neuzil KM**, Canh DG, Thiem VD, Janmohamed A, Huong VM, Tang Y, Diep NT, Tsu V, LaMontagne DS. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA. 2011 Apr 13;305(14):1424-31. doi: 10.1001/jama.2011.407. PMID: 21486975.
68. Ortiz JR, Zhou H, Shay DK, **Neuzil KM**, Fowlkes AL, Goss CH. Monitoring influenza activity in the United States: a comparison of traditional surveillance systems with Google Flu Trends. PLoS One. 2011 Apr 27;6(4):e18687. doi: 10.1371/journal.pone.0018687. PMID: 21556151; PMCID: PMC3083406.
69. Schrag SJ; Global Group B Streptococcal Vaccine Working Group (including **Neuzil KM**). Group B streptococcal vaccine for resource-poor countries. Lancet. 2011 Jul 2;378(9785):11-2. doi: 10.1016/S0140-6736(10)61932-0. Epub 2011 Mar 4. PMID: 21377722.
70. Ortiz JR, Englund JA, **Neuzil KM**. Influenza vaccine for pregnant women in resource-constrained countries: a review of the evidence to inform policy decisions. Vaccine. 2011 Jun 15;29(27):4439-52. doi: 10.1016/j.vaccine.2011.04.048. Epub 2011 May 6. PMID: 21550377.
71. **Neuzil KM**, Parashar UD, Steele AD. Rotavirus vaccines for children in developing countries: understanding the science, maximizing the impact, and sustaining the effort. Vaccine. 2012 Apr 27;30 Suppl 1:A1-2. doi: 10.1016/j.vaccine.2011.10.108. PMID: 22520117.
72. Shin S, Anh DD, Zaman K, Yunus M, Mai le TP, Thiem VD, Azim T, Victor JC, Dallas MJ, Steele AD, **Neuzil KM**, Ciarlet M. Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam. Vaccine. 2012 Apr 27;30 Suppl 1:A106-13. doi: 10.1016/j.vaccine.2011.11.091. PMID: 22520119.
73. Nakagomi T, Nakagomi O, Dove W, Doan YH, Witte D, Ngwira B, Todd S, Duncan Steele A, **Neuzil KM**, Cunliffe NA. Molecular characterization of rotavirus strains detected during a clinical trial of a human rotavirus vaccine in Blantyre, Malawi. Vaccine. 2012 Apr 27;30 Suppl 1(0 1):A140-51. doi: 10.1016/j.vaccine.2011.09.119. PMID: 22520123; PMCID: PMC3982048.
74. Lewis KD, Dallas MJ, Victor JC, Ciarlet M, Mast TC, Ji M, Armah G, Zaman K, Ferraro A, **Neuzil KM**. Comparison of two clinical severity scoring systems in two multi-center, developing country rotavirus vaccine trials in Africa and Asia. Vaccine. 2012 Apr 27;30 Suppl 1:A159-66. doi: 10.1016/j.vaccine.2011.07.126. PMID: 22520126.
75. Breiman RF, Zaman K, Armah G, Sow SO, Anh DD, Victor JC, Hille D, Ciarlet M, **Neuzil KM**. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine. 2012 Apr 27;30 Suppl 1:A24-9. doi: 10.1016/j.vaccine.2011.08.124. PMID: 22520132.
76. Cunliffe NA, Witte D, Ngwira BM, Todd S, Bostock NJ, Turner AM, Chimpeni P, Victor JC, Steele AD, Bouckenooghe A, **Neuzil KM**. Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial. Vaccine. 2012 Apr 27;30 Suppl 1(0 1):A36-43. doi: 10.1016/j.vaccine.2011.09.120. PMID: 22520135; PMCID: PMC3982044.
77. Madhi SA, Kirsten M, Louw C, Bos P, Aspinall S, Bouckenooghe A, **Neuzil KM**, Steele AD. Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children over two consecutive rotavirus-seasons: a randomized, double-blind, placebo-controlled trial. Vaccine. 2012 Apr 27;30 Suppl 1:A44-51. doi: 10.1016/j.vaccine.2011.08.080. PMID: 22520136.
78. Feikin DR, Laserson KF, Ojwando J, Nyambane G, Ssempijja V, Audi A, Nyakundi D, Oyieko J, Dallas MJ, Ciarlet M, **Neuzil KM**, Breiman RF. Efficacy of pentavalent rotavirus vaccine in a high HIV prevalence population in Kenya. Vaccine. 2012 Apr 27;30 Suppl 1:A52-60. doi: 10.1016/j.vaccine.2011.08.043. PMID: 22520137.
79. Laserson KF, Nyakundi D, Feikin DR, Nyambane G, Cook E, Oyieko J, Ojwando J, Rivers SB, Ciarlet M, **Neuzil KM**, Breiman RF. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants. Vaccine. 2012 Apr 27;30 Suppl 1:A61-70. doi: 10.1016/j.vaccine.2011.09.026. PMID: 22520138.
80. Sow SO, Tapia M, Haidara FC, Ciarlet M, Diallo F, Kodio M, Doumbia M, Dembélé RD, Traoré O, Onwuchekwa UU, Lewis KD, Victor JC, Steele AD, **Neuzil KM**, Kotloff KL, Levine MM. Efficacy of the oral pentavalent rotavirus vaccine in Mali. Vaccine. 2012 Apr 27;30 Suppl 1:A71-8. doi: 10.1016/j.vaccine.2011.11.094. PMID: 22520140.
81. Tapia MD, Armah G, Breiman RF, Dallas MJ, Lewis KD, Sow SO, Rivers SB, Levine MM, Laserson KF, Feikin DR, Victor JC, Ciarlet M, **Neuzil KM**, Steele AD. Secondary efficacy endpoints of the pentavalent rotavirus vaccine against gastroenteritis in sub-Saharan Africa. Vaccine. 2012 Apr 27;30 Suppl 1:A79-85. doi: 10.1016/j.vaccine.2012.01.022. PMID: 22520141.
82. Armah GE, Breiman RF, Tapia MD, Dallas MJ, **Neuzil KM**, Binka FN, Sow SO, Ojwando J, Ciarlet M, Steele AD. Immunogenicity of the pentavalent rotavirus vaccine in African infants. Vaccine. 2012 Apr 27;30 Suppl 1:A86-93. doi: 10.1016/j.vaccine.2011.10.006. PMID: 22520142.
83. Zaman K, Yunus M, El Arifeen S, Azim T, Faruque AS, Huq E, Hossain I, Luby SP, Victor JC, Dallas MJ, Lewis KD, Rivers SB, Steele AD, **Neuzil KM**, Ciarlet M, Sack DA. Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh. Vaccine. 2012 Apr 27;30 Suppl 1:A94-100. doi: 10.1016/j.vaccine.2011.07.117. PMID: 22520143.
84. **Neuzil KM**, Tsvetnitsky V, Nyari LJ, Bright RA, Boslego JW; PATH's Influenza Vaccine Project team. PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries. Expert Rev Vaccines. 2012 Aug;11(8):939-47. doi: 10.1586/erv.12.76. PMID: 23002975.
85. Steele AD, **Neuzil KM**, Cunliffe NA, Madhi SA, Bos P, Ngwira B, Witte D, Todd S, Louw C, Kirsten M, Aspinall S, Van Doorn LJ, Bouckenooghe A, Suryakiran PV, Han HH. Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial. BMC Infect Dis. 2012 Sep 13;12:213. doi: 10.1186/1471-2334-12-213. PMID: 22974466; PMCID: PMC3462149.
86. Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman C, Marques A, Toney J, Keller PM, Li X, Chan IS, Annunziato P; Shingles Prevention Study Group (including **Neuzil KM**). Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012 Nov 15;55(10):1320-8. doi: 10.1093/cid/cis638. Epub 2012 Jul 24. PMID: 22828595; PMCID: PMC4542855.
87. Ortiz JR, **Neuzil KM**, Ahonkhai VI, Gellin BG, Salisbury DM, Read JS, Adegbola RA, Abramson JS. Translating vaccine policy into action: a report from the Bill & Melinda Gates Foundation Consultation on the prevention of maternal and early infant influenza in resource-limited settings. Vaccine. 2012 Nov 26;30(50):7134-40. doi: 10.1016/j.vaccine.2012.09.034. Epub 2012 Sep 29. PMID: 23026690.
88. Fiore AE, Epperson S, Perrotta D, Bernstein H, **Neuzil K**. Expanding the recommendations for annual influenza vaccination to school-age children in the United States. Pediatrics. 2012 Mar;129 Suppl 2:S54-62. doi: 10.1542/peds.2011-0737C. PMID: 22383482.
89. **Neuzil KM**, Fiore AE, Schieber RA. Evolution of the pediatric influenza vaccination program in the United States. Pediatrics. 2012 Mar;129 Suppl 2:S51-3. doi: 10.1542/peds.2011-0737B. PMID: 22383481.
90. Steele D, **Neuzil K**, Quadros Cd, Tharmaphornpilas P, Serhan F, Santosham M, Patel M, Glass R. Progress with rotavirus vaccines: summary of the Tenth International Rotavirus Symposium. Expert Rev Vaccines. 2013 Feb;12(2):113-7. doi: 10.1586/erv.12.148. PMID: 23414403.
91. Gessner BD, Brooks WA, **Neuzil KM**, Vernet G, Bright RA, Tam JS, Bresee J, Monto AS. Vaccines as a tool to estimate the burden of severe influenza in children of low-resourced areas (November 30-December 1, 2012, Les Pensieres, Veyrier-du-Lac, France). Vaccine. 2013 Jul 11;31(32):3222-8. doi: 10.1016/j.vaccine.2013.05.017. Epub 2013 May 22. PMID: 23707161.
92. Morrison VA, Oxman MN, Levin MJ, Schmader KE, Guatelli JC, Betts RF, Gelb LD, Pachucki CT, Keay SK, Menzies B, Griffin MR, Kauffman CA, Marques AR, Toney JF, Simberkoff MS, Serrao R, Arbeit RD, Gnann JW, Greenberg RN, Holodniy M, Keitel WA, Yeh SS, Davis LE, Crawford GE, **Neuzil KM**, Johnson GR, Zhang JH, Harbecke R, Chan IS, Keller PM, Williams HM, Boardman KD, Silber JL, Annunziato PW; Shingles Prevention Study Group. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013 Aug 15;208(4):559-63. doi: 10.1093/infdis/jit182. Epub 2013 Apr 30. PMID: 23633406; PMCID: PMC3719896.
93. Ortiz JR, **Neuzil KM**, Rue TC, Zhou H, Shay DK, Cheng PY, Cooke CR, Goss CH. Population-based incidence estimates of influenza-associated respiratory failure hospitalizations, 2003 to 2009. Am J Respir Crit Care Med. 2013 Sep 15;188(6):710-5. doi: 10.1164/rccm.201212-2341OC. PMID: 23855650.
94. LaMontagne DS, Thiem VD, Huong VM, Tang Y, **Neuzil KM**. Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J Infect Dis. 2013 Oct 15;208(8):1325-34. doi: 10.1093/infdis/jit363. Epub 2013 Jul 30. PMID: 23901077.
95. Cheuvart B, **Neuzil KM**, Steele AD, Cunliffe N, Madhi SA, Karkada N, Han HH, Vinals C. Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis: analysis of clinical trials of human rotavirus vaccine. Hum Vaccin Immunother. 2014;10(2):505-11. doi: 10.4161/hv.27097. Epub 2013 Nov 13. PMID: 24240068; PMCID: PMC4185910.
96. Victor JC, Gatchalian S, Yao Y, Zhou B, Zhang L, Yoksan S, Yaïch M, **Neuzil KM**. Corrigendum to “Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants” [Vaccine 26 (2008) 2234–2241]. Vaccine. 32 (2014) 306-308.
97. Rudenko L, Kiseleva I, Naykhin AN, Erofeeva M, Stukova M, Donina S, Petukhova G, Pisareva M, Krivitskaya V, Grudinin M, Buzitskaya Z, Isakova-Sivak I, Kuznetsova S, Larionova N, Desheva J, Dubrovina I, Nikiforova A, Victor JC, **Neuzil K,** Flores J, Tsvetnitsky V, Kiselev O. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine. PLoS One. 2014 Feb 12;9(2):e87962. doi: 10.1371/journal.pone.0087962. PMID: 24533064; PMCID: PMC3922724.
98. Talaat, KR, Luke CJ, Khurana S, Manischewitz J, King LR, McMahon BA, Karron RA, Lewis KD, Qin J, Follmann DA, Golding H, **Neuzil KM**, Subbarao K. A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis. 2014 Jun 15;209(12):1860-9. doi: 10.1093/infdis/jiu123. Epub 2014 Mar 5. Erratum in: J Infect Dis. 2014 Dec 15;210(12):2021. PMID: 24604819; PMCID: PMC4047295.
99. Wijesinghe PR, Abeysinghe MR, Yoksan S, Yao Y, Zhou B, Zhang L, Yaich M, **Neuzil KM**, Victor JC. Safety and immunogenicity of live-attenuated Japanese encephalitis SA 14-14-2 vaccine co-administered with measles vaccine in 9-month-old infants in Sri Lanka. Vaccine. 2014 Aug 20;32(37):4751-7. doi: 10.1016/j.vaccine.2014.06.036. Epub 2014 Jun 18. PMID: 24951871.
100. **Neuzil KM**, Zaman K, Victor JC. A proposed framework for evaluating and comparing efficacy estimates in clinical trials of new rotavirus vaccines. Vaccine. 2014 Aug 11;32 Suppl 1:A179-84. doi: 10.1016/j.vaccine.2014.04.074. PMID: 25091673.
101. Ortiz JR, **Neuzil KM**, Shay DK, Rue TC, Neradilek MB, Zhou H, Seymour CW, Hooper LG, Cheng PY, Goss CH, Cooke CR. The burden of influenza-associated critical illness hospitalizations. Crit Care Med. 2014 Nov;42(11):2325-32. doi: 10.1097/CCM.0000000000000545. PMID: 25148596; PMCID: PMC4620028.
102. Madhi, SA, Cutland CL, Locadiah K, Weinberg A, Hugo A, Jones S, Adrian PV, van Niekerk N, Treurnicht F, Ortiz JR, Venter M, Violari A, **Neuzil KM**, Simoes EA, Klugman KP, Nunes M. Influenza Vaccination of Pregnant Women and Protection of Their Infants. N Engl J Med. 2014 Dec 11;371(24):2340. doi:10.1056/NEJMc1412050.
103. Keller- -Stanislawski B, Englund JA, Kang G, Mangtani P, **Neuzil K**, Nohynek H, Pless R, Lambach P, Zuber P. Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. Vaccine. 2014 Dec 12;32(52):7057-64. doi: 10.1016/j.vaccine.2014.09.052. Epub 2014 Oct 5. PMID: 25285883.
104. Ortiz JR, **Neuzil KM**, Cooke CR, Neradilek MB, Goss CH, Shay DK. Influenza pneumonia surveillance among hospitalized adults may underestimate the burden of severe influenza disease. PLoS One. 2014 Nov 25;9(11):e113903. doi: 10.1371/journal.pone.0113903. PMID: 25423025; PMCID: PMC4244176.
105. Morrison VA, Johnson GR, Schmader KE, Levin MJ, Zhang JH, Looney DJ, Betts R, Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman CA, Marques A, Toney J, Boardman K, Su SC, Li X, Chan IS, Parrino J, Annunziato P, Oxman MN; Shingles Prevention Study Group (**including Neuzil KM**). Long-term persistence of zoster vaccine efficacy. Clin Infect Dis. 2015 Mar 15;60(6):900-9. doi: 10.1093/cid/ciu918. Epub 2014 Nov 20. PMID: 25416754; PMCID: PMC4357816.
106. Ortiz JR, Goswami D, Lewis KD, Sharmeen AT, Ahmed M, Rahman M, Rahman MZ, Feser J, **Neuzil KM**, Brooks WA. Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh. Vaccine. 2015 Jun 26;33(29):3415-21. doi: 10.1016/j.vaccine.2015.04.048. Epub 2015 Apr 24. PMID: 25917680.
107. Nunes MC, Cutland CL, Dighero B, Bate J, Jones S, Hugo A, van Niekerk N, Kuwanda L, Izu A, Weinberg A, Madhi SA; Matflu Team (including **Neuzil KM**). Kinetics of Hemagglutination-Inhibiting Antibodies Following Maternal Influenza Vaccination Among Mothers With and Those Without HIV Infection and Their Infants. J Infect Dis. 2015 Dec 15;212(12):1976-87. doi: 10.1093/infdis/jiv339. Epub 2015 Jun 16. Erratum in: J Infect Dis. 2019 Sep 13;220(8):1392. PMID: 26080370; PMCID: PMC4655859.
108. Omer SB, SB, Richards JL, Madhi SA, Tapia MD, Steinhoff MC, Aqil AR, Wairagkar N; BMGF Supported Maternal Influenza Immunization Trials Investigators Group (including **Neuzil KM**). Three randomized trials of maternal influenza immunization in Mali, Nepal, and South Africa: Methods and expectations. Vaccine. 2015 Jul 31;33(32):3801-12. doi: 10.1016/j.vaccine.2015.05.077. Epub 2015 Jun 19. PMID: 26095508.
109. [Rudenko L](http://www.ncbi.nlm.nih.gov/pubmed/?term=Rudenko%20L%5BAuthor%5D&cauthor=true&cauthor_uid=26296497), Kiseleva I, Stukova M, Erofeeva M, Naykhin A, Donina S, Larionova N, Pisareva M, Krivitskaya V, Flores J; Russian LAIV Trial Study Group (including **Neuzil KM**). Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study. Vaccine. 2015 Sep 22;33(39):5110-7. doi: 10.1016/j.vaccine.2015.08.019. Epub 2015 Aug 19. PMID: 26296497.
110. Zaman K, Fleming JA, Victor JC, Yunus M, Bari TI, Azim T, Rahman M, Mowla SM, Bellini WJ, McNeal M, Icenogle JP, Lopman B, Parashar U, Cortese MM, Steele AD, **Neuzil KM**. Noninterference of Rotavirus Vaccine With Measles-Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus Immunity: A Randomized Trial. J Infect Dis. 2016 Jun 1;213(11):1686-93. doi: 10.1093/infdis/jiw024. Epub 2016 Jan 27. PMID: 26823338; PMCID: PMC4857472.
111. Yen C, Healy K, Tate JE, Parashar UD, Bines J, **Neuzil K**, Santosham M, Steele AD. Rotavirus vaccination and intussusception - Science, surveillance, and safety: A review of evidence and recommendations for future research priorities in low and middle income countries. Hum Vaccin Immunother. 2016 Oct 2;12(10):2580-2589. doi: 10.1080/21645515.2016.1197452. Epub 2016 Jun 20. PMID: 27322835; PMCID: PMC5084992.
112. Hooper LG, Dieye Y, Ndiaye A, Diallo A, Fan VS, **Neuzil KM**, Ortiz JR. Estimating pediatric asthma prevalence in rural senegal: A cross-sectional survey. Pediatr Pulmonol. 2017 Mar;52(3):303-309. doi: 10.1002/ppul.23545. Epub 2016 Aug 23. PMID: 27551858.
113. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, Han HH, **Neuzil KM**. Effect of human rotavirus vaccine on severe diarrhea in African infants. Malawi Med J. 2016 Sep;28(3):108-114. PMID: 27895844; PMCID: PMC5117000.
114. Brooks WA, Zaman K, Lewis KD, Ortiz JR, Goswami D, Feser J, Sharmeen AT, Nahar K, Rahman M, Rahman MZ, Barin B, Yunus M, Fry AM, Bresee J, Azim T, **Neuzil KM**. Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial. Lancet Glob Health. 2016 Dec;4(12):e946-e954. doi: 10.1016/S2214-109X(16)30200-5. Epub 2016 Oct 13. PMID: 27746226; PMCID: PMC5118223.
115. Victor JC, Lewis KD, Diallo A, Niang MN, Diarra B, Dia N, Ortiz JR, Widdowson MA, Feser J, Hoagland R, Emery SL, Lafond KE, **Neuzil KM**. Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial. Lancet Glob Health. 2016 Dec;4(12):e955-e965. doi: 10.1016/S2214-109X(16)30201-7. Epub 2016 Oct 13. PMID: 27746224; PMCID: PMC5118222.
116. Schwartz LM, Halloran ME, Rowhani-Rahbar A, **Neuzil KM**, Victor JC. Rotavirus vaccine effectiveness in low-income settings: An evaluation of the test-negative design. Vaccine. 2017 Jan 3;35(1):184-190. doi: 10.1016/j.vaccine.2016.10.077. Epub 2016 Nov 18. PMID: 27876198; PMCID: PMC5154240.
117. Madhi S, Nunes MC, Weinberg A, Kuwanda L, Hugo A, Jones S, van Niekerk N, Ortiz JR, **Neuzil KM**, Klugman KP, Simões EAF, Cutland CL; Maternal Flu Trial (Matflu) Team. Contribution of Serologic Assays in the Evaluation of Influenza Virus Infection Rates and Vaccine Efficacy in Pregnant Women: Report From Randomized Controlled Trials. Clin Infect Dis. 2017 Jun 15;64(12):1773-1779. doi: 10.1093/cid/cix241. PMID: 28369198; PMCID: PMC5447878.
118. Zaman K, Sack DA, **Neuzil KM**, Yunus M, Moulton LH, Sugimoto JD, Fleming JA, Hossain I, Arifeen SE, Azim T, Rahman M, Lewis KDC, Feller AJ, Qadri F, Halloran ME, Cravioto A, Victor JC. Effectiveness of a live oral human rotavirus vaccine after programmatic introduction in Bangladesh: A cluster-randomized trial. PLoS Med. 2017 Apr 18;14(4):e1002282. doi: 10.1371/journal.pmed.1002282. PMID: 28419095; PMCID: PMC5395158.
119. Nunes MC, Cutland CL, Jones S, Downs S, Weinberg A, Ortiz JR, **Neuzil KM**, Simões EAF, Klugman KP, Madhi SA. Efficacy of Maternal Influenza Vaccination Against All-Cause Lower Respiratory Tract Infection Hospitalizations in Young Infants: Results From a Randomized Controlled Trial. Clin Infect Dis. 2017 Oct 1;65(7):1066-1071. doi: 10.1093/cid/cix497. PMID: 28575286; PMCID: PMC5848298.
120. Somayaji R, Goss CH, Khan U, Neradilek M, **Neuzil KM**, Ortiz JR. Cystic Fibrosis Pulmonary Exacerbations Attributable to Respiratory Syncytial Virus and Influenza: A Population-Based Study. Clin Infect Dis. 2017 Jun 15;64(12):1760-1767. doi: 10.1093/cid/cix203. PMID: 28329304; PMCID: PMC5848232.
121. Rotrosen ET, Zaman K, Feser J, Ortiz JR, Goswami D, Sharmeen AT, Rahman M, Lewis KDC, Rahman MZ, Barin B, Brooks WA, **Neuzil KM**. Influenza Among Young Children in Bangladesh: Clinical Characteristics and Outcomes From a Randomized Clinical Trial. Clin Infect Dis. 2017 Nov 13;65(11):1914-1920. doi: 10.1093/cid/cix674. PMID: 29028980; PMCID: PMC5850015.
122. Fell DB, Johnson J, Mor Z, Katz MA, Skidmore B, **Neuzil KM**, et al. Incidence of laboratory-confirmed influenza disease among infants under six months of age: a systematic review. BMJ Open. 2017 Sept 7;7(9):e016526.
123. Gessner BD, Kaslow D, Louis J, **Neuzil K**, O'Brien KL, Picot V, Pang T, Parashar UD, Saadatian-Elahi M, Nelson CB. Estimating the full public health value of vaccination. Vaccine. 2017 Nov 1;35(46):6255-6263. doi: 10.1016/j.vaccine.2017.09.048. Epub 2017 Oct 3. PMID: 28986035.
124. Pecenka C, Munthali S, Chunga P, Levin A, Morgan W, Lambach P, Bhat N, **Neuzil KM**, Ortiz JR, Hutubessy R. Maternal influenza immunization in Malawi: Piloting a maternal influenza immunization program costing tool by examining a prospective program. PLoS One. 2017 Dec 27;12(12):e0190006. doi: 10.1371/journal.pone.0190006. PMID: 29281710; PMCID: PMC5744963.
125. **Neuzil KM**, Bresee JS, de la Hoz F, Johansen K, Karron RA, Krishnan A, Madhi SA, Mangtani P, Spiro DJ, Ortiz JR; WHO Preferred Product Characteristics for Next-Generation Influenza Vaccines Advisory Group. Data and product needs for influenza immunization programs in low- and middle-income countries: Rationale and main conclusions of the WHO preferred product characteristics for next-generation influenza vaccines. Vaccine. 2017 Oct 13;35(43):5734-5737. doi: 10.1016/j.vaccine.2017.08.088. Epub 2017 Sep 20. PMID: 28893473.
126. Meiring JE, Gibani M; TyVAC Consortium Meeting Group (including **Neuzil KM**): The Typhoid Vaccine Acceleration Consortium (TyVAC): Vaccine effectiveness study designs: Accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26-27 October 2016, Oxford, UK. Vaccine. 2017 Sep 12;35(38):5081-5088. doi: 10.1016/j.vaccine.2017.08.001. Epub 2017 Aug 10. PMID: 28802757.
127. Newman LP, Bhat N, Fleming JA, **Neuzil KM**. Global influenza seasonality to inform country-level vaccine programs: An analysis of WHO FluNet influenza surveillance data between 2011 and 2016. PLoS One. 2018 Feb 21;13(2):e0193263. doi: 10.1371/journal.pone.0193263. PMID: 29466459; PMCID: PMC5821378.
128. Haidara FC, Tapia MD, Sow SO, Doumbia M, Coulibaly F, Diallo F, Traoré A, Kodio M, Kelly CL, Fitzpatrick M, Kotloff K, Victor JC, **Neuzil K**. Evaluation of a Booster Dose of Pentavalent Rotavirus Vaccine Coadministered With Measles, Yellow Fever, and Meningitis A Vaccines in 9-Month-Old Malian Infants. J Infect Dis. 2018 Jul 13;218(4):606-613. doi: 10.1093/infdis/jiy215. Erratum in: J Infect Dis. 2019 Jan 7;219(2):339. PMID: 29659924; PMCID: PMC6047426.
129. Samai M, Seward JF, Goldstein ST, Mahon BE, Lisk DR, Widdowson MA, Jalloh MI, Schrag SJ, Idriss A, Carter RJ, Dawson P, Kargbo SAS, Leigh B, Bawoh M, Legardy-Williams J, Deen G, Carr W, Callis A, Lindblad R, Russell JBW, Petrie CR, Fombah AE, Kargbo B, McDonald W, Jarrett OD, Walker RE, Gargiullo P, Bash-Taqi D, Gibson L, Fofanah AB, Schuchat A; STRIVE Study Team (including **Neuzil, KM**). The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSV∆G-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak. J Infect Dis. 2018 May 18;217(suppl\_1):S6-S15. doi: 10.1093/infdis/jiy020. Erratum in: J Infect Dis. 2018 Jul 2;218(3):508-507. PMID: 29788345; PMCID: PMC5961340.
130. Fleming JA, Baltrons R, Rowley E, Quintanilla I, Crespin E, Ropero AM, Ortiz JR, Lambach P, **Neuzil KM**, Stepanchak M, Hombach J, Bhat N. Implementation of maternal influenza immunization in El Salvador: Experiences and lessons learned from a mixed-methods study. Vaccine. 2018 Jun 27;36(28):4054-4061. doi: 10.1016/j.vaccine.2018.05.096. Epub 2018 May 30. PMID: 29859803.
131. Gessner BD, Jiang Q, Van Werkhoven CH, Sings HL, Webber C, Scott D, **Neuzil KM**, O'Brien KL, Wunderink RG, Grobbee DE, Bonten MJM, Jodar L. A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands. Vaccine. 2019 Sep 10;37(38):5777-5787. doi: 10.1016/j.vaccine.2018.05.097. Epub 2018 May 31. PMID: 29861177.
132. Debullet F, Hendrix N, Ortiz JR, Lambach P, **Neuzil KM**, Bhat N, Pecenka C. Forecasting demand for maternal influenza immunization in low- and lower-middle-income countries. PLoS One. 2018 Jun 22;13(6):e0199470. doi: 10.1371/journal.pone.0199470. PMID: 29933402; PMCID: PMC6014664.
133. Ortiz JR, Hickling J, Jones R, Donabedian A, Engelhardt OG, Katz JM, Madhi SA, **Neuzil KM**, Rimmelzwaan GF, Southern J, Spiro DJ, Hombach J. Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23-24 August 2016. Vaccine. 2018 Feb 8;36(7):932-938. doi: 10.1016/j.vaccine.2017.11.061. Epub 2017 Dec 6. PMID: 29221895.
134. Chen WH, **Neuzil KM**, Boyce CR, Pasetti MF, Reymann MK, Martellet L, Hosken N, LaForce FM, Dhere RM, Pisal SS, Chaudhari A, Kulkarni PS, Borrow R, Findlow H, Brown V, McDonough ML, Dally L, Alderson MR. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. Lancet Infect Dis. 2018 Oct;18(10):1088-1096. doi: 10.1016/S1473-3099(18)30400-6. Epub 2018 Aug 14. PMID: 30120069.
135. Diallo A, Victor JC, Feser J, Ortiz JR, Kanesa-Thasan N, Ndiaye M, Diarra B, Cheikh S, Diene D, Ndiaye T, Ndiaye A, Lafond KE, Widdowson MA, **Neuzil KM**. Immunogenicity and safety of MF59-adjuvanted and full-dose unadjuvanted trivalent inactivated influenza vaccines among vaccine-naïve children in a randomized clinical trial in rural Senegal. Vaccine. 2018 Oct 15;36(43):6424-6432. doi: 10.1016/j.vaccine.2018.08.032. Epub 2018 Sep 14. PMID: 30224199; PMCID: PMC6327321.
136. Thang HV, Huong VM, Victor JC, Van CB, Nga NT, Be LV, Cuong NP, Tsvetnitsky V, **Neuzil KM**, Power M, Flores J. Safety and immunogenicity of inactivated monovalent influenza A/H1N1 vaccine candidate manufactured in Vietnam. Vaccine. 2018 Nov 12;36(46):6918-6925. doi: 10.1016/j.vaccine.2018.10.013. Epub 2018 Oct 15. PMID: 30337172.
137. Lewis KDC, Ortiz JR, Rahman MZ, Levine MZ, Rudenko L, Wright PF, Katz JM, Dally L, Rahman M, Isakova-Sivak I, Ilyushina NA, Matyushenko V, Fry AM, Lindstrom SE, Bresee JS, Brooks WA, **Neuzil KM**. Immunogenicity and Viral Shedding of Russian-Backbone, Seasonal, Trivalent, Live, Attenuated Influenza Vaccine in a Phase II, Randomized, Placebo-Controlled Trial Among Preschool-Aged Children in Urban Bangladesh. Clin Infect Dis. 2019 Aug 16;69(5):777-785. doi: 10.1093/cid/ciy1003. PMID: 30481272; PMCID: PMC6695509.
138. Hooper LG, Dieye Y, Ndiaye A, Diallo A, Sack CS, Fan VS, **Neuzil KM**, Ortiz JR. Traditional cooking practices and preferences for stove features among women in rural Senegal: Informing improved cookstove design and interventions. PLoS One. 2018 Nov 20;13(11):e0206822. doi: 10.1371/journal.pone.0206822. PMID: 30458001; PMCID: PMC6245512.
139. Brickley EB, Wright PF, Khalenkov A, **Neuzil KM**, Ortiz JR, Rudenko L, Levine MZ, Katz JM, Brooks WA. The effect of pre-existing immunity on virus detection and immune responses in a phase II randomized trial of a Russian-backbone live attenuated influenza vaccine in Bangladeshi children. Clin Infect Dis 2018 Nov 27: ciy1004, <https://doi.org/10.1093/cid/ciy1004>.
140. Diallo A, Diop OM, Diop D, Niang MN, Sugimoto JD, Ortiz JR, Faye EHA, Diarra B, Goudiaby D, Lewis KDC, Emery SL, Zangeneh SZ, Lafond KE, Sokhna C, Halloran ME, Widdowson MA, **Neuzil KM**, Victor JC. Effectiveness of Seasonal Influenza Vaccination in Children in Senegal During a Year of Vaccine Mismatch: A Cluster-randomized Trial. Clin Infect Dis. 2019 Oct 30;69(10):1780-1788. doi: 10.1093/cid/ciz066. PMID: 30689757; PMCID: PMC6821165.
141. **Neuzil KM**, Fitzpatrick MC. The Impact of Influenza Vaccine: It's the Size of the Glass. Clin Infect Dis. 2019 Nov 13;69(11):1854-1855. doi: 10.1093/cid/ciz078. PMID: 30715260.
142. Schwartz LM, Zaman K, Yunus M, Basunia AH, Faruque ASG, Ahmed T, Rahman M, Sugimoto JD, Halloran ME, Rowhani-Rahbar A, **Neuzil KM**, Victor JC. Impact of rotavirus vaccine introduction in children less than 2 years of age presenting for medical care with diarrhea in rural Matlab, Bangladesh. Clin Infect Dis. 2019 Feb.12. ciz133, <https://doi.org/10.1093/cid/ciz133>.
143. **Neuzil KM**, Pollard AJ, Marfin AA. Introduction of Typhoid Conjugate Vaccines in Africa and Asia. Clin Infect Dis. 2019 Feb 15;68(Suppl 1):S27-S30. doi: 10.1093/cid/ciy878. PMID: 30767005; PMCID: PMC6376078.
144. Debellut F Hendrix N, Pitzer VE, **Neuzil KM**, Constenla D, Bar-Zeev N, Marfin A, Pecenka C. Forecasting Demand for the Typhoid Conjugate Vaccine in Low- and Middle-income Countries. Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S154-S160. doi: 10.1093/cid/ciy1076. PMID: 30845321; PMCID: PMC6405267.
145. Meiring JE, Laurens MB, Patel P, Patel P, Misiri T, Simiyu K, Mwakiseghile F, Tracy JK, Masesa C, Liang Y, Henrion M, Rotrosen E, Gmeiner M, Heyderman R, Kotloff K, Gordon MA, **Neuzil KM**. Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi. Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S50-S58. doi: 10.1093/cid/ciy1103. PMID: 30845320; PMCID: PMC6405268.
146. Theiss-Nyland K, Colin-Jones R, Voysey M, Smith N, Farooq YG, Pollard A, Karkey A, Shakya M, Dongol S, Pant D, **Neuzil KM**, Basnyat B, Shrestha S. Assessing the impact of a Vi-Polysaccharide Conjugate Vaccine in preventing typhoid infections among Napalese children: A protocol for a Phase III randomized control trial. Clin Infect Dis. 2019 Mar 7;68(Supplement\_2): S67-S73. doi: 10.1093/cid/ciy1106.
147. Jamka LP, Simiyu KW, Bentsi-Enchill AD, Mwisongo AJ, Matzger H, Marfin AA, Pollard AJ, **Neuzil KM**. Accelerating Typhoid Conjugate Vaccine Introduction: What Can Be Learned From Prior New Vaccine Introduction Initiatives? Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S171-S176. doi: 10.1093/cid/ciy1118. PMID: 30845328; PMCID: PMC6405264.
148. Laurens, MB, Sirima SB, Rotrosen ET, Siribie M, Tiono A, Ouedraogo A, Liang Y, Jamka LP, Kotloff KL, **Neuzil KM**. A Phase II, Randomized, Double-blind, Controlled Safety and Immunogenicity Trial of Typhoid Conjugate Vaccine in Children Under 2 Years of Age in Ouagadougou, Burkina Faso: A Methods Paper. Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S59-S66. doi: 10.1093/cid/ciy1104. PMID: 30845330; PMCID: PMC6405275.
149. Ortiz JR, **Neuzil KM**. Influenza Immunization in Low- and Middle-Income Countries: Preparing for Next-Generation Influenza Vaccines. J Infect Dis. 2019 Apr 8;219(Suppl\_1):S97-S106. doi: 10.1093/infdis/jiz024. PMID: 30715348.
150. Bilcke J, Antillon M, Pieters Z, Kuylen E, Abboud L, **Neuzil KM**, Pollard AJ, Paltiel AD, Pitzer VE. Cost-effectiveness of typhoid conjugate vaccine delivery strategies in Gavi-eligible countries: a modelling study. Lancet Global Health. 2019 May 23; DOI: [https://doi.org/10.1016/S1473-3099(18)30804-1](https://doi.org/10.1016/S1473-3099%2818%2930804-1).
151. Ortiz JR, **Neuzil KM**. Influenza vaccine programs for children in low- and middle-income countries: current status and way forward. Expert Rev Vaccines. 2019 Jul;18(7):711-724. doi: 10.1080/14760584.2019.1635462. Epub 2019 Jul 5. PMID: 31226895.
152. Simões EAF, Nunes MC, Carosone-Link P, Madimabe R, Ortiz JR, **Neuzil KM**, Klugman KP, Cutland CL, Madhi SA; Matflu Team. Trivalent influenza vaccination randomized control trial of pregnant women and adverse fetal outcomes. Vaccine. 2019 Aug 23;37(36):5397-5403. doi: 10.1016/j.vaccine.2019.07.024. Epub 2019 Jul 19. PMID: 31331777; PMCID: PMC6694200.
153. Fleming JA, Munthali A, Ngwira B, Kadzandira J, Jamili-Phiri M, Ortiz JR, Lambach P, Hombach J, **Neuzil KM**, Stepanchak M, Bhat N. Maternal immunization in Malawi: A mixed methods study of community perceptions, programmatic considerations, and recommendations for future planning. Vaccine. 2019 Jul 26;37(32):4568-4575. doi: 10.1016/j.vaccine.2019.06.020. PMID: 31319932; PMCID: PMC6642336.
154. Potter GE, Wong J, Sugimoto J, Diallo A, Victor JC, **Neuzil K**, Halloran ME. Networks of face-to-face social contacts in Niakhar, Senegal. PLoS One. 2019 Aug 6;14(8):e0220443. doi: 10.1371/journal.pone.0220443. PMID: 31386686; PMCID: PMC6684077.
155. Sah P, Alfaro-Murillo JA, Fitzpatrick MC, **Neuzil KM**, Meyers LA, Singer BH, Galvani AP. Future epidemiological and economic impacts of universal influenza vaccines. Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20786-20792. doi: 10.1073/pnas.1909613116. Epub 2019 Sep 23. Erratum in: Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22409. PMID: 31548402; PMCID: PMC6789917.
156. Ortiz JR, Sugimoto JD, **Neuzil KM**, Halloran ME, Victor JC. Reply to

 Skowronski and De Serres. Clin Infect Dis. 2019 Nov 27;69(12):2231-2232. doi:

10.1093/cid/ciz352. PMID: 31056688.

1. Shakya M, M, Colin-Jones R, Theiss-Nyland K, Voysey M, Pant D, Smith N, Liu X, Tonks S, Mazur O, Farooq YG, Clarke J, Hill J, Adhikari A, Dongol S, Karkey A, Bajracharya B, Kelly S, Gurung M, Baker S, **Neuzil KM**, Shrestha S, Basnyat B, Pollard AJ; TyVAC Nepal Study Team. Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal. N Engl J Med. 2019 Dec 5;381(23):2209-2218. doi: 10.1056/NEJMoa1905047. PMID: 31800986; PMCID: PMC6785806.
2. Bower WA, Schiffer J, Atmar RL, Keitel WA, Friedlander AM, Liu L, Yu Y, Stephens DS, Quinn CP, Hendricks K; ACIP Anthrax Vaccine Work Group (including **Neuzil KM**). Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019. MMWR Recomm Rep. 2019 Dec 13;68(4):1-14. doi:10.15585/mmwr.rr6804a1. PMID: 31834290; PMCID: PMC6918956.
3. Nunes MC, Cutland CL, Moultrie A, Jones S, Ortiz JR, **Neuzil KM**, Klugman KP, Simões EAF, Weinberg A, Madhi SA; Maternal Flu Trial Team. Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial. Lancet HIV. 2020 Feb;7(2):e91-e103. doi: 10.1016/S2352-3018(19)30322-4. Epub 2020 Jan 3. PMID: 31911146; PMCID: PMC7167514.
4. Birkhold, M., Coulibaly Y, Coulibaly O, Dembélé P, Kim DS, Sow S, **Neuzil KM**. Morbidity and Mortality of Typhoid Intestinal Perforation Among Children in Sub-Saharan Africa 1995-2019: A Scoping Review. World J Surg. 2020 Sep;44(9):2892-2902. doi: 10.1007/s00268-020-05567-2. PMID: 32430740; PMCID: PMC7236653. Somayaji R, Neradilek MB, Szpiro AA, Lofy KH, Jackson ML, Goss CH, Duchin JS, Neuzil KM, Ortiz JR. Effects of Air Pollution and Other Environmental Exposures on Estimates of Severe Influenza Illness, Washington, USA. Emerg Infect Dis. 2020 May;26(5):920–9. doi: 10.3201/eid2605.190599. PMID: 32310747; PMCID: PMC7181929.
5. Omer SB, Clark DR, Madhi SA, Tapia MD, Nunes MC, Cutland CL, Simões EAF, Aqil AR, Katz J, Tielsch JM, Steinhoff MC, Wairagkar N; BMGF Supported Maternal Influenza Immunization Trials Investigators Group (including **Neuzil KM**). Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: a pooled analysis of three randomised controlled trials. Lancet Respir Med. 2020 Jun;8(6):597-608. doi: 10.1016/S2213-2600(19)30479-5. PMID: 32526188; PMCID: PMC7284303.
6. Deming ME, Michael NL, Robb M, Cohen MS, **Neuzil KM**. Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models. N Engl J Med. 2020 Sep 3;383(10):e63. doi: 10.1056/NEJMp2020076. Epub 2020 Jul 1. PMID: 32610006; PMCID: PMC7968616.
7. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, Flach B, Doria-Rose NA, Corbett KS, Morabito KM, O'Dell S, Schmidt SD, Swanson PA 2nd, Padilla M, Mascola JR, **Neuzil KM**, Bennett H, Sun W, Peters E, Makowski M, Albert J, Cross K, Buchanan W, Pikaart-Tautges R, Ledgerwood JE, Graham BS, Beigel JH; mRNA-1273 Study Group. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020 Nov 12;383(20):1920-1931. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14. PMID: 32663912; PMCID: PMC7377258.
8. Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, Corbett KS, Swanson PA 2nd, Padilla M, **Neuzil KM**, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Martinez DR, Baric R, Buchanan W, Luke CJ, Phadke VK, Rostad CA, Ledgerwood JE, Graham BS, Beigel JH; mRNA-1273 Study Group. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020 Dec 17;383(25):2427-2438. doi: 10.1056/NEJMoa2028436. Epub 2020 Sep 29. PMID: 32991794; PMCID: PMC7556339.
9. Ortiz JR, Robertson J, Hsu JS, Yu SL, Driscoll AJ, Williams SR, Chen WH, Fitzpatrick MC, Sow S, Biellik RJ, Okwo-Bele JM, **Neuzil KM**. The operational impact of deploying SARS-CoV-2 vaccines in countries of the WHO African Region. medRxiv [Preprint]. 2020 Nov 1:2020.08.13.20147595. doi: 10.1101/2020.08.13.20147595. Update in: Vaccine. 2021 Apr 8;39(15):2165-2176. PMID: 32817984; PMCID: PMC7430629.
10. Capeding MR, Alberto E, Feser J, Mooney J, Tang Y, Audet SA, Beeler JA, Ellison DW, Zhang L, Letson GW, **Neuzil KM**, Marfin AA. Immunogenicity and safety

of concurrent or sequential administration of live, attenuated SA 14-14-2

Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in

infants 9-12 months of age in the Philippines: A non-inferiority Phase 4

randomized clinical trial. Vaccine X. 2020 Aug 14;6:100074. doi:10.1016/j.jvacx.2020.100074. PMID: 33005887; PMCID: PMC7509462

1. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, **Neuzil K**, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Şahin U, Jansen KU. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020 Oct;586(7830):589-593. doi: 10.1038/s41586-020-2639-4. Epub 2020 Aug 12. Erratum in: Nature. 2021 Feb;590(7844):E26. PMID: 32785213.
2. Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, **Neuzil K**, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen KU, Şahin U, Gruber WC. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14. PMID: 33053279; PMCID: PMC7583697.
3. Niang M, Deming ME, Goudiaby D, Diop OM, Dia N, Diallo A, Ortiz JR, Diop D, Lewis KDC, Lafond KE, Widdowson MA, Victor JC, **Neuzil KM**. Immunogenicity of seasonal inactivated influenza and inactivated polio vaccines among children in Senegal: Results from a cluster-randomized trial. Vaccine. 2020 Nov 3;38(47):7526-7532. doi: 10.1016/j.vaccine.2020.09.059. Epub 2020 Oct 2. PMID: 33012603; PMCID: PMC7936169.
4. Sirima SB, Ouedraogo A, Barry N, Siribie M, Tiono AB, Nébié I, Konaté AT, Berges GD, Diarra A, Ouedraogo M, Soulama I, Hema A, Datta S, Liang Y, Rotrosen ET, Tracy JK, Jamka LP, **Neuzil KM**, Laurens MB. Safety and immunogenicity of co-administration of meningococcal type A and measles-rubella vaccines with typhoid conjugate vaccine in children aged 15-23 months in Burkina Faso. Int J Infect Dis. 2021 Jan;102:517-523. doi: 10.1016/j.ijid.2020.10.103. Epub 2020 Nov 8. PMID: 33176205; PMCID: PMC7762715.
5. Williams SR, Driscoll AJ, LeBuhn HM, Chen WH, **Neuzil KM**, Ortiz JR. National routine

adult immunisation programmes among World Health Organization Member States: an

assessment of health systems to deploy COVID-19 vaccines. Euro Surveill. 2021

Apr;26(17). doi: 10.2807/1560-7917.ES.2021.26.17.2001195. PMID: 33928899.

1. Barnabas RV, Brown E, Bershteyn A, Miller RS, Wener M, Celum C, Wald A, Chu H, Wesche D, Baeten JM; Hydroxychloroquine COVID-19 PEP Study Team (including **Neuzil, KM**). Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jun 3;21(1):475. doi: 10.1186/s13063-020-04446-4. PMID: 32493478; PMCID: PMC7268961.
2. Niang MN, Sugimoto JD, Diallo A, Diarra B, Ortiz JR, Lewis KDC, Lafond KE, Halloran ME, Widdowson MA, **Neuzil KM**, Victor JC. Estimates of Inactivated Influenza Vaccine Effectiveness Among Children in Senegal: Results From 2 Consecutive Cluster-Randomized Controlled Trials in 2010 and 2011. Clin Infect Dis. 2021 Jun 15;72(12):e959-e969. doi: 10.1093/cid/ciaa1689. PMID: 33165566; PMCID: PMC8204774.
3. Mehrotra DV, Janes HE, Fleming TR, Annunziato PW, **Neuzil KM**, Carpp LN, Benkeser D, Brown ER, Carone M, Cho I, Donnell D, Fay MP, Fong Y, Han S, Hirsch I, Huang Y, Huang Y, Hyrien O, Juraska M, Luedtke A, Nason M, Vandebosch A, Zhou H, Cohen MS, Corey L, Hartzel J, Follmann D, Gilbert PB. Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. Ann Intern Med. 2021 Feb;174(2):221-228. doi: 10.7326/M20-6169. Epub 2020 Oct 22. PMID: 33090877; PMCID: PMC7596738.
4. Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, Meyers LA, **Neuzil KM**, Langley JM, Fitzpatrick MC, Galvani AP. The impact of vaccination on COVID-19 outbreaks in the United States. medRxiv [Preprint]. 2020 Nov 30:2020.11.27.20240051. doi: 10.1101/2020.11.27.20240051. Update in: Clin Infect Dis. 2021 Jan 30; PMID: 33269359; PMCID: PMC7709178.
5. Widge AT, Rouphael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens, LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O'Dell S, Schmidt SD, **Neuzil KM**, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara VV, Floyd K, Suthar MS, Buchanan W, Luke CJ, Ledgerwood JE, Mascola JR, Graham BS, Beigel JH; mRNA-1273 Study Group. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Engl J Med. 2021 Jan 7;384(1):80-82. doi: 10.1056/NEJMc2032195. Epub 2020 Dec 3. PMID: 33270381; PMCID: PMC7727324.
6. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, **Neuzil K**, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30. PMID: 33378609; PMCID: PMC7787219.
7. Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, Meyers LA, **Neuzil KM**, Langley JM, Fitzpatrick MC, Galvani AP. The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. Clin Infect Dis. 2021 Dec 16;73(12):2257-2264. doi: 10.1093/cid/ciab079. PMID: 33515252; PMCID: PMC7929033.
8. Rapaka RR, Hammershaimb EA, **Neuzil KM**. Are Some COVID-19 Vaccines Better Than Others? Interpreting and Comparing Estimates of Efficacy in Vaccine Trials. Clin Infect Dis. 2022 Jan 29;74(2):352-358. doi: 10.1093/cid/ciab213. PMID: 33693552; PMCID: PMC7989512.
9. Barnabas RV, Brown ER, Bershteyn A, Stankiewicz Karita HC, Johnston C, Thorpe LE, Kottkamp A, **Neuzil KM**, Laufer MK, Deming M, Paasche-Orlow MK, Kissinger PJ, Luk A, Paolino K, Landovitz RJ, Hoffman R, Schaafsma TT, Krows ML, Thomas KK, Morrison S, Haugen HS, Kidoguchi L, Wener M, Greninger AL, Huang ML, Jerome KR, Wald A, Celum C, Chu HY, Baeten JM. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial. Ann Intern Med. 2021 Mar;174(3):344-352. doi: 10.7326/M20-6519. Epub 2020 Dec 8. Erratum in: Ann Intern Med. 2021 Mar;174(3):435. PMID: 33284679; PMCID: PMC7732017.
10. Ortiz JR, Robertson J, Hsu JS, Yu SL, Driscoll AJ, Williams SR, Chen WH, Fitzpatrick MC, Sow S, Biellik RJ, **Neuzil KM**. The potential effects of deploying SARS-Cov-2 vaccines on cold storage capacity and immunization workload in countries of the WHO African Region. Vaccine. 2021 Apr 8;39(15):2165-2176. doi: 10.1016/j.vaccine.2021.02.037. Epub 2021 Feb 19. PMID: 33744049; PMCID: PMC7894202.
11. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, Offergeld K, Scheper G, Taylor KL, Robb ML, Treanor J, Barouch DH, Stoddard J, Ryser MF, Marovich MA, **Neuzil KM**, Corey L, Cauwenberghs N, Tanner T, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M; ENSEMBLE Study Group. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021 Jun 10;384(23):2187-2201. doi: 10.1056/NEJMoa2101544. Epub 2021 Apr 21. PMID: 33882225; PMCID: PMC8220996.
12. Sirima SB, Ouedraogo A, Barry N, Siribie M, Tiono A, Nébié I, Konaté A, Berges GD, Diarra A, Ouedraogo M, Bougouma EC, Soulama I, Hema A, Datta S, Liang Y, Rotrosen ET, Tracy JK, Jamka LP, Oshinsky JJ, Pasetti MF, **Neuzil KM**, Laurens MB. Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial. Int J Infect Dis. 2021 Jul;108:465-472. doi: 10.1016/j.ijid.2021.05.061. Epub 2021 Jun 1. PMID: 34082090; PMCID: PMC8298254.
13. Williams SR, Driscoll AJ, LeBuhn HM, Chen WH, **Neuzil KM**, Ortiz JR. National routine adult immunisation programmes among World Health Organization Member States: an assessment of health systems to deploy COVID-19 vaccines. Euro Surveill. 2021 Apr;26(17). doi: 10.2807/1560-7917.ES.2021.26.17.2001195. PMID: 33928899.
14. Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, Ledgerwood JE, Mascola JR, Graham BS, Lin BC, O'Dell S, Schmidt SD, Widge AT, Edara VV, Anderson EJ, Lai L, Floyd K, Rouphael NG, Zarnitsyna V, Roberts PC, Makhene M, Buchanan W, Luke CJ, Beigel JH, Jackson LA, **Neuzil KM**, Bennett H, Leav B, Albert J, Kunwar P; mRNA-1273 Study Group. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021 Jun 10;384(23):2259-2261. doi: 10.1056/NEJMc2103916. Epub 2021 Apr 6. PMID: 33822494.
15. Follmann D, Fintzi J, Fay MP, Janes HE, Baden LR, El Sahly HM, Fleming TR, Mehrotra DV, Carpp LN, Juraska M, Benkeser D, Donnell D, Fong Y, Han S, Hirsch I, Huang Y, Huang Y, Hyrien O, Luedtke A, Carone M, Nason M, Vandebosch A, Zhou H, Cho I, Gabriel E, Kublin JG, Cohen MS, Corey L, Gilbert PB, **Neuzil KM**. A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. Ann Intern Med. 2021 Aug;174(8):1118-1125. doi: 10.7326/M20-8149. Epub 2021 Apr 13. PMID: 33844575; PMCID: PMC8099035.
16. Ortiz JR, Yu SL, Driscoll AJ, Williams SR, Robertson J, Hsu JS, Chen WH, Biellik RJ, Sow S, Kochhar S, **Neuzil KM**. The Operational Feasibility of Vaccination Programs Targeting Influenza Risk Groups in the World Health Organization (WHO) African and South-East Asian Regions. Clin Infect Dis. 2022 Jan 29;74(2):227-236. doi: 10.1093/cid/ciab393. PMID: 33949661; PMCID: PMC8800189.
17. Laufer RS, Driscoll AJ, Baral R, Buchwald AG, Campbell JD, Coulibaly F, Diallo F, Doumbia M, Galvani AP, Haidara FC, Kotloff KL, Keita AM, **Neuzil KM**, Orenstein EW, Orenstein LAV, Pecenka C, Sow S, Tapia MD, Ortiz JR, Fitzpatrick MC. Cost-effectiveness of infant respiratory syncytial virus preventive interventions in Mali: A modeling study to inform policy and investment decisions. Vaccine. 2021 Aug 16;39(35):5037-5045. doi: 10.1016/j.vaccine.2021.06.086. Epub 2021 Jul 26. PMID: 34325934.
18. Qadri F, Khanam F, Liu X, Theiss-Nyland K, Biswas PK, Bhuiyan AI, Ahmmed F, Colin-Jones R, Smith N, Tonks S, Voysey M, Mujadidi YF, Mazur O, Rajib NH, Hossen MI, Ahmed SU, Khan A, Rahman N, Babu G, Greenland M, Kelly S, Ireen M, Islam K, O'Reilly P, Scherrer KS, Pitzer VE, **Neuzil KM**, Zaman K, Pollard AJ, Clemens JD. Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. Lancet. 2021 Aug 21;398(10301):675-684. doi: 10.1016/S0140-6736(21)01124-7. Epub 2021 Aug 9. PMID: 34384540; PMCID: PMC8387974.
19. Shakya M, **Neuzil KM**, Pollard AJ. Prospects of Future Typhoid and Paratyphoid Vaccines in Endemic Countries. J Infect Dis. 2021 Dec 20;224(Supplement\_7):S770-S774. doi: 10.1093/infdis/jiab393. PMID: 34374785; PMCID: PMC8687069.
20. Birger, Ruthie and Antillon, Marina and Bilcke, Joke and Dolecek, Christiane and Dougan, Gordon and Pollard, Andrew and **Neuzil, Kathleen M.** and Frost, Isabel and Laxminarayan, Ramanan and Laxminarayan, Ramanan and Pitzer, Virginia E., Estimating the Impact of Vaccination on Antimicrobial-Resistant Typhoid Fever in Gavi-73 Countries. Available SSRN: [https://ssrn.com/abstract=3844858](https://ssrn.com/abstract%3D3844858) or [http://dx.doi.org/10.2139/ssrn.3844858](https://dx.doi.org/10.2139/ssrn.3844858).
21. Patel PD, Patel P, Liang Y, Meiring JE, Misiri T, Mwakiseghile F, Tracy JK, Masesa C, Msuku H, Banda D, Mbewe M, Henrion M, Adetunji F, Simiyu K, Rotrosen E, Birkhold M, Nampota N, Nyirenda OM, Kotloff K, Gmeiner M, Dube Q, Kawalazira G, Laurens MB, Heyderman RS, Gordon MA, **Neuzil KM**; TyVAC Malawi Team. Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children. N Engl J Med. 2021 Sep 16;385(12):1104-1115. doi: 10.1056/NEJMoa2035916. PMID: 34525285; PMCID: PMC8202713.
22. Birkhold M, Mwisongo A, Pollard AJ, **Neuzil KM**. Typhoid Conjugate Vaccines: Advancing the Research and Public Health Agendas. J Infect Dis. 2021 Dec 20;224(Supplement\_7):S781-S787. doi: 10.1093/infdis/jiab449. PMID: 34528085; PMCID: PMC8687070.
23. El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, **Neuzil KM**, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Schödel F, Tomassini JE, Zhou H, Miller J; COVE Study Group. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021 Nov 4;385(19):1774-1785. doi: 10.1056/NEJMoa2113017. Epub 2021 Sep 22. PMID: 34551225; PMCID: PMC8482810.
24. Baden LR, El Sahly HM, Essink B, Follmann D, **Neuzil KM**, August A, Clouting H, Fortier G, Deng W, Han S, Zhao X, Leav B, Talarico C, Girard B, Paila YD, Tomassini JE, Schödel F, Pajon R, Zhou H, Das R, Miller J. Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge. medRxiv [Preprint]. 2021 Sep 22:2021.09.17.21263624. doi: 10.1101/2021.09.17.21263624. Update in: N Engl J Med. 2021 Nov 3;: PMID: 34611666; PMCID: PMC8491857.
25. Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, **Neuzil KM**, Hahn W, Hunt J, Mulligan MJ, McEvoy C, DeJesus E, Hassman M, Little SJ, Pahud BA, Durbin A, Pickrell P, Daar ES, Bush L, Solis J, Carr QO, Oyedele T, Buchbinder S, Cowden J, Vargas SL, Guerreros Benavides A, Call R, Keefer MC, Kirkpatrick BD, Pullman J, Tong T, Brewinski Isaacs M, Benkeser D, Janes HE, Nason MC, Green JA, Kelly EJ, Maaske J, Mueller N, Shoemaker K, Takas T, Marshall RP, Pangalos MN, Villafana T, Gonzalez-Lopez A; AstraZeneca AZD1222 Clinical Study Group. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. N Engl J Med. 2021 Dec 16;385(25):2348-2360. doi: 10.1056/NEJMoa2105290. Epub 2021 Sep 29. PMID: 34587382; PMCID: PMC8522798.
26. Theiss-Nyland K, Shakya M, Colin-Jones R, Voysey M, Smith N, Karkey A, Dongol S, Pant D, Farooq YG, Mazur O, Darlow C, **Neuzil KM**, Shrestha S, Basnyat B, Pollard AJ. Corrigendum to: Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial. Clin Infect Dis. 2021 Nov 16;73(10):1950. doi: 10.1093/cid/ciab802. Erratum for: Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S67-S73. PMID: 34698813.
27. Shakya M, Voysey M, Theiss-Nyland K, Colin-Jones R, Pant D, Adhikari A, Tonks S, Mujadidi YF, O'Reilly P, Mazur O, Kelly S, Liu X, Maharjan A, Dahal A, Haque N, Pradhan A, Shrestha S, Joshi M, Smith N, Hill J, Clarke J, Stockdale L, Jones E, Lubinda T, Bajracharya B, Dongol S, Karkey A, Baker S, Dougan G, Pitzer VE, **Neuzil KM**, Shrestha S, Basnyat B, Pollard AJ; TyVAC Nepal Team. Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial. Lancet Glob Health. 2021 Nov;9(11):e1561-e1568. doi: 10.1016/S2214-109X(21)00346-6. PMID: 34678198; PMCID: PMC8551681.
28. Pegu A, O'Connell SE, Schmidt SD, O'Dell S, Talana CA, Lai L, Albert J, Anderson E, Bennett H, Corbett KS, Flach B, Jackson L, Leav B, Ledgerwood JE, Luke CJ, Makowski M, Nason MC, Roberts PC, Roederer M, Rebolledo PA, Rostad CA, Rouphael NG, Shi W, Wang L, Widge AT, Yang ES; mRNA-1273 Study Group§, Beigel JH, Graham BS, Mascola JR, Suthar MS, McDermott AB, Doria-Rose NA, Arega J, Beigel JH, Buchanan W, Elsafy M, Hoang B, Lampley R, Kolhekar A, Koo H, Luke C, Makhene M, Nayak S, Pikaart-Tautges R, Roberts PC, Russell J, Sindall E, Albert J, Kunwar P, Makowski M, Anderson EJ, Bechnak A, Bower M, Camacho-Gonzalez AF, Collins M, Drobeniuc A, Edara VV, Edupuganti S, Floyd K, Gibson T, Ackerley CMG, Johnson B, Kamidani S, Kao C, Kelley C, Lai L, Macenczak H, McCullough MP, Peters E, Phadke VK, Rebolledo PA, Rostad CA, Rouphael N, Scherer E, Sherman A, Stephens K, Suthar MS, Teherani M, Traenkner J, Winston J, Yildirim I, Barr L, Benoit J, Carste B, Choe J, Dunstan M, Erolin R, Ffitch J, Fields C, Jackson LA, Kiniry E, Lasicka S, Lee S, Nguyen M, Pimienta S, Suyehira J, Witte M, Bennett H, Altaras NE, Carfi A, Hurley M, Leav B, Pajon R, Sun W, Zaks T, Coler RN, Larsen SE, **Neuzil KM**, Lindesmith LC, Martinez DR, Munt J, Mallory M, Edwards C, Baric RS, Berkowitz NM, Boritz EA, Carlton K, Corbett KS, Costner P, Creanga A, Doria-Rose NA, Douek DC, Flach B, Gaudinski M, Gordon I, Graham BS, Holman L, Ledgerwood JE, Leung K, Lin BC, Louder MK, Mascola JR, McDermott AB, Morabito KM, Novik L, O'Connell S, O'Dell S, Padilla M, Pegu A, Schmidt SD, Shi W, Swanson PA 2nd, Talana CA, Wang L, Widge AT, Yang ES, Zhang Y, Chappell JD, Denison MR, Hughes T, Lu X, Pruijssers AJ, Stevens LJ, Posavad CM, Gale M Jr, Menachery V, Shi PY. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021 Sep 17;373(6561):1372-1377. doi: 10.1126/science.abj4176. Epub 2021 Aug 13. PMID: 34385356.
29. Shakya M, **Neuzil KM**, Pollard AJ. Prospects of Future Typhoid and Paratyphoid Vaccines in Endemic Countries. J Infect Dis. 2021 Dec 20;224(12 Suppl 2):S770-S774. doi: 10.1093/infdis/jiab393. PMID: 34374785; PMCID: PMC8687069.
30. Potter, G.E., Carnegie, N.B., Sugimoto, J.D., Diallo, A., Victor, J.C., **Neuzil, K.M.** and Elizabeth Halloran, M. (2021), Using social contact data to improve the overall effect estimate of a cluster-randomized influenza vaccination program in Senegal. J R Stat Soc Series C. <https://doi.org/10.1111/rssc.12522>.
31. Strohmeier S, Amanat F, Zhu X, McMahon M, Deming ME, Pasetti MF, **Neuzil KM**, Wilson IA, Krammer F. A Novel Recombinant Influenza Virus Neuraminidase Vaccine Candidate Stabilized by a Measles Virus Phosphoprotein Tetramerization Domain Provides Robust Protection from Virus Challenge in the Mouse Model. mBio. 2021 Dec 21;12(6):e0224121. doi: 10.1128/mBio.02241-21. Epub 2021 Nov 23. PMID: 34809451; PMCID: PMC8609353.
32. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Castellino F, Flach B, Lin BC, O'Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Huynh C, Miller J, El Sahly HM, Baden LR, Baron M, De La Cruz L, Gay C, Kalams S, Kelley CF, Andrasik MP, Kublin JG, Corey L, **Neuzil KM**, Carpp LN, Pajon R, Follmann D, Donis RO, Koup RA; Immune Assays Team§; Moderna, Inc. Team§; Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team§; United States Government (USG)/CoVPN Biostatistics Team§. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022 Jan 7;375(6576):43-50. doi: 10.1126/science.abm3425. Epub 2021 Nov 23. PMID: 34812653.
33. Dunkle LM, Kotloff KL, Gay CL, Áñez G, Adelglass JM, Barrat Hernández AQ, Harper WL, Duncanson DM, McArthur MA, Florescu DF, McClelland RS, Garcia-Fragoso V, Riesenberg RA, Musante DB, Fried DL, Safirstein BE, McKenzie M, Jeanfreau RJ, Kingsley JK, Henderson JA, Lane DC, Ruíz-Palacios GM, Corey L, **Neuzil KM**, Coombs RW, Greninger AL, Hutter J, Ake JA, Smith K, Woo W, Cho I, Glenn GM, Dubovsky F; 2019nCoV-301 Study Group. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. N Engl J Med. 2022 Feb 10;386(6):531-543. doi: 10.1056/NEJMoa2116185. Epub 2021 Dec 15. PMID: 34910859; PMCID: PMC8693692.
34. Moghadas SM, Vilches TN, Zhang K, Wells CR, Shoukat A, Singer BH, Meyers LA, **Neuzil KM**, Langley JM, Fitzpatrick MC, Galvani AP. The Impact of Vaccination on Coronavirus Disease 2019 (COVID-19) Outbreaks in the United States. Clin Infect Dis. 2021 Dec 16;73(12):2257-2264. doi: 10.1093/cid/ciab079. PMID: 33515252; PMCID: PMC7929033.PMC8693692.
35. Stankiewicz Karita HC, Dong TQ, Johnston C, **Neuzil KM**, Paasche-Orlow MK, Kissinger PJ, Bershteyn A, Thorpe LE, Deming M, Kottkamp A, Laufer M, Landovitz RJ, Luk A, Hoffman R, Roychoudhury P, Magaret CA, Greninger AL, Huang ML, Jerome KR, Wener M, Celum C, Chu HY, Baeten JM, Wald A, Barnabas RV, Brown ER. Trajectory of Viral RNA Load Among Persons With Incident SARS-CoV-2 G614 Infection (Wuhan Strain) in Association With COVID-19 Symptom Onset and Severity. JAMA Netw Open. 2022 Jan 4;5(1):e2142796. doi: 10.1001/jamanetworkopen.2021.42796. PMID: 35006245; PMCID: PMC8749477.
36. McIntyre PB, Aggarwal R, Jani I, Jawad J, Kochhar S, MacDonald N, Madhi SA, Mohsni E, Mulholland K, **Neuzil KM**, Nohynek H, Olayinka F, Pitisuttithum P, Pollard AJ, Cravioto A. COVID-19 vaccine strategies must focus on severe disease and global equity. Lancet. 2022 Jan 22;399(10322):406-410. doi: 10.1016/S0140-6736(21)02835-X. Epub 2021 Dec 16. PMID: 34922639; PMCID: PMC8676417.
37. Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW Jr, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, Coler RN, Posavad CM, Archer JI, Crandon S, Nayak SU, Szydlo D, Zemanek JA, Dominguez Islas CP, Brown ER, Suthar MS, McElrath MJ, McDermott AB, O'Connell SE, Montefiori DC, Eaton A, **Neuzil KM**, Stephens DS, Roberts PC, Beigel JH; DMID 21-0012 Study Group. Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022 Mar 17;386(11):1046-1057. doi: 10.1056/NEJMoa2116414. Epub 2022 Jan 26. PMID: 35081293; PMCID: PMC8820244.
38. Birger R, Antillón M, Bilcke J, Dolecek C, Dougan G, Pollard AJ, **Neuzil KM**, Frost I, Laxminarayan R, Pitzer VE. Estimating the effect of vaccination on antimicrobial-resistant typhoid fever in 73 countries supported by Gavi: a mathematical modelling study. Lancet Infect Dis. 2022 May;22(5):679-691. doi: 10.1016/S1473-3099(21)00627-7. Epub 2022 Feb 3. PMID: 35123673; PMCID: PMC9021026.
39. Zaman K, Yunus M, Aziz AB, Feser J, Mooney J, Tang Y, Ellison DW, Thaisomboonsuk B, Zhang L, **Neuzil KM**, Marfin AA, Letson GW. Antibody persistence and immune memory response following primary vaccination and boosting with live attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) in Bangladesh: A phase 4 open-label clinical trial. Vaccine X. 2022 Feb 5;10:100143. doi: 10.1016/j.jvacx.2022.100143. PMID: 35243320; PMCID: PMC8857502.
40. Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Van Dromme I, Spiessens B, Vingerhoets J, Custers J, Scheper G, Robb ML, Treanor J, Ryser MF, Barouch DH, Swann E, Marovich MA, **Neuzil KM**, Corey L, Stoddard J, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M; ENSEMBLE Study Group. Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S. N Engl J Med. 2022 Mar 3;386(9):847-860. doi: 10.1056/NEJMoa2117608. Epub 2022 Feb 9. PMID: 35139271; PMCID: PMC8849184.
41. Henschke N, Bergman H, Hungerford D, Cunliffe NA, Grais RF, Kang G, Parashar UD, Wang SA, **Neuzil KM**. The efficacy and safety of rotavirus vaccines in countries in Africa and Asia with high child mortality. Vaccine. 2022 Mar 15;40(12):1707-1711. doi: 10.1016/j.vaccine.2022.02.003. Epub 2022 Feb 17. PMID: 35184924; PMCID: PMC8914343.
42. Fong Y, McDermott AB, Benkeser D, Roels S, Stieh DJ, Vandebosch A, Gars ML, Van Roey GA, Houchens CR, Martins K, Jayashankar L, Castellino F, Amoa-Awua O, Basappa M, Flach B, Lin BC, Moore C, Naisan M, Naqvi M, Narpala S, O'Connell S, Mueller A, Serebryannyy L, Castro M, Wang J, Petropoulos CJ, Luedtke A, Hyrien O, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Kenny A, Carone M, Wolfe DN, Sadoff J, Gray GE, Grinsztejn B, Goepfert PA, Little SJ, de Sousa LP, Maboa R, Randhawa AK, Andrasik MP, Hendriks J, Truyers C, Struyf F, Schuitemaker H, Douoguih M, Kublin JG, Corey L, **Neuzil KM**, Carpp LN, Follmann D, Gilbert PB, Koup RA, Donis RO; Janssen Team; Coronavirus Vaccine Prevention Network (CoVPN)/ENSEMBLE Team; United States Government (USG)/CoVPN Biostatistics Team. Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial. medRxiv [Preprint]. 2022 Apr 12:2022.04.06.22272763. doi: 10.1101/2022.04.06.22272763. Update in: Nat Microbiol. 2022 Nov 10;: PMID: 35441174; PMCID: PMC9016647.
43. Ortiz JR, Spearman PW, Goepfert PA, Cross K, Buddy Creech C, Chen WH, Parker S, Overton ET, Dickey M, Logan HL, Wegel A, **Neuzil KM**. Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial. Vaccine. 2022 May 20;40(23):3253-3262. doi: 10.1016/j.vaccine.2022.03.055. Epub 2022 Apr 22. PMID: 35465983.
44. Evan J. Anderson, Lisa A. Jackson, Nadine G. Rouphael, **KM Neuzil**, et al. Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent Vaccines, 26 April 2022, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-1594631/v1].
45. Munoz FM, Beigi RH, Posavad CM, Richardson BA, Chu HY, Bok K, Campbell J, Cardemil C, DeFranco E, Frenck RW, Makhene M, Piper JM, Sheffield J, Miller A, **Neuzil KM**. Multi-site observational maternal and infant COVID-19 vaccine study (MOMI-vax): a study protocol. BMC Pregnancy Childbirth. 2022 May 12;22(1):402. doi: 10.1186/s12884-022-04500-w. PMID: 35550037; PMCID: PMC9096328.
46. Edwards KM, **Neuzil KM**. Understanding COVID-19 through human challenge models. Nat Med. 2022 May;28(5):903-904. doi: 10.1038/s41591-022-01778-3. PMID: 35361993.
47. Lin DY, Baden LR, El Sahly HM, Essink B, **Neuzil KM**, Corey L, Miller J; COVE Study Group. Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial. JAMA Netw Open. 2022 Jun 1;5(6):e2215984. doi: 10.1001/jamanetworkopen.2022.15984. PMID: 35675078; PMCID: PMC9178430.
48. Sparrow E, Adetifa I, Chaiyakunapruk N, Cherian T, Fell DB, Graham BS, Innis B, Kaslow DC, Karron RA, Nair H, **Neuzil KM**, Saha S, Smith PG, Srikantiah P, Were F, Zar HJ, Feikin D. WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use. Vaccine. 2022 Jun 9;40(26):3506-3510. doi: 10.1016/j.vaccine.2022.02.040. Epub 2022 Feb 17. PMID: 35184927; PMCID: PMC9176315.
49. Munoz FM, Posavad CM, Richardson BA, Badell ML, Bunge K, Mulligan MJ, Parameswaran L, Kelly C, Olsen-Chen C, Novak RM, Brady RC, Pasetti M, DeFranco E, Gerber JS, Shriver M, Suthar MS, Moore K, Coler R, Berube B, Kim SH, Piper JM, Miller A, Cardemil C, **Neuzil KM**, Beigi R; DMID Study Group. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn (DMID 21-0004). medRxiv [Preprint]. 2022 Jun 13:2022.06.13.22276354. doi: 10.1101/2022.06.13.22276354. PMID: 35734087; PMCID: PMC9216723.
50. Laufer, R. S., Baral, R., Buchwald, A. G., Campbell, J. D., Coulibaly, F., Diallo, F., Doumbia, M., Driscoll, A. J., Galvani, A. P., Keita, A. M., **Neuzil, KM**., Sow, S., Pecenka, C., Ortiz, J. R., & Fitzpatrick, M. C. (2022, January 1). Optimizing next-generation RSV Prevention in Mali: A cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis. medRxiv. Retrieved June 15, 2022, from https://www.medrxiv.org/content/10.1101/2022.05.19.22275309v1.
51. Braunfeld JB, Carson HN, Williams SR, Schwartz LM, **Neuzil KM**, Ortiz JR. Clinical endpoints to inform vaccine policy: A systematic review of outcome measures from pediatric influenza vaccine efficacy trials. Vaccine. 2022 Jul 30;40(32):4339-4347. doi: 10.1016/j.vaccine.2022.06.028. Epub 2022 Jun 16. PMID: 35717265.
52. Lyke KE, Atmar RL, Islas CD, Posavad CM, Szydlo D, Paul Chourdhury R, Deming ME, Eaton A, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW Jr, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, Coler RN, Archer JI, Crandon S, Zemanek JA, Brown ER, **Neuzil KM**, Stephens DS, Post DJ, Nayak SU, Suthar MS, Roberts PC, Beigel JH, Montefiori DC; DMID 21-0012 Study Group. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med. 2022 Jul 19;3(7):100679. doi: 10.1016/j.xcrm.2022.100679. Epub 2022 Jun 20. PMID: 35798000; PMCID: PMC9212999.
53. Branche AR, Rouphael NG, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Anderson EJ, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Malkin E, Bethony JM, Walsh EE, Graciaa DS, Samaha H, Sherman AC, Walsh SR, Abate G, Oikonomopoulou Z, El Sahly HM, Martin TCS, Rostad CA, Smith MJ, Ladner BG, Porterfield L, Dunstan M, Wald A, Davis T, Atmar RL, Mulligan MJ, Lyke KE, Posavad CM, Meagher MA, Stephens DS, **Neuzil KM**, Abebe K, Hill H, Albert J, Lewis TC, Giebeig LA, Eaton A, Netzl A, Wilks SH, Türeli S, Makhene M, Crandon S, Lee M, Nayak SU, Montefiori DC, Makowski M, Smith DJ, Roberts PC, Beigel JH; COVAIL Study Group. SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses. medRxiv [Preprint]. 2022 Jul 15:2022.07.12.22277336. doi: 10.1101/2022.07.12.22277336. PMID: 35898343; PMCID: PMC9327623.
54. Bershteyn A, Dahl AM, Dong TQ, Deming ME, Celum CL, Chu HY, Kottkamp AC, Greninger AL, Hoffman RM, Jerome KR, Johnston CM, Kissinger PJ, Landovitz RJ, Laufer MK, Luk A, **Neuzil KM**, Paasche-Orlow MK, Pitts RA, Schwartz MD, Stankiewicz Karita HC, Thorpe LE, Wald A, Zheng CY, Wener MH, Barnabas RV, Brown ER. Self-Assessed Severity as a Determinant of Coronavirus Disease 2019 Symptom Specificity: A Longitudinal Cohort Study. Clin Infect Dis. 2022 Aug 24;75(1):e1180-e1183. doi: 10.1093/cid/ciac129. PMID: 35152299; PMCID: PMC8903379.
55. Friedman-Klabanoff DJ, Fitzpatrick MC, Deming ME, Agrawal V, Sitar S, Schaafsma T, Brown E, **Neuzil KM**, Barnabas RV, Laufer MK; Hydroxychloroquine COVID-19 Postexposure Prophylaxis Study Team. Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition Is Associated With Individual Exposure but Not Community-Level Transmission. J Infect Dis. 2022 Aug 24;226(2):225-235. doi: 10.1093/infdis/jiac029. PMID: 35134185; PMCID: PMC8903329.
56. **Neuzil KM**. Prevention and Control of Coronavirus Disease 2019: Where Do We Go From Here? Clin Infect Dis. 2022 Aug 24;75(1):e692-e694. doi: 10.1093/cid/ciac090. PMID: 35134147; PMCID: PMC890338.
57. Nampota-Nkomba N, Nyirenda OM, Khonde L, Mapemba V, Mbewe M, Ndaferankhande JM, Msuku H, Masesa C, Misiri T, Mwakiseghile F, Patel PD, Patel P, Johnson-Mayo I, Pasetti MF, Heyderman RS, Tracy JK, Datta S, Liang Y, **Neuzil KM**, Gordon MA, Laurens MB; Typhoid Vaccine Acceleration Consortium team. Safety and immunogenicity of a typhoid conjugate vaccine among children aged 9 months to 12 years in Malawi: a nested substudy of a double-blind, randomised controlled trial. Lancet Glob Health. 2022 Sep;10(9):e1326-e1335. doi: 10.1016/S2214-109X(22)00275-3. PMID: 35961356; PMCID: PMC9380257.
58. Deming ME, Dong TQ, Agrawal V, Mills MG, Huang MLW, Greninger AL, Jerome KR, Wener MH, Paasche-Orlow MK, Kissinger P, Luk A, Hoffman RM, Stewart J, Kottkamp AC, Bershteyn A, Chu HY, Stankiewicz Karita HC, Johnston CM, Wald A, Barnabas R, Brown ER, **Neuzil KM**. Detection and Kinetics of Subgenomic Severe Acute Respiratory Syndrome Coronavirus 2 RNA Viral Load in Longitudinal Diagnostic RNA-Positive Samples. J Infect Dis. 2022 Sep 13;226(5):788-796. doi: 10.1093/infdis/jiac048. PMID: 35150571; PMCID: PMC8903395.
59. Sobieszczyk ME, Maaske J, Falsey AR, Sproule S, Robb ML, Frenck RW Jr, Tieu HV, Mayer KH, Corey L, **Neuzil KM**, Tong T, Brewinski Isaacs M, Janes H, Bansal H, Edwards LM, Green JA, Kelly EJ, Shoemaker K, Takas T, White T, Bhuyan P, Villafana T, Hirsch AI; AstraZeneca AZD1222 Clinical Study Group. Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months. J Clin Invest. 2022 Sep 15;132(18):e160565. doi: 10.1172/JCI160565. PMID: 36106642; PMCID: PMC9479753.
60. Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, Kotloff K, Desjardins M, Corey L, **Neuzil KM**, Miller JM, El Sahly HM, Baden LR. Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. Ann Intern Med. 2022 Sep;175(9):1258-1265. doi: 10.7326/M22-1300. Epub 2022 Jul 5. PMID: 35785530; PMCID: PMC9258784.
61. Yuanyuan Liang, Amanda J Driscoll, Priyanka D Patel, Shrimati Datta, Merryn Voysey, Neil French, Leslie P Jamka, Marc Y R Henrion, Latif Ndeketa, Matthew B Laurens, Robert S Heyderman, Melita A Gordon, **Neuzil KM**,Typhoid conjugate vaccine effectiveness in Malawi: evaluation of a test-negative design using randomised, controlled clinical trial data,The Lancet Global Health, 2022 Nov 25,ISSN 2214-109X,https://doi.org/10.1016/S2214-109X(22)00466-1.
62. Kumbhakar R, Neradilek M, Barnabas RV, Stewart J, Stankiewicz Karita HC, Landovitz RJ, Kissinger PJ, Jerome KR, Paasche-Orlow MK, Bershteyn A, Chu HY, **Neuzil KM**, Greninger AL, Luk A, Wald A, Brown ER, Johnston C. Using time-weighted average change from baseline of SARS-CoV-2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID-19. J Med Virol. 2022 Dec;94(12):6091-6096. doi: 10.1002/jmv.28054. Epub 2022 Aug 23. PMID: 35940869; PMCID: PMC9538473.
63. Fong Y, McDermott AB, Benkeser D, Roels S, Stieh DJ, Vandebosch A, Le Gars M, Van Roey GA, Houchens CR, Martins K, Jayashankar L, Castellino F, Amoa-Awua O, Basappa M, Flach B, Lin BC, Moore C, Naisan M, Naqvi M, Narpala S, O'Connell S, Mueller A, Serebryannyy L, Castro M, Wang J, Petropoulos CJ, Luedtke A, Hyrien O, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Kenny A, Carone M, Wolfe DN, Sadoff J, Gray GE, Grinsztejn B, Goepfert PA, Little SJ, Paiva de Sousa L, Maboa R, Randhawa AK, Andrasik MP, Hendriks J, Truyers C, Struyf F, Schuitemaker H, Douoguih M, Kublin JG, Corey L, **Neuzil KM**, Carpp LN, Follmann D, Gilbert PB, Koup RA, Donis RO; Immune Assays Team; the Coronavirus Vaccine Prevention Network (CoVPN)/ENSEMBLE Team; and the United States Government (USG)/CoVPN Biostatistics Team. Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. Nat Microbiol. 2022 Dec;7(12):1996-2010. doi: 10.1038/s41564-022-01262-1. Epub 2022 Nov 10. PMID: 36357712.
64. **Neuzil KM**, Anderson EJ, Frenck RW, Frey SE, Walter EB, Rupp R, Rotrosen ET, Rouphael NG, Brady RC, Graham I, Schmader KE, Porterfield L, Ortiz JR, Swamy GK, El Sahly HM, Jeevan T, Sitaula R, Wegel A, Webby RJ, Bryant C; Influenza A/H5N8 Virus Vaccine Group. Safety and Immunogenicity of Influenza A/H5N8 Virus Vaccine in Healthy Adults: Durability and Cross-reactivity of Antibody Responses. Clin Infect Dis. 2023 Jan 5:ciac982. doi: 10.1093/cid/ciac982. Epub ahead of print. PMID: 36610728.
65. Franklin R Toapanta, PhD, Paula Bernal, PhD, Jingping Hu, PhD, Paul C Roberts, PhD, Catherine J Luke, Ph.D., Mamodikoe K Makhene, MD, MPH, Justin Ortiz, MD, **Kathleen Neuzil, MD**, Marcelo Sztein, MD, 486. A/California/07/2009-pdm-like (H1N1) Influenza Virus Controlled Human Infection Model (CHIM) Activates Various Immune Cells Despite Induction of Mild Symptomatology, *Open Forum Infectious Diseases*, Volume 9, Issue Supplement\_2, December 2022, <https://doi.org/10.1093/ofid/ofac492.544>.
66. Mena Lora AJ, Long JE, Huang Y, Baden LR, El Sahly HM, Follmann D, Goepfert P, Gray G, Grinsztejn B, Kotloff K, Rouphael N, Sobieszczyk M, Walsh SR, Andriesen J, Shah KA, Zhang Y, Gilbert P, Janes H, Gay CL, Falsey AR, Tripp RL, Gorman RL, Tong T, Marovich M, **Neuzil K**, Corey L, Kublin JG; COVID-19 Prevention Network. Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. JAMA Netw Open. 2023 Jan 3;6(1):e2251974. doi: 10.1001/jamanetworkopen.2022.51974. PMID: 36689221.
67. Ortiz JR, Bernstein DI, Hoft DF, Woods CW, McClain MT, Frey SE, Brady RC, Bryant C, Wegel A, Frenck RW, Walter EB, Abate G, Williams SR, Atmar RL, Keitel WA, Rouphael N, Memoli MJ, Makhene MK, Roberts PC, **Neuzil KM**; Influenza Controlled Human Infection Study Group Members. A Multi-Center, Controlled Human Infection Study of Influenza A (H1N1)pdm09 in Healthy Adults. J Infect Dis. 2023 Jan 26:jiad021. doi: 10.1093/infdis/jiad021. Epub ahead of print. PMID: 36702771.
68. Follmann D, Janes HE, Chu E, Jayashankar L, Petropoulos CJ, Serebryannyy L, Carroll R, Jean-Baptiste N, Narpala S, Lin BC, McDermott A, Novak RM, Graciaa DS, Rolsma S, Magaret CA, Doria-Rose N, Corey L, **Neuzil KM**, Pajon R, Miller JM, Donis RO, Koup RA, Baden LR, El Sahly HM. Kinetics of the Antibody Response to Symptomatic SARS-CoV-2 Infection in Vaccinated and Unvaccinated Individuals in the Blinded Phase of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. Open Forum Infect Dis. 2023 Feb 13;10(3):ofad069. doi: 10.1093/ofid/ofad069. PMID: 36895286; PMCID: PMC9991588.
69. Phillips MT, Antillon M, Bilcke J, Bar-Zeev N, Limani F, Debellut F, Pecenka C, **Neuzil KM**, Gordon MA, Thindwa D, Paltiel AD, Yaesoubi R, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study. BMC Infect Dis. 2023 Mar 8;23(1):143. doi: 10.1186/s12879-023-08105-2. PMID: 36890448; PMCID: PMC9993384.
70. Benkeser D, Fong Y, Janes HE, Kelly EJ, Hirsch I, Sproule S, Stanley AM, Maaske J, Villafana T, Houchens CR, Martins K, Jayashankar L, Castellino F, Ayala V, Petropoulos CJ, Leith A, Haugaard D, Webb B, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Carpp LN, Randhawa AK, Andrasik MP, Kublin JG, Isaacs MB, Makhene M, Tong T, Robb ML, Corey L, **Neuzil KM**, Follmann D, Hoffman C, Falsey AR, Sobieszczyk M, Koup RA, Donis RO, Gilbert PB; AstraZeneca AZD1222 Clinical Study Group; Immune Assays Team; United States Government (USG)/CoVPN Biostatistics Team. Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine. NPJ Vaccines. 2023 Mar 11;8(1):36. doi: 10.1038/s41541-023-00630-0. PMID: 36899062; PMCID: PMC10005913.
71. Fong Y, Huang Y, Benkeser D, Carpp LN, Áñez G, Woo W, McGarry A, Dunkle LM, Cho I, Houchens CR, Martins K, Jayashankar L, Castellino F, Petropoulos CJ, Leith A, Haugaard D, Webb B, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Randhawa AK, Andrasik MP, Kublin JG, Hutter J, Keshtkar-Jahromi M, Beresnev TH, Corey L, **Neuzil KM**, Follmann D, Ake JA, Gay CL, Kotloff KL, Koup RA, Donis RO, Gilbert PB; Immune Assays Team; Coronavirus Vaccine Prevention Network (CoVPN)/2019nCoV-301 Principal Investigators and Study Team; United States Government (USG)/CoVPN Biostatistics Team. Publisher Correction: Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial. Nat Commun. 2023 Mar 22;14(1):1581. doi: 10.1038/s41467-023-37367-2. Erratum for: Nat Commun. 2023 Jan 19;14(1):331. PMID: 36949083; PMCID: PMC10031713.
72. Laufer RS, Baral R, Buchwald AG, Campbell JD, Coulibaly F, Diallo F, Doumbia M, Driscoll AJ, Galvani AP, Keita AM, **Neuzil KM**, Sow S, Pecenka C, Ortiz JR, Fitzpatrick MC. Optimizing next-generation RSV prevention in Mali: A cost-effectiveness analysis of pediatric vaccination, maternal vaccination, and extended half-life monoclonal antibody immunoprophylaxis. PLOS Glob Public Health. 2023 May 5;3(5):e0001432. doi: 10.1371/journal.pgph.0001432. PMID: 37145993; PMCID: PMC10162555.
73. Áñez G, Dunkle LM, Gay CL, Kotloff KL, Adelglass JM, Essink B, Campbell JD, Cloney-Clark S, Zhu M, Plested JS, Roychoudhury P, Greninger AL, Patel N, McGarry A, Woo W, Cho I, Glenn GM, Dubovsky F; 2019nCoV-301–Pediatric Expansion Study Group (including **Neuzil KM**). Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial. JAMA Netw Open. 2023 Apr 3;6(4):e239135. doi: 10.1001/jamanetworkopen.2023.9135. PMID: 37099299.
74. Benkeser D, Montefiori DC, McDermott AB, Fong Y, Janes HE, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Castellino F, Flach B, Lin BC, O'Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Borate B, van der Laan LWP, Hejazi NS, Kenny A, Carone M, Williamson BD, Garver J, Altonen E, Rudge T, Huynh C, Miller J, El Sahly HM, Baden LR, Frey S, Malkin E, Spector SA, Andrasik MP, Kublin JG, Corey L, **Neuzil KM**, Carpp LN, Pajon R, Follmann D, Donis RO, Koup RA, Gilbert PB; Immune Assays; Moderna Inc.; Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE); United States Government (USG)/CoVPN Biostatistics Teams. Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial. Sci Transl Med. 2023 Apr 19;15(692):eade9078. doi: 10.1126/scitranslmed.ade9078. Epub 2023 Apr 19. PMID: 37075127.
75. Deichsel EL, Keita AM, Verani JR, Powell H, Jamka LP, Hossain MJ, Jones JCM, Omore R, Awuor AO, Sow SO, Sanogo D, Tapia MD, **Neuzil KM**, Kotloff KL. Management of Diarrhea in Young Children in Sub-Saharan Africa: Adherence to World Health Organization Recommendations During the Global Enteric Multisite Study (2007-2011) and the Vaccine Impact of Diarrhea in Africa (VIDA) Study (2015-2018). Clin Infect Dis. 2023 Apr 19;76(76 Suppl 1):S23-S31. doi: 10.1093/cid/ciac926. PMID: 37074440; PMCID: PMC10116557.
76. Keita AM, Doh S, Sow SO, Powell H, Omore R, Jahangir Hossain M, Ogwel B, Ochieng JB, Jones JCM, Zaman SMA, Awuor AO, Juma J, Nasrin D, Liu J, Traoré A, Onwuchekwa U, Badji H, Sarwar G, Antonio M, Houpt ER, Tennant SM, Kasumba IN, Jamka LP, Roose A, Platts-Mills JA, Verani JR, Tate JE, Parashar UD, **Neuzil KM**, Kotloff KL. Prevalence, Clinical Severity, and Seasonality of Adenovirus 40/41, Astrovirus, Sapovirus, and Rotavirus Among Young Children With Moderate-to-Severe Diarrhea: Results From the Vaccine Impact on Diarrhea in Africa (VIDA) Study. Clin Infect Dis. 2023 Apr 19;76(76 Suppl1):S123-S131. doi: 10.1093/cid/ciad060. PMID: 37074439; PMCID: PMC10116545.
77. Schwartz LM, Oshinsky J, Reymann M, Esona MD, Bowen MD, Jahangir Hossain M, Zaman SMA, Jones JCM, Antonio M, Badji H, Sarwar G, Sow SO, Sanogo D, Keita AM, Tamboura B, Traoré A, Onwuchekwa U, Omore R, Verani JR, Awuor AO, Ochieng JB, Juma J, Ogwel B, Parashar UD, Tate JE, Kasumba IN, Tennant SM, **Neuzil KM**, Rowhani-Rahbar A, Elizabeth Halloran M, Atmar RL, Pasetti MF, Kotloff KL. Histo-Blood Group Antigen Null Phenotypes Associated With a Decreased Risk of Clinical Rotavirus Vaccine Failure Among Children <2 Years of Age Participating in the Vaccine Impact on Diarrhea in Africa (VIDA) Study in Kenya, Mali, and the Gambia. Clin Infect Dis. 2023 Apr 19;76(76 Suppl1):S153-S161. doi: 10.1093/cid/ciac910. PMID: 37074435; PMCID: PMC10116560.
78. Kasumba IN, Powell H, Omore R, Hossain MJ, Sow SO, Ochieng JB, Badji H, Verani JR, Widdowson MA, Sen S, Nasrin S, Permala-Booth J, Jones JA, Roose A, Nasrin D, Sugerman CE, Juma J, Awuor A, Jones JCM, Doh S, Okoi C, Zaman SMA, Antonio M, Hunsperger E, Onyango C, Platts-Mills J, Liu J, Houpt E, **Neuzil KM**, Kotloff KL, Tennant SM. Prevalence of Salmonella in Stool During the Vaccine Impact on Diarrhea in Africa (VIDA) Study, 2015-2018. Clin Infect Dis. 2023 Apr 19;76(76 Suppl1):S87-S96. doi: 10.1093/cid/ciac985. PMID: 37074429; PMCID: PMC10116559.
79. Powell H, Liang Y, **Neuzil KM**, Jamka LP, Nasrin D, Sow SO, Hossain MJ, Omore R, Kotloff KL. A Description of the Statistical Methods for the Vaccine Impact on Diarrhea in Africa (VIDA) Study. Clin Infect Dis. 2023 Apr 19;76(76 Suppl 1):S5-S11. doi: 10.1093/cid/ciac968. PMID: 37074428; PMCID: PMC10116558.
80. Ortiz JR, Laufer RS, Brunwasser SM, Coulibaly F, Diallo F, Doumbia M, Driscoll AJ, Fell DB, Haidara FC, Hartert TV, Keita AM, **Neuzil KM**, Snyder BM, Sow S, Fitzpatrick MC. Model-estimated impacts of pediatric respiratory syncytial virus prevention programs in Mali on asthma prevalence. J Allergy Clin Immunol Glob. 2023 May;2(2):100092. doi: 10.1016/j.jacig.2023.100092. PMID: 37215432; PMCID: PMC10193369.
81. Branche A, Rouphael N, Diemert D, Falsey A, Losada C, Baden LR, Frey S, Whitaker J, Little S, Anderson E, Walter E, Novak R, Rupp R, Jackson L, Babu T, Kottkamp A, Luetkemeyer A, Immergluck L, Presti R, Backer M, Winokur P, Mahgoub S, Goepfert P, Fusco D, Malkin E, Bethony J, Walsh E, Graciaa D, Samaha H, Sherman A, Walsh S, Abate G, Oikonomopoulou Z, Sahly HE, Martin T, Kamidani S, Smith M, Ladner B, Porterfield L, Dunstan M, Wald A, Davis T, Atmar R, Mulligan M, Lyke K, Posavad C, Meagher M, Stephens D, **Neuzil K**, Abebe K, Hill H, Albert J, Telu K, Mu J, Lewis T, Giebeig L, Eaton A, Netzl A, Wilks S, Tureli S, Makhene M, Crandon S, Montefiori D, Makowski M, Smith D, Nayak S, Roberts P, Beigel J. Bivalent and Monovalent SARS-CoV-2 Variant Vaccine Boosters Improve coverage of the known Antigenic Landscape: Results of the COVID-19 Variant Immunologic Landscape (COVAIL) Trial. Res Sq [Preprint]. 2023 May 5:rs.3.rs-2653179. doi: 10.21203/rs.3.rs-2653179/v1. PMID: 37205592; PMCID: PMC10187423.
82. Birkhold M, Datta S, Pak GD, Im J, Ogundoyin OO, Olulana DI, Lawal TA, Afuwape OO, Kehinde A, Phoba MF, Nkoji G, Aseffa A, Teferi M, Yeshitela B, Popoola O, Owusu M, Nana LRW, Cakpo EG, Ouedraogo M, Ouangre E, Ouedraogo I, Heroes AS, Jacobs J, Mogeni OD, Haselbeck A, Sukri L, **Neuzil KM,** Metila OL, Owusu-Dabo E, Adu-Sarkodie Y, Bassiahi AS, Rakotozandrindrainy R, Okeke IN, Zellweger RM, Marks F. Characterization of Typhoid Intestinal Perforation in Africa: Results From the Severe Typhoid Fever Surveillance in Africa Program. Open Forum Infect Dis. 2023 Jun 2;10(Suppl 1):S67-S73. doi: 10.1093/ofid/ofad138. PMID: 37274524; PMCID: PMC10236516.
83. Munoz FM, Posavad CM, Richardson BA, Badell ML, Bunge KE, Mulligan MJ, Parameswaran L, Kelly CW, Olson-Chen C, Novak RM, Brady RC, Pasetti MF, Defranco EA, Gerber JS, Shriver MC, Suthar MS, Coler RN, Berube BJ, Kim SH, Piper JM, Miller AM, Cardemil CV, **Neuzil KM**, Beigi RH; DMID 21-0004 Study Group. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn. Vaccine. 2023 Jun 13:S0264-410X(23)00698-9. doi: 10.1016/j.vaccine.2023.06.032. Epub ahead of print. PMID: 37451878; PMCID: PMC10261713.
84. Turley CB, Tables L, Fuller T, Sanders LJ, Scott H, Moodley A, Woodward Davis A, Leav B, Miller J, Schoemaker K, Vandebosch A, Sadoff J, Woo W, Cho I, Dunkle LM, Li S, van der Laan L, Gilbert PB, Follmann D, Jaynes H, Kublin JG, Baden LR, Goepfert P, Kotloff K, Gay CL, Falsey AR, El Sahly HM, Sobieszczyk ME, Huang Y, **Neuzil KM**, Corey L, Grinsztejn B, Gray G, Rouphael N, Luedtke A; COVID-19 Prevention Network CoVPN. Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials. Vaccine. 2023 Jun 23:S0264-410X(23)00755-7. doi: 10.1016/j.vaccine.2023.06.066. Epub ahead of print. PMID: 37385888; PMCID: PMC10288314.
85. Theodore DA, Branche AR, Zhang L, Graciaa DS, Choudhary M, Hatlen TJ, Osman R, Babu TM, Robinson ST, Gilbert PB, Follmann D, Janes H, Kublin JG, Baden LR, Goepfert P, Gray GE, Grinsztejn B, Kotloff KL, Gay CL, Leav B, Miller J, Hirsch I, Sadoff J, Dunkle LM, **Neuzil KM**, Corey L, Falsey AR, El Sahly HM, Sobieszczyk ME, Huang Y; COVID-19 Prevention Network (CoVPN). Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults: A Secondary Cross-Protocol Analysis of 4 Randomized Clinical Trials. JAMA Netw Open. 2023 Jul 3;6(7):e2323349. doi: 10.1001/jamanetworkopen.2023.23349. PMID: 37440227; PMCID: PMC10346130.
86. Lyke KE, Atmar RL, Dominguez Islas C, Posavad CM, Deming ME, Branche AR, Johnston C, El Sahly HM, Edupuganti S, Mulligan MJ, Jackson LA, Rupp RE, Rostad CA, Coler RN, Bäcker M, Kottkamp AC, Babu TM, Dobrzynski D, Martin JM, Brady RC, Frenck RW Jr, Rajakumar K, Kotloff K, Rouphael N, Szydlo D, PaulChoudhury R, Archer JI, Crandon S, Ingersoll B, Eaton A, Brown ER, McElrath MJ, **Neuzil KM**, Stephens DS, Post DJ, Lin BC, Serebryannyy L, Beigel JH, Montefiori DC, Roberts PC; DMID 21-0012 Study Group. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants. NPJ Vaccines. 2023 Jul 11;8(1):98. doi: 10.1038/s41541-023-00693-z. PMID: 37433788; PMCID: PMC10336079.
87. El Sahly HM, Yildirim I, Frey SE, Winokur P, Jackson LA, Bernstein DI, Creech CB, Chen WH, Rupp RE, Whitaker JA, Phadke V, Hoft DF, Ince D, Brady RC, Edwards KM, Ortiz JR, Berman MA, Weiss J, Wegel A; DMID 17-0090 Study Group (including **Neuzil KM**). Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial. J Infect Dis. 2023 Jul 19:jiad276. doi: 10.1093/infdis/jiad276. Epub ahead of print. PMID: 37466221.
88. Ortiz JR, Bernstein DI, Hoft DF, Woods CW, McClain MT, Frey SE, Brady RC, Bryant C, Wegel A, Frenck RW, Walter EB, Abate G, Williams SR, Atmar RL, Keitel WA, Rouphael N, Memoli MJ, Makhene MK, Roberts PC, **Neuzil KM**. A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy Adults. J Infect Dis. 2023 Aug 11;228(3):287-298. doi: 10.1093/infdis/jiad021. PMID: 36702771; PMCID: PMC10420403.
89. Munoz FM, Posavad CM, Richardson BA, Badell ML, Bunge K, Mulligan MJ, Parameswaran L, Kelly C, Olsen-Chen C, Novak RM, Brady RC, Pasetti M, DeFranco E, Gerber JS, Shriver M, Suthar MS, Moore K, Coler R, Berube B, Kim SH, Piper JM, Miller A, Cardemil C, **Neuzil KM,** Beigi R; DMID Study Group. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn (DMID 21-0004). medRxiv [Preprint]. 2022 Jun 13:2022.06.13.22276354. doi: 10.1101/2022.06.13.22276354. Update in: Vaccine. 2023 Jun 13;: PMID: 35734087; PMCID: PMC9216723.
90. Carey ME, Dyson ZA, Ingle DJ, Amir A, Aworh MK, Chattaway MA, Chew KL, Crump JA, Feasey NA, Howden BP, Keddy KH, Maes M, Parry CM, Van Puyvelde S, Webb HE, Afolayan AO, Alexander AP, Anandan S, Andrews JR, Ashton PM, Basnyat B, Bavdekar A, Bogoch II, Clemens JD, da Silva KE, De A, de Ligt J, Diaz Guevara PL, Dolecek C, Dutta S, Ehlers MM, Francois Watkins L, Garrett DO, Godbole G, Gordon MA, Greenhill AR, Griffin C, Gupta M, Hendriksen RS, Heyderman RS, Hooda Y, Hormazabal JC, Ikhimiukor OO, Iqbal J, Jacob JJ, Jenkins C, Jinka DR, John J, Kang G, Kanteh A, Kapil A, Karkey A, Kariuki S, Kingsley RA, Koshy RM, Lauer AC, Levine MM, Lingegowda RK, Luby SP, Mackenzie GA, Mashe T, Msefula C, Mutreja A, Nagaraj G, Nagaraj S, Nair S, Naseri TK, Nimarota-Brown S, Njamkepo E, Okeke IN, Perumal SPB, Pollard AJ, Pragasam AK, Qadri F, Qamar FN, Rahman SIA, Rambocus SD, Rasko DA, Ray P, Robins-Browne R, Rongsen-Chandola T, Rutanga JP, Saha SK, Saha S, Saigal K, Sajib MSI, Seidman JC, Shakya J, Shamanna V, Shastri J, Shrestha R, Sia S, Sikorski MJ, Singh A, Smith AM, Tagg KA, Tamrakar D, Tanmoy AM, Thomas M, Thomas MS, Thomsen R, Thomson NR, Tupua S, Vaidya K, Valcanis M, Veeraraghavan B, Weill FX, Wright J, Dougan G, Argimón S, Keane JA, Aanensen DM, Baker S, Holt KE; Global Typhoid Genomics Consortium Group Authorship (**including Neuzil, KM).** Global diversity and antimicrobial resistance of typhoid fever pathogens: Insights from a meta-analysis of 13,000 Salmonella Typhi genomes. Elife. 2023 Sep 12;12:e85867. doi: 10.7554/eLife.85867. PMID: 37697804; PMCID: PMC10506625.
91. Ouedraogo A, Diarra A, Nébié I, Barry N, Kabore JM, Tiono AB, Datta S, Liang Y, Mayo I, Oshinsky JJ, Tracy JK, Girmay T, Pasetti MF, Jamka LP, **Neuzil KM**, Sirima SB, Laurens MB. Durable Anti-Vi IgG and IgA Antibody Responses in 15-Month-Old Children Vaccinated With Typhoid Conjugate Vaccine in Burkina Faso. J Pediatric Infect Dis Soc. 2023 Sep 27;12(9):513-518. doi: 10.1093/jpids/piad058. PMID: 37589596; PMCID: PMC10533206.
92. Fitzpatrick MC, Laufer RS, Baral R, Driscoll AJ, Feikin DR, Fleming JA, Jit M, Kim S, Koltai M, Li Y, Li X, Nair H, **Neuzil KM**, Pecenka C, Sparrow E, Srikantiah P, Ortiz JR. Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022. Vaccine. 2023 Sep 28:S0264-410X(23)01110-6. doi: 10.1016/j.vaccine.2023.09.040. Epub ahead of print. PMID: 37777450.
93. Huang Y, Hejazi NS, Blette B, Carpp LN, Benkeser D, Montefiori DC, McDermott AB, Fong Y, Janes HE, Deng W, Zhou H, Houchens CR, Martins K, Jayashankar L, Flach B, Lin BC, O'Connell S, McDanal C, Eaton A, Sarzotti-Kelsoe M, Lu Y, Yu C, Kenny A, Carone M, Huynh C, Miller J, El Sahly HM, Baden LR, Jackson LA, Campbell TB, Clark J, Andrasik MP, Kublin JG, Corey L, **Neuzil KM**, Pajon R, Follmann D, Donis RO, Koup RA, Gilbert PB, On Behalf Of The Immune Assays, Moderna Inc, Coronavirus Vaccine Prevention Network CoVPN/Coronavirus Efficacy Cove, United States Government Usg/CoVPN Biostatistics Teams. Stochastic Interventional Vaccine Efficacy and Principal Surrogate Analyses of Antibody Markers as Correlates of Protection against Symptomatic COVID-19 in the COVE mRNA-1273 Trial. Viruses. 2023 Sep 29;15(10):2029. doi: 10.3390/v15102029. PMID: 37896806; PMCID: PMC10612023.
94. Branche AR, Rouphael NG, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Anderson EJ, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Malkin E, Bethony JM, Walsh EE, Graciaa DS, Samaha H, Sherman AC, Walsh SR, Abate G, Oikonomopoulou Z, El Sahly HM, Martin TCS, Kamidani S, Smith MJ, Ladner BG, Porterfield L, Dunstan M, Wald A, Davis T, Atmar RL, Mulligan MJ, Lyke KE, Posavad CM, Meagher MA, Stephens DS, **Neuzil KM**, Abebe K, Hill H, Albert J, Telu K, Mu J, Lewis TC, Giebeig LA, Eaton A, Netzl A, Wilks SH, Türeli S, Makhene M, Crandon S, Montefiori DC, Makowski M, Smith DJ, Nayak SU, Roberts PC, Beigel JH; COVAIL Study Group. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. Nat Med. 2023 Sep;29(9):2334-2346. doi: 10.1038/s41591-023-02503-4. Epub 2023 Aug 28. PMID: 37640860; PMCID: PMC10504073.
95. Rick AM, Laurens MB, Huang Y, Yu C, Martin TCS, Rodriguez CA, Rostad CA, Maboa RM, Baden LR, El Sahly HM, Grinsztejn B, Gray GE, Gay CL, Gilbert PB, Janes HE, Kublin JG, Huang Y, Leav B, Hirsch I, Struyf F, Dunkle LM, **Neuzil KM**, Corey L, Goepfert PA, Walsh SR, Follmann D, Kotloff KL; NIAID-funded COVID-19 Prevention Network (CoVPN). Risk of COVID-19 after natural infection or vaccination. EBioMedicine. 2023 Oct;96:104799. doi: 10.1016/j.ebiom.2023.104799. Epub 2023 Sep 20. PMID: 37738833; PMCID: PMC10518569.
96. Dayan GH, Rouphael N, Walsh SR, Chen A, Grunenberg N, Allen M, Antony J, Asante KP, Bhate AS, Beresnev T, Bonaparte MI, Celle M, Ceregido MA, Corey L, Dobrianskyi D, Fu B, Grillet MH, Keshtkar-Jahromi M, Juraska M, Kee JJ, Kibuuka H, Koutsoukos M, Masotti R, Michael NL, **Neuzil KM**, Reynales H, Robb ML, Villagómez Martínez SM, Sawe F, Schuerman L, Tong T, Treanor J, Wartel TA, Diazgranados CA, Chicz RM, Gurunathan S, Savarino S, Sridhar S; VAT00008 Study Team. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial. Lancet Respir Med. 2023 Nov;11(11):975-990. doi: 10.1016/S2213-2600(23)00263-1. Epub 2023 Sep 13. PMID: 37716365.
97. Fitzpatrick MC, Laufer RS, Baral R, Driscoll AJ, Feikin DR, Fleming JA, Jit M, Kim S, Koltai M, Li Y, Li X, Nair H, **Neuzil KM,** Pecenka C, Sparrow E, Srikantiah P, Ortiz JR. Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022. Vaccine. 2023 Nov 22;41(48):7047-7059. doi: 10.1016/j.vaccine.2023.09.040. Epub 2023 Sep 28. PMID: 37777450; PMCID: PMC10680976.
98. Meiring JE, Khanam F, Basnyat B, Charles RC, Crump JA, Debellut F, Holt KE, Kariuki S, Mugisha E, **Neuzil KM**, Parry CM, Pitzer VE, Pollard AJ, Qadri F, Gordon MA. Typhoid fever. Nat Rev Dis Primers. 2023 Dec 14;9(1):71. doi: 10.1038/s41572-023-00480-z. PMID: 38097589.
99. Jackson LA, Stapleton JT, Walter EB, Chen WH, Rouphael NG, Anderson EJ, **Neuzil KM**, Winokur PL, Smith MJ, Schmader KE, Swamy GK, Thompson AB, Mulligan MJ, Rostad CA, Cross K, Tsong R, Wegel A, Roberts PC. Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults. Vaccine. 2024 Jan 12;42(2):295-309. doi: 10.1016/j.vaccine.2023.12.001. Epub 2023 Dec 16. PMID: 38105137; PMCID: PMC10790638.
100. Patel PD, Liang Y, Meiring JE, Chasweka N, Patel P, Misiri T, Mwakiseghile F, Wachepa R, Banda HC, Shumba F, Kawalazira G, Dube Q, Nampota-Nkomba N, Nyirenda OM, Girmay T, Datta S, Jamka LP, Tracy JK, Laurens MB, Heyderman RS, **Neuzil KM**, Gordon MA; TyVAC team. Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children. Lancet. 2024 Feb 3;403(10425):459-468. doi: 10.1016/S0140-6736(23)02031-7. Epub 2024 Jan 25. PMID: 38281499; PMCID: PMC10850983.

**Editorials, commentaries, and reviews**

1. **Neuzil KM**. Upper-extremity involvement in giant cell arteritis. Intern Med 1992:13:36-38.
2. **Neuzil KM**. Pharmacologic therapy for human immunodeficiency virus infection: a review. Amer J Med Sci 1994; 307: 368-373.
3. **Neuzil KM**, Graham BS. Cytokine Release and Innate Immunity in Respiratory Viral Infection, Semin Virol 1996; 7: 255-264.
4. **Neuzil KM**. Influenza: New insights into an old disease. Current Infect Dis Reports, 2000; 2: 224-230.
5. **Neuzil KM**. Influenza: A disease for all ages. Inside Influenza 2001;1: 1-7. (CME activity).
6. **Neuzil KM**. Influenza vaccine for children with asthma: Why no progress? (Invited editorial). J Pediatr 2001; 138: 301-3.
7. **Neuzil KM**, Griffin MR, Schaffner WS. Influenza vaccine: Issues and opportunities. Infectious Disease Clinics of North America 2001; 15: 35-52.
8. **Neuzil KM**. Treatment of influenza virus infection. Current Treatment Opin in Infect Dis 2002;4:37-42.
9. **Neuzil KM**. Safety of inactivated influenza vaccine in adults and children with asthma. J Pediatr 2002; 140: 632.
10. **Neuzil KM**, Edwards KM. Influenza vaccines in children. Semin Pediatr Infec Dis 2002; 13: 165-173.
11. Griffin MR, **Neuzil KM**. The global implications of influenza in Hong Kong. N Engl J Med 2002; 347:2159-62.
12. Jackson LA, **Neuzil KM**. Book Notes: The Vaccine Handbook: A Practical Guide for Clinicians. Ann Intern Med 2004; 140:76.
13. **Neuzil KM**. Influenza vaccines for children. Clin Infect Dis 2004; 38: 689-91.
14. **Neuzil KM**, Griffin MR. Vaccine safety: Achieving the proper balance. JAMA 2005; 294: 2763-5.
15. **Neuzil KM**, Englund JA. Influenza vaccines for children- Two doses are better than one. J Pediatr. 2006; 149: 737-8.
16. Levi J, **Neuzil KM**, Cimons M. Pandemic Influenza: The State of the Science. Trust for America’s Health/IDSA October 2006.
17. **Neuzil KM**. Book Reviews. State of Immunity. New Engl J Med 2007;356: 2117.
18. Patel MM, Widdowson MA, Cortese MM, Gentsch JR, Glass RI, Parashar UD, **Neuzil KM**, Steele AD. Generic protocol for monitoring impact of rotavirus vaccination on rotavirus disease burden and viral rotavirus strains, WHO/IVB/08.16, December 2008.
19. **Neuzil KM**, Bright, RA, Influenza Vaccine Manufacture: Keeping Up with Change. J Infect Dis. 2009; 200(6):835-7.
20. **Neuzil, KM**. Pandemic influenza vaccine policy—considering the early evidence. N Engl J Med. 2009;361(25):e59.
21. Fiore AE, **Neuzil KM**. 2009 influenza A(H1N1) monovalent vaccines for children. JAMA. 2010 Jan 6;303(1):73-4.
22. **Neuzil KM**, Armah GE, Parashar UD, Steele AD. Rotavirus in Africa: shifting the focus to disease prevention. J Infect Dis. 2010 Sep 1;202 Suppl:S1-4.
23. Ortiz JR, **Neuzil KM**. The promise of maternal vaccination to prevent influenza in young infants. Arch Pediatr Adolesc Med. 2011 Feb;165(2):179-80.
24. **Neuzil KM**. Influenza vaccines: New options and new opportunities. J Infect Dis 2012; 205: 700 - 1.
25. **Neuzil KM**. Influenza vaccination in 2013-2014: achieving 100% participation. JAMA. 2013 Oct 23;310(16):1681-2.
26. **Neuzil KM**, Victor JC. Editorial commentary: annual studies of influenza vaccine effectiveness: evaluating performance, informing policy, and generating new questions. Clin Infect Dis. 2014 Feb;58(3):328-9.
27. **Neuzil KM**. How Can We Solve the Enigma of Influenza Vaccine-Induced Protection? J Infect Dis. 2015 May 15;211(10):1517-8.
28. **Neuzil KM,** Kotloff KL. Community-acquired diarrhea in a world with rotavirus vaccine: a glimpse into the future. Lancet Global Health.2015 Sep;3(9):e510-1.
29. Ortiz JR, **Neuzil KM**, Cooke CR. Comment on “The burden of influenza- associated critical illness hospitalizations” [Crit Care Med. 2014] and “Influenza and other respiratory viruses are underdiagnosed in critically ill patients” [Crit Care Med. 2015 Apr;43(4):e118.
30. **Neuzil KM.** [Progress toward a Respiratory Syncytial Virus Vaccine.](http://www.ncbi.nlm.nih.gov/pubmed/26818954) Clin Vaccine Immunol. 2016 Jan 27;23(3):186-8.
31. **Neuzil KM**. The Art and Science of Delivering Influenza Vaccines. J Infect Dis. 2016 Oct 15;214(8):1129-31.
32. Neuzil **KM,** Griffin MR. Herpes Zoster and its complications in older adults. New

Engl J Med. 2016 Sept 15;375(11):1079-80.

1. Rotrosen ET, **Neuzil KM**. Influenza: A global perspective. Pediatr Clin North Am. 2017 Aug;64(4):911-936.
2. **Neuzil KM**, WC. Influenza Vaccines for Older Persons: Progress and Pitfalls. J Infect Dis. 2017 Aug 15;216(4):397-398.
3. Ortiz JR, **Neuzil KM**. Influenza vaccine for pregnant women in resource-constrained countries: an update for funding and implementation decisions. Curr Opin Infect Dis. 2017 Oct;30(5):455-462.
4. Sow SA, Steele AD, Mwenda JM, Armah GE, **Neuzil KM**. Reaching every child with rotavirus vaccine: Report from the 10th African rotavirus symposium held in Bamako, Mali. Vaccine 2017 Oct 9;35(42):5511-18.
5. **Neuzil KM**. Commentary: Quantifying the Impact of Maternal Influenza Vaccination-Beyond Laboratory-Confirmed Efficacy. Pediatr Infect Dis J. 2018 May;37(5):441-442. doi: 10.1097/INF.0000000000001967. PMID: 29485522.
6. Schaffner W, Chen WH, Hopkins RH, **Neuzil K**. Effective immunization of older adults against seasonal influenza. Am J Med. 2018 Aug;131(8);865-873.
7. **Neuzil KM**, Rotrosen ET. How do we best prevent influenza in young children? Lancet Respir Med. 2018: 6: 317-319.
8. **Neuzil KM,** Fitzpatrick MC**.** The impact of influenza vaccine: It’s the size of the glass. Clin Infect Dis 2019 March 5; 69 (11): 1854-1855.
9. Pollard AJ, Marfin AA, **Neuzil KM**. The time is now to control typhoid. Clin Infect Dis. 2019 March 7;68(Supplement\_2):S47-S49. doi:10.1093/cid/ciy1115.
10. **Neuzil KM**, Basnyat B, Clemens JD, Gordon MA, Patel PD, Pollard AJ, Shakya M, Qadri F. Early Insights From Clinical Trials of Typhoid Conjugate Vaccine. Clin Infect Dis. 2020 Jul 29;71(Suppl 2):S155-S159. doi: 10.1093/cid/ciaa370. PMID:32725230; PMCID: PMC7388715.
11. **Neuzil KM**, [Interplay between Emerging SARS-CoV-2 Variants and Pandemic Control.](https://pubmed.ncbi.nlm.nih.gov/33951359/) N Engl J Med. 2021 May 20; 384(20):1952-1954. doi: 10.1056/NEJMe2103931. Epub 2021 May 5.PMID: 33951359.
12. Ortiz JR**, Neuzil KM.** Lancet. 2021 Nov 3:S0140-6736(21)02322-9. doi: 10.1016/S0140-6736(21)02322-9. Online ahead of print.PMID: 34741819.
13. **Neuzil KM**. Prevention and Control of Coronavirus Disease 2019: Where Do We Go From Here? Clin Infect Dis. 2022 Aug 24;75(1):e692-e694. doi: 10.1093/cid/ciac090. PMID: 35134147; PMCID: PMC890338.
14. Edwards KM, **Neuzil KM**. Developing mucosal vaccines for SARS-CoV-2: What will it take? Clin Infect Dis. 2022 Dec 9:ciac935. doi: 10.1093/cid/ciac935. Epub ahead of print. PMID: 36482757.
15. **Neuzil KM**. Enteric Fever - Tools for Prevention. N Engl J Med. 2023 Apr 20;388(16):1526-1528. doi: 10.1056/NEJMe2300753. PMID: 37075145.
16. Nampota-Nkomba N, Carey ME, Jamka LP, Fecteau N, **Neuzil KM**. Using Typhoid Conjugate Vaccines to Prevent Disease, Promote Health Equity, and Counter Drug-Resistant Typhoid Fever. Open Forum Infect Dis. 2023 Jun 2;10(Suppl 1):S6-S12. doi: 10.1093/ofid/ofad022. PMID: 37274532; PMCID: PMC10236511.
17. Coughlan L, **Neuzil KM**. Outpacing antiviral resistance: new treatments for influenza virus infection. Lancet Infect Dis. 2024 Feb 5:S1473-3099(23)00820-4. doi: 10.1016/S1473-3099(23)00820-4. Epub ahead of print. PMID: 38330976.

**Book Chapters**

1. Morrow JM, **Neuzil KM**. Pharmacology of antimicrobial agents used in the therapy of gastrointestinal infections. Chapter 89 In: Infections of the Gastrointestinal Tract. Blaser MJ, Smith PD, Ravdin JI, Greenberg HB, Guerrant RL, eds. Raven Press, New York, 1995, 1345-84.
2. **Neuzil KM**, Wright PF. Respiratory Viruses. In: Textbook of Internal Medicine Third Edition. William N. Kelley, ed. Lippincott-Raven, New York, 1997, 1751 - 1757.
3. **Neuzil KM**, Rubin DH. Human Herpesviruses 6, 7, and 8. In: Infectious Diseases Second Edition. Gorbach SL, Bartlett JG, Blacklow NR, eds. W. B. Saunders Company, Philadelphia, 1998.
4. Rubin DH, **Neuzil KM**. Human Herpesviruses 6, 7, and 8. In: Infectious Diseases Third Edition. Gorbach SL, Bartlett JG, Blacklow NR, eds. W. B. Saunders Company, Philadelphia, 2004.
5. Wright PF, **Neuzil KM**. Influenza Viruses. In: Infectious Diseases Third Edition. Gorbach SL, Bartlett JG, Blacklow NR, eds. W. B. Saunders Company, Philadelphia, 2004.
6. Jackson LA, **Neuzil KM**. Pneumococcal polysaccharide vaccine. In: Vaccines. Plotkin and Orenstein. 2007.
7. Keitel WA, **Neuzil KM**, Treanor J. Immunogenicity and efficacy of inactivated/live virus seasonal and pandemic vaccines. In: Textbook of Influenza. Second Edition. Wester RG, Monto AS, Braciale TJ, Lamb RS,eds. Wiley Blackwell, West Sussex, UK, 2013.
8. **Neuzil KM**, Ortiz JS. Influenza Vaccines. In: The Vaccine Book. Second Edition. Bloom BR, Lambert P, eds. Academic Press, 2016.
9. **Neuzil KM,** Wright PF. Influenza Vaccines. In: Harrison’s Principles of Internal Medicine. 21st Edition. 2021.
10. **Neuzil, KM** . Lessons Learned: Stories from Women Physician Leaders. American Association for Physician Leadership, February 28, 2022.
11. Levine MM, **Neuzil KM**, Pollard AJ. Typhoid fever vaccines. In: Vaccines 8th Edition. Orenstein, Offit, Edwards and Plotkin. 2023. Elsevier Books.
12. Gandhi RT, **Neuzil KM**. COVID-19 Treatment and Vaccination. In: Goldman-Cecil Medicine, 27th Edition. Goldman and Cooney. 2023 Elsevier Books.

**Major Invited Speeches (since 1998)**

**Local**

1. Department of Medicine Grand Rounds, University of Washington, “Influenza 1999: Challenges and Controversies,” September 9, 1999.
2. Swedish Medical Center Grand Rounds, “Influenza Update,” September 16, 1999.
3. Department of Pediatrics Grand Rounds, University of Washington, Children’s Hospital, “Preventing influenza in children: controversies and challenges,” October 21, 1999.
4. Providence Medical Center CME Series, “Disease Prevention in Nursing Homes – Focus on Influenza,” October 23, 1999.
5. Swedish Medical Center Grand Rounds, “Immunization Update,” March 9, 2000.
6. State of Washington Immunization Action Coalition, Children’s Hospital, “Influenza in Children,” June 14, 2000.
7. Pacific Northwest Conference for Primary Care Practitioners, sponsored by the University of Washington School of Nursing, “The Brave New World of Influenza,” September 28, 2000.
8. Current Concepts in Drug Therapy Course, sponsored by the University of Washington Department of Medicine, “Adult Immunizations,” November 2, 2000.
9. King County Medical Society Historical Committee “Adult Immunizations: Past and Present,” December 13, 2000.
10. Auburn Regional Medical Center CME Series. “The In and Out of Hospital Pneumonias,” June 26, 2001.
11. Group Health Cooperative of Puget Sound Center for Health Studies. “Measuring influenza morbidity in populations: a recurring problem.” June 26, 2001.
12. Virginia Mason Medical Center Grand Rounds “Influenza 2001: Challenges and controversies,” October 5, 2001.
13. Polyclinic Grand Rounds, Seattle, WA “Influenza Vaccine: Issues for 2001,” October 9, 2001.
14. Plenary speaker, Washington State ACP-ASIM Annual Meeting, Seattle, WA “Adult immunization update,” October 19, 2001.
15. State of Washington Immunization Action Coalition, Children’s Hospital. “Influenza vaccine for persons with asthma.” January 23, 2002.
16. Providence St. Peter Hospital’s Immunization Update, Olympia, WA “Influenza: Is it time for universal immunization?” November 2, 2002.
17. Department of Medicine Grand Rounds, University of Washington, “Influenza: Here, There and Everywhere,” February 20, 2003.
18. Pacific Northwest Dermatology Conference, Skamania, WA. “Herpes zoster: new insights into epidemiology, treatment and prevention,” July 12, 2003.
19. Virginia Mason Medical Center Grand Rounds: “Influenza: History Repeats Itself,” February 6, 2004.
20. Keynote speaker. Infection Control for a New Age, Yakima, WA “Vaccine-preventable viral diseases: Past, Present and Future,” April 30, 2004.
21. Faculty, Public Health Seattle-King County Immunization and Communicable Disease Update 2004. “Influenza in Children,” June 9-10, 2004.
22. Invited speaker. Influenza vaccination programs during an influenza vaccine shortage. Immunization Action Coalition of Washington. October 20, 2004.
23. Invited speaker, Respiratory Viral Infections, Kapi’olani Medical Center, Honolulu, HI. “Influenza – Population impact of the disease” and “Changing recommendations for influenza vaccination,” November 20, 2004.
24. Invited Speaker, 20th Annual Infectious Disease Conference, Providence Everett Medical Center, “Influenza and SARS,” Seattle, WA, December 11, 2004.
25. Department of Medicine Grand rounds, University of Washington, “The Fragile State of Influenza control,” February 3, 2005.
26. Invited Speaker, “Respiratory etiquette in ambulatory care,” ADA Primary Care Update, Seattle, WA, April 28, 2005.
27. Invited Speaker, “Seasonal and pandemic influenza,” AAFP Board Review Course, Seattle, WA, June 27, 2006.
28. Invited Panelist, “HPV Vaccine: Issues for Introduction,” University of Washington AIDS and STD Research Symposium, Seattle, WA, December 11, 2006.
29. Department of Medicine Grand rounds, University of Washington, “Varicella Vaccines Across the Lifespan,” February 3, 2006.
30. Women’s Business Exchange Forum, “Global Health: Passion, Persistence and Partnerships,” Seattle, WA, January 11, 2007.
31. Panel Member, “Pandemic Influenza: Are We Ready,” City Club, Seattle, WA, February 14, 2007.
32. Invited Speaker, Fred Hutchinson Cancer Research Institute, VIDI Lecture Series, “Rotavirus Vaccines for the Developing World: Are We There Yet?”, Seattle, WA, October 31, 2008.
33. Invited Speaker, Infectious Diseases Society of Washington Fall Meeting, “Influenza Vaccination: Will Current Strategies Carry Us Into the Future?”, November 19, 2008, Seattle, WA.
34. Moderator, Washington Global Health Alliance, Discovery Series, “Vaccines: A Panel Discussion,” January 22, 2009, Seattle, WA.
35. Invited Speaker, “Influenza at the animal-human interface” Zoo Venture Dinner, Woodland Park Zoo, Seattle, WA, June 4, 2009.
36. Invited Speaker and Panelist, Medical Response to Infectious Disease Outbreaks and Public Health Emergencies, “Pandemic Influenza: From Preparedness to Action,” University of Washington, Seattle, WA, September 25, 2009.
37. Invited Panelist, Infectious Diseases Society of Washington Fall Meeting, “Pandemic Influenza,” Seattle, WA, November 4, 2009.
38. Invited Speaker, “H1N1 Influenza,” Washington Vaccine Alliance (WAVA) Vaccine Development Forum, Seattle, WA, March 31, 2010.
39. Invited speaker, “Vaccines and Equity”, Disease and Social Responsibility, Seattle Preparatory School April 29, 2010.
40. Invited speaker, “Meningitis and rotavirus vaccines for low resource populations”, Pierce Country Immunization Coalition Symposium, Tacoma, WA March 1, 2012.
41. Invited speaker, “Vaccines for low resource populations”, Disease and Social Responsibility, Seattle Preparatory School April 19, 2013.
42. Invited speaker, “Vaccine value chain: Development to delivery. Case study: Japanese encephalitis vaccines.” Seattle Global Health Ambassador event. Bill and Melinda Gates Foundation, Seattle, WA. June 27, 2014.
43. Invited speaker, “Rotavirus vaccines in low resource countries: What challenges remain?” Fred Hutchinson Cancer Center Vaccines and Infectious Diseases Seminar, Seattle, WA, October 14, 2014.
44. Keynote speaker, “HPV vaccines for low resource settings: Overcoming challenges with innovation”. 2014 STD & AIDS Research Symposium, University of Washington, Seattle, WA October 29, 2014.
45. Speaker, Board of Directors, University of Maryland Medical System, “Vaccine Research: A Powerful Tool to Achieve Health Equity,” Baltimore, MD, March 9, 2016.
46. Department of Internal Medicine Grand Rounds, MedStar Harbor Hospital, “Influenza Vaccine: New Options, New Opportunities,” Baltimore, MD, April 29, 2016.
47. Invited speaker, “Vaccine Research: A Powerful Tool to Achieve Health Equity.” The University of Maryland School of Medicine Board of Visitors, Baltimore, MD, Sept. 27, 2016.
48. Invited Panelist, Zika Global to Local: Addressing the Epidemic from and International and Interprofessional Lens, University of Maryland, Baltimore, MD, February 15, 2017.
49. Invited Panelist, The Dean’s Research Strategy Forum, University of Maryland, Baltimore, MD, May 1, 2017.
50. Invited Speaker, “Success in science and global health: persistence, partnerships, passion”, STEM Graduate and Professional School Forum, Morgan State University, Baltimore, MD, September 21, 2017.
51. Session Co-Chair, “Session E: Public Health Science and Responses – From Local to Global”, 19th Annual International Meeting of the Institute of Human Virology, Baltimore, MD, October 24, 2017.
52. Invited Speaker, “Typhoid Vaccine Acceleration Consortium”, Tropical Medicine Dinner Club Talk, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, November 1, 2017.
53. Symposium Organizer and Moderator, “Controlling Typhoid Disease: New Insights on Vaccines and Vaccination Strategies”, 26th Annual Meeting American Society of Tropical Medicine & Hygiene, Baltimore, MD, November 8, 2017.
54. Invited speaker. “Influenza”. Global Virology Network 2018 Short Course in Virology. Baltimore, MD August 8, 2018.
55. Webinar presenter. “Updates from October 2018 ACIP Meeting”, National Foundation for Infectious Diseases Webinar, November 6, 2018.
56. Invited Panelist, “Women in Medicine and Science - Acquiring Professional Confidence and Visibility”, University of Maryland School of Medicine, Baltimore, MD, January 9, 2019.
57. Invited Speaker, “Typhoid fever, Antimicrobial Resistance, and Vaccines”, UMMC Medical Grand Rounds, Baltimore, MD, February 27, 2019.
58. Moderator, “Center for Vaccine Development and Global Health”, UMB Global Health Summit, Baltimore, MD, May 29, 2019.
59. Invited Speaker, “Using Human Challenge Models to Understand Disease Pathogenesis”, Infectious Disease Grand Rounds, Baltimore, MD, August 19, 2019.
60. Invited Speaker, Typhoid Fever, Antimicrobial Resistance, and Vaccines”, Mercy Hospital Grand Rounds, Baltimore, MD, September 18, 2019.
61. Invited Speaker, “Center for Vaccine Development and Global Health”, University of Maryland, Baltimore Board Meeting, Baltimore, MD, November 6, 2019.
62. Invited Speaker, “Overview: Global Health Research at the UMSOM”, University of Maryland Baltimore SOM Festival of Science, Baltimore, MD, November 21, 2019.
63. Invited Speaker, “Center for Vaccine Development & Global Health” University of Maryland, Baltimore School of Medicine Spotlight, Baltimore, MD, January 9, 2020.
64. Moderator, “Women Leaders in Vaccinology Panel Discussion” 2020 NFID Annual Conference on Vaccinology Research (ACVR) Webinar, Baltimore, MD, March 24, 2020.
65. Invited Speaker, “COVID-19: What Every AD Should Know About Medical Management of their Department” The LEAD1 Webinar, Baltimore, MD, March 26, 2020.
66. Invited Webinar Speaker, “Face-to-Face Townhall with Interim President Dr. Bruce Jarrell – COVID”, Baltimore, MD. April 9, 2020.
67. Dean’s Weekly Video Interview with Larry Roberts “Coronavirus Update”. Baltimore, MD. April 16, 2020.
68. Invited Webinar Speaker, “Face-to-Face Townhall with Interim President Dr. Bruce Jarrell – COVID”, Baltimore, MD. May 14, 2020.
69. Invited Webinar Speaker, “Support for Community Providers during the COVID-19 Pandemic”, “Center for Vaccine Development & Global Health” University of Maryland, Baltimore School of Medicine, Baltimore, MD, May 21, 2020.
70. Invited Webinar Speaker, “Coronavirus Vaccines” University of Maryland, Baltimore School of Medicine Grand Rounds, June 3, 2020.
71. Invited Webinar Speaker, “Coronavirus – Research & Public Health Efforts” University of Maryland, Board of Visitors’ Meeting, Baltimore, MD, June 9, 2020.
72. Invited Webinar Speaker, “Latest Development of COVID-19 Vaccines and Therapies”, SOM Town Hall, Baltimore, MD, June 18, 2020.
73. Invited Webinar Speaker, “Update on COVID Vaccine Development & Proposed Treatment Modalities”, General Medical Staff Meeting, SOM, Baltimore, MD June 30, 2020.
74. Dean’s Weekly Video Interview with Larry Roberts,” Vaccine Development/Leadership Update on COVID-19”. Baltimore, MD. July 9, 2020.
75. Invited Webinar Speaker, “USM Pandemic Preparedness Center”, USM COVID Research & Innovation Task Force. Baltimore, MD. July 23, 2020.
76. Invited Webinar speaker for “Town Hall to Constituents” hosted by U.S. Senator Chris Van Hollen (D-Md), August 3, 2020.
77. Invited Webinar Speaker “COVID-19”, virtual event at the Center Club, Baltimore, MD. August 28, 2020.
78. Invited Webinar Speaker, COVID-19 Innovations & Great Progress of the School of Medicine, University of Maryland School of Medicine Board of Visitors Coronavirus Research & Public Health Efforts Update Meeting, Baltimore, MD, September 11, 2020.
79. Invited webinar speaker, “COVID-19 Vaccines and Treatment”, University of MD Mini-Med School. November 3, 2020. Baltimore, MD.
80. Invited webinar speaker, “Current Status on the Development of SARS-CoV2 Vaccine”, Baltimore City Medical Society Furlong Lecture. November 18, 2020. Baltimore City, MD.
81. Virtual Face-to-Face with President Bruce Jarrell with an update on the COVID-19 Vaccines. December 10, 2020. Baltimore, Maryland.
82. UMMC COVID Update Town Hall. Presented on the Current Status in the Development of SARS-CoV-2 Vaccines. December 23, 2020.
83. Panelist and presenter at the Greater Baltimore Committee (GBC) Newsmakers Series. Presented on Vaccines on the way: Development and Distribution. January 19, 2021. Baltimore, Maryland.
84. Keynote speaker at Zoom Town Hall for the residents of Baltimore County presented by Delegate Dr. Jay Jalisi of MD General Assembly. Topic of the discussion was COVID-19 Prevention and Vaccination. February 6, 2021. Baltimore, MD.
85. Medical Grand Rounds, for the University of Maryland Institute for Clinical and Translational Research on COVID-19 Vaccines: Past, Present and Future. February 24, 2021.
86. Presented at the 2022 UMSOM WIMS Educational Speaker Series on her Leadership in Times of Crisis: The Example of a Pandemic. November 4, 2021.
87. Fireside chat participant, Baltimore Business Journal’s Leaders in Health Care 2021 Virtual event. December 10, 2021.
88. Presented at the Mercy Medical Center, Baltimore, MD, Grand Rounds on *COVID-19 Vaccines: The Evolving Policy Questions.* January 5, 2022.
89. Presented at the Johns Hopkins Intercession Course on the Science of People, Policy & Science related to COVID. January 11, 2022.
90. Virtual Face-to-Face with President Bruce Jarrell where she answered questions on COVID. January 13, 2022.
91. Co-Chair and Co-Host at the 2022 Baltimore Area Council Boy Scouts of America Health Services Awards banquet. Baltimore, MD. November 14, 2023.
92. Invited guest lecturer for the Virtual JHU Vaccine Policy Course “The Spotlight on Global Vaccine Policy: Lessons Learned from Salmonella typhi. March 8, 2023.
93. Invited speaker for the University of Maryland Baltimore MD-IHC Symposium on “Realizing Population Benefits Through Precision Vaccinology”. Baltimore, MD. May 31, 2023.
94. Invited speaker at the 2023 UMSOM OB/GYN Grand Rounds presenting on “Maternal Immunizations”. Baltimore, MD. June 2, 2023.

National

1. Faculty participant, “What’s new with the flu – cost-effectiveness of influenza vaccine,” CME Symposium at ICAAC, San Diego, CA, September 1998.
2. Vanderbilt University Infectious Diseases Grand Rounds “Preventing Influenza: Challenges and Controversies,” Nashville, TN, October 28, 1999.
3. Oregon Health Sciences University Medical Grand Rounds: “Influenza 2000,” Portland, OR, November 23, 1999.
4. Faculty participant, panel session: “Adult Immunization – Influenza Vaccine,” ACP/ASIM Annual Session, Philadelphia, PA, April 15, 2000.
5. Faculty participant, “Respiratory Viral Vaccines for Prevention of Otitis Media – Epidemiology of respiratory viral illnesses in children.” CME Symposium preceding 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, September 7, 2000.
6. Anchorage, AL CME series: Alaska Native Medical Center, Providence Medical Center. “The Brave New World of Influenza” and “Update on Adult Immunizations.” October 19-20, 2000.
7. University of South Carolina Medical Grand Rounds. “Influenza: New Insights into an Old Disease,” Charleston, SC, November 7, 2000.
8. Advisory Committee for Immunization Practices, CDC, “Review of inactivated influenza vaccine safety and efficacy/effectiveness,” Atlanta, GA, October 17, 2001.
9. Meet the Professor Session “Principles, Priorities and Practicalities of Immunizing Adolescents and Adults,” 39th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, October 27-28, 2001.
10. Meet the Expert Session “Prevention and Treatment of Influenza,” 41st Annual ICAAC, Chicago, IL, December 17, 2001.
11. Advisory Committee for Immunization Practices, CDC, “The economics of vaccinating children younger than 5 years with influenza vaccine,” Atlanta, GA, February 20, 2002.
12. Moderator and speaker, Meet the Professor session: “Adult Immunization,” ACP/ASIM Annual Session, Philadelphia, PA, April 11 and 12, 2002.
13. National Foundation for Infectious Diseases, “The epidemiology of influenza virus infection in children.” Washington, DC, November 1, 2002.
14. Plenary lecture, “Influenza vaccine for children,” National Immunization Conference, Chicago, IL, March 18, 2003.
15. Moderator and speaker, Meet the Professor session: “Immunization for adults: an ounce of prevention,” ACP Annual Session, San Diego, CA, April 4-5, 2003.
16. Advisory Committee for Immunization Practices, CDC, “Safety and efficacy of influenza vaccine in young children,” Atlanta, GA, October 17, 2003.
17. Faculty participant, “Increasing pediatric influenza immunization in infants and children,” Symposium sponsored by National Foundation for Infectious Diseases at AAP Annual Meeting, New Orleans, LA, November 2, 2003.
18. Moderator, Symposium, “Influenza: New Strains and New Approaches,” 44th Annual ICAAC, October 31, 2004, and speaker “The Fragile State of Influenza Prevention,” 44th Annual ICAAC, Washington, DC, October 31, 2004.
19. Plenary speaker, “Vaccine-preventable viral diseases: Past, present and future,” AORN/APIC/Kimberly-Clark Ninth Conference on Infectious Diseases, Atlanta, GA, December 8, 2004.
20. Invited Speaker, “Accelerating vaccine introduction in the developing world,” World Health Week, Vanderbilt University School of Medicine, Nashville, TN, March 28, 2006.
21. Advisory Committee for Immunization Practices, CDC, “One vs two doses of TIV in children: review of recent data,” Atlanta, GA, June 29, 2006.
22. Moderator, Plenary Session, “Pandemic Influenza,” 45th Annual Meeting of the Infectious Diseases Society of America, Toronto, CA, October 15, 2006.
23. Faculty speaker, NFID Vaccine Course, “Influenza Vaccination for Adults,” Atlanta, GA, November 3, 2006.
24. Faculty speaker, NFID Vaccine Course, “Influenza Vaccination Strategy,” Atlanta, GA, November 4, 2006.
25. Plenary speaker, “Pandemic Influenza,” Western Society for Clinical Investigation, Carmel, CA, February 1, 2007.
26. Invited speaker, “Preventing morbidity and mortality from vaccine-preventable diseases: A comprehensive approach,” Vanderbilt University School of Medicine, Nashville, TN, February 23, 2007.
27. Moderator, “Vaccine Effectiveness and Safety Issues,” CSTE Meeting on “Routine Vaccination against Influenza for Older Children (5-18 years) – Developing Plans to Address Evidence Gaps and Implementation Challenges,” Atlanta, GA, September 10, 2007.
28. Moderator, Plenary Session, “Pandemic Influenza: From 1918 to 2007,” 45th Annual Meeting of the IDSA, San Diego, CA, October 4, 2007.
29. Faculty, NFID Vaccine Course, “Influenza: An overview of available vaccines, schedules and future vaccination strategies,” Bethesda, MD, November 9, 2007.
30. Co-Chair, WHO Meeting, “Rotavirus Vaccines: Evaluating Clinical Trial Data and Guiding Future Research,” Atlanta, GA, November 27-29, 2007.
31. Meeting Co-Chair and Invited Speaker, “Influenza Control Policy: How Can Influenza Vaccines and Antivirals be Best Delivered in the U.S.?” IDSA Seasonal and Pandemic Influenza Conference, Washington, DC, May 18-20, 2008.
32. Meeting Co-Chair and Invited Speaker, “Vaccines: Update on Recommendations for Adults” and “US Recommendations on Influenza Vaccines for Children: Who, Why, and How?” 46th Annual Meeting of the IDSA, Washington, DC, October 2008.
33. Faculty, NFID Vaccine Course, “Influenza: An Overview,” and “Influenza,” Bethesda, MD, November 14-15, 2008.
34. Meeting Co-Chair, and Invited Speaker, “Changing Landscape of Vaccines,” IDSA Seasonal and Pandemic Influenza Conference, Washington, DC, February 2-3, 2009.
35. Panelist, “Vaccines: Filtering the Noise,” Meeting of the Association of Health Care Journalists, April 17, 2009, Seattle, WA.
36. Invited Speaker, “New Vaccine Strategies,” for the “What’s New in Seasonal Influenza Symposium,” 46th Annual Meeting of the IDSA, Philadelphia, PA, October 30, 2009.
37. Invited Speaker, “Vaccine Challenges in Pandemic Response,” 5th Decennial Internal Conference on Healthcare-Associated Infections, Atlanta, GA, March 22, 2010.
38. Invited Speaker, Plenary Session, “Technological Challenges in Global Health: Influenza Vaccine,” XXV Congress of the International Society for Advancement of Cytometry, Seattle, WA, May 10, 2010.
39. Presenter, “Update on influenza vaccines”, NFID Clinical Vaccinology Course, Bethesda, MD, November 10, 2010.
40. Visiting professor, “Rotavirus vaccines for low resource countries” and “Alternative schedules for HPV vaccines”, UT Southwestern School of Medicine, April 27, 2011.
41. Invited Speaker, “Rotavirus Vaccines: A Review of Vaccine Trial Results” Annual Conference on Vaccine Research, Baltimore, MD May 7, 2012.
42. Invited speaker, “The Promise and Challenge of a Maternal Immunization Approach to RSV Prevention in Low-resource Countries”. RSV Symposium, Santa Fe, New Mexico September 30, 2012.
43. Invited speaker, “Global Impact of Rotavirus Vaccines”, Johns Hopkins University School of Medicine Biennial Meeting, Baltimore, Md, June 8, 2013.
44. Invited speaker, “A glimpse into the future of influenza vaccines”. Infectious Diseases Society of America Annual Meeting, San Diego, CA, October 2, 2013.
45. Keynote speaker, “Success in Global Health: persistence, partnership, passion.” Clinical and Translational Research Annual Retreat, Vanderbilt University, Nashville, TN October 3, 2013.
46. Faculty, “Influenza vaccines: Giving the right dose at the right time.” National Foundation for Infectious Diseases Clinical Vaccinology Course. Seattle, WA, March 24, 2014.
47. Invited Speaker, “Vaccines for the Developing World: Japanese Encephalitis Vaccine”, Annual Conference on Vaccine Research, Bethesda, Md. April 29, 2014.
48. Invited Speaker, “Maternal immunization: an introduction to PATH’s work”. NIH symposium on including pregnant women in clinical trials. Bethesda, Md. September 29, 2014.
49. Invited Speaker, “Vaccines in low resource settings: What is on the horizon?” Infectious Diseases Society of America Annual Meeting, Philadelphia, PA, October 11, 2014.
50. Moderator, Keynote I: “Towards a universal influenza virus vaccine,” 19th Annual Conference on Vaccine Research, Baltimore, MD, April 17, 2016.
51. Invited Speaker, “Vaccines for the global community,” for the “Dr. Richard J. Duma Meet the Experts Breakfast Sessions,” 19th Annual Conference on Vaccine Research, Baltimore, MD, April 20, 2016.
52. Invited Speaker, “Vaccine research: A powerful tool to achieve health equity,” Plenary Session for Vanderbilt MPH 2016 Reunion and 20th Anniversary, Nashville, TN, October 21, 2016.
53. Invited Speaker, “Influenza vaccines: Giving the right dose at the right time,” National Foundation for Infectious Diseases Clinical Vaccinology Course, Philadelphia, PA, November 4, 2016.
54. Invited Speaker, “Rotavirus vaccine: A powerful tool to achieve health equity,” Seminar Series for the Yale School of Public Health, Department of Epidemiology of Microbial Diseases, New Haven, CT, January 19, 2017.
55. Moderator, “Development and approval pathways of vaccines for the prevention of emerging infectious diseases,” Annual Conference on Vaccine Research (ACVR), Bethesda, MD, April 24, 2017.
56. Invited Speaker, “Developing and deploying influenza vaccines: The pandemic-seasonal interplay,” Association of University Anesthesiologists (AUA), Washington, DC, May 4, 2017.
57. Invited panelist, “Hot Topics in Vaccinology.” ASM Microbe 2017, New Orleans, LA, June 4, 2017.
58. Session Chair, “New Influenza Vaccines”, 11th Vaccine Congress, San Diego, CA, September 18, 2017.
59. Session Chair, “New Vaccines – Old Diseases”, 11th Vaccine Congress, San Diego, CA, September 19, 2017.
60. Invited panelist, “Science-Policy Interphase Roundtable Session”, 11th Vaccine Congress, San Diego, CA, September 19, 2017.
61. B.H. Kean-Boxer Family Foundation Lecture in Global Health, “Vaccine Research: A Powerful Tool for Health Equity,” Medicine Grand Rounds, Weill Cornell Medicine New York Presbyterian Hospital, New York City, NY, October 11, 2017.
62. Invited Speaker, “Giving the Right Dose at the Right Time,” NFID Vaccine Course, Bethesda, MD, November 4, 2017.
63. William Kirby Lectureship, “Influenza Research: A Lesson in Humility,” University of Washington School of Medicine Division of Allergy & Infectious Diseases, Seattle, WA, December 6, 2017.
64. William Kirby Lectureship, “Vaccines, Antimicrobial Resistance, and Health Equity,” Medicine Grand Rounds, University of Washington School of Medicine, Seattle, WA, December 7, 2017.
65. Invited Speaker, “Interim VIDA results: Changes in overall and etiology-specific diarrhea incidence VIDA ISAC Meeting,” Jan. 20, 31, 2018, Seattle, Washington.
66. Invited Speaker, “Vaccines, Antimicrobial Resistance, and Health Equity,” Jefferson Vaccine Center Annual 2018 Symposium, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, March 13, 2018.
67. Moderator, “Using Vaccines to Combat Antimicrobial Resistance,” Annual Conference on Vaccinology Research, Bethesda, MD, April 23, 2018.
68. Invited Speaker, “Case Study: Typhoid Vaccines in Low-resource Settings,” Annual Conference on Vaccinology Research, Bethesda, MD, April 23, 2018.
69. Moderator, “Building Research Careers in Vaccinology”, Annual Conference on Vaccinology Research, Bethesda, MD, April 24, 2018.
70. Moderator, “Live Attenuated Influenza Vaccine (LAIV): What Have We Learned & Where Do We Go Next?”, Annual Conference on Vaccinology Research, Bethesda, MD, April 25, 2018.
71. Plenary Speaker, “Rotavirus Vaccines: Evidence to Action to Impact” University of Washington Seattle Children’s Hospital Science Day, Seattle, WA, May 24, 2018.
72. Moderator, “Maternal-infant Immunization: Clinical Implementation and Public Health Benefits”. ASM Annual Meeting. Atlanta, Ga June 11, 2018.
73. Invited speaker. “Influenza Vaccine Research in the International Setting: Trials, Tribulations and Lessons Learned.” NIAID Influenza Interest Group Seminar Series. Bethesda, MD August 3, 2018.
74. Discussion Leader, “Session IV. Discussion and Questions from Participants”, Workshop on the Epidemiology and Evolutionary Dynamics of Broadly Protective Influenza Vaccines, Bethesda, MD, September 20, 2018.
75. Plenary speaker, “Time 101: Optimizing Meetings”, Infectious Diseases Society of America Annual Meeting, San Francisco, CA, October 5, 2018.
76. Plenary speaker, “The Ghost of the Future: Universal Influenza Vaccine”, Infectious Diseases Society of America Annual Meeting, San Francisco, CA, October 6, 2018.
77. Invited speaker, “Decision-Making on Typhoid Vaccines at the Country Level: Evidence, Action and Sustainability”, American Society of Tropical Medicine & Hygiene, New Orleans, LA, October 29, 2018.
78. Invited speaker, “From Identifying a Vaccine to Scaling up: The Critical Role of Partners”, American Society of Tropical Medicine & Hygiene, New Orleans, LA, November 1, 2018.
79. Invited speaker, “Influenza Vaccines and Vaccination Strategies, “Fall 2018 Clinical Vaccinology Course (CVC), Bethesda, MD, November 10, 2018.
80. Invited speaker, “Influenza Vaccine Research in the International Setting: What Can We Learn?”, Harvard Infectious Disease Epidemiology Spring Seminar Series, Boston, MA, February 21, 2019.
81. Invited speaker, “Tdap vs Td Vaccine for Pregnant Women in Mali: Current Status and Future Plans”, Annual Meeting of the Vaccine and Treatment Evaluation Units (VTEUs), Rockville, MD, May 8, 2019.
82. Moderator, “Influenza Vaccines”, Infectious Disease Week 2019, Washington, DC, October 4, 2019.
83. Moderator, “Vaccines and Antimicrobial Resistance”, Infectious Disease Week 2019, Washington, DC, October 4, 2019.
84. Invited speaker, “Current Influenza Vaccines: Are We Ready for Different Vaccines for Different Populations?”, Infectious Disease Week 2019, Washington, DC, October 4, 2019.
85. Moderator, “Maternal Immunization: Progress and Challenges”, Infectious Disease Week 2019, Washington, DC, October 5, 2019.
86. Invited Speaker, “Influenza Vaccines and Vaccination Strategies”, NFID, Washington, DC, November 16, 2019.
87. Co-Chair, “Early Lessons with TCV Introduction: Decision-Making, Pre-Introduction and Implementation”, ASTMH, National Harbor, MD, November 22, 2019.
88. Invited Speaker, “Next Generation Influenza Vaccines”, Infectious Disease Conference, Seattle, WA, December 13, 2019.
89. Invited Speaker, “Typhoid Fever, Antimicrobial Resistance, and Vaccines”, Vanderbilt University Medicine Grand Rounds, Nashville, TN, February 27, 2020.
90. Invited speaker, “The Race for a Coronavirus Vaccine”, National Press Foundation, Washington DC, April 3, 2020.
91. Invited speaker, “COVID Vaccine Development: From Discovery to Impact”, National Academy of Medicine and The American Public Health Association, Washington DC, June 10, 2020.
92. Invited roundtable participant, “Vaccine Development for Novel Coronavirus Response”, ACVR hosted by NFID, Bethesda, MD, June 18, 2020.
93. Invited speaker, “Partnering to Discover, Develop, and Deliver Vaccines for Global Health”, ACVR hosted by NFID, Bethesda, MD, June 19,2020.
94. Invited speaker, “Coronavirus Vaccines”, ACIP, Atlanta Georgia, June 24, 2020.
95. Invited speaker, “COVID-19/Moderna/Pfizer Coronavirus Vaccine Updates”, WHO/SAGE, Washington DC, July 23, 2020.
96. Invited speaker, “COVID VE” at the Haiven/CDC Annual Meeting. August 17, 2020.
97. Invited speaker, “COVID-19 Vaccines”, IDSA ID Division Director’s Call. Arlington, VA. August 21, 2020.
98. Invited speaker, “COVID-19” at Virtual Grand Rounds at Morristown Medical Center Multidisciplinary. September 2, 2020.
99. Invited speaker, “Update on Vaccines for COVID-19”, ID Division Weekly Research Seminar for Emory Infectious Diseases. September 17, 2020. Atlanta, GA.
100. Invited panelist, “Communicating About Safety of Vaccines – A Focus on Pregnant Woman”, US Dept. of Health and Human Services (HHS) Vaccine Confidence Meeting. September 17, 2020. Rockville, MD.
101. Invited speaker, “Coronavirus Current Trials Landscape”, CDC/IDSA COVID-19 Clinician Call. September 26, 2020. Arlington, VA.
102. Panelist for discussion on COVID-19, IDSA-HIVMA-PIDS Congressional Staff Briefing. September 29, 2020. Arlington, VA.
103. Moderator on “Regulatory Integrity and the Assessment of Vaccine Safety and Efficacy”, JHU-University of Washington Symposium on Preserving the Scientific Integrity of Getting COVID-19 Vaccines for Clinical Trials to Public Allocation. October 6, 2020. Seattle, Washington.
104. Moderator for 3 discussions, “Vaccines: Beyond the Guidelines, Vaccines: Going Global and Moving Toward Broadly Reactive Influenza”, ID Week – IDSA Chasing the Sun Vaccines. October 21, 2020. Arlington, Va.
105. Keynote Speaker, “Updates on COVID Vaccines”, 1st University of Alabama- Birmingham COVID-19 Research Symposium. October 28, 2020. Birmingham, AL.
106. Invited speaker, “COVID-19 Current Vaccine Developments”, XVIIII Annual Research Matters Conference of the State of Academic Centers. November 5, 2020. Baltimore, MD.
107. Invited speaker, “Coronavirus Vaccines Updates”, ICAP Webinar- COVID-19 Vaccines Where We Stand. November 10, 2020. New York, NY.
108. Invited speaker, “Coronavirus Vaccines Current Status and Outlook”, FIA Expo Virtual Conference. November 12, 2020. Washington, DC.
109. Invited speaker, “Managing the Impact of a Pandemic”, National Foundation for Infectious Diseases Clinical Vaccinology Clinic. November 15, 2020. Bethesda, MD.
110. Invited speaker, “Influenza Vaccines to Help #FightFlu”, National Foundation for Infectious Diseases Clinical Vaccinology Clinic. November 17, 2020. Bethesda, MD.
111. Moderator, “Evidence to Action: Accelerating Introduction of Typhoid Conjugate Vaccines in Africa”, American Society of Tropical Medicine and Hygiene. November 18, 2020. Arlington, VA.
112. Invited Keynote Speaker, “Vaccine – COVID Current Status in the Development of a SARS-CoV-2 Vaccine”, Minnesota Department of Health Emergency Infections Conference. November 20, 2020. Minnesota.
113. Invited speaker. ISV Virtual Congress-North America Influenza Vaccine Symposium on The Role of Human Challenge Models in Evaluation of Broadly Reactive Influenza Vaccines. December 2, 2020.
114. Invited Speaker, IDSA Press Briefing r – COVID-19 Vaccine Progress Report. December 3, 2020.
115. Invited speaker, Keystone eSymposia Virtual Event on COVID-19 One Year Later.: Update on Vaccine Trials. February 8, 2021.
116. Invited lecturer, Stanford MED232: Lecture & Fireside Chat on Vaccines as Tools of Health Equity. February 10, 2021.
117. Testified as an expert witness before the House Committee on Science, Space, and Technology – The Science of COVID-19 and Encouraging Vaccine Uptake. February 19, 2021.
118. Panelist, Chancellor’s Lecture Series – Vanderbilt in the Vanguard: The Decades-long Journey to a Coronavirus Vaccine. March 23, 2021.
119. Panelist, CR Forum Industry Roundtable on COVID-19. April 1, 2021.
120. Moderator, at the ACVR/NFID session, Opening Keynote: Mary Lou Clements-Mann Memorial Lecture in Vaccine Sciences and a panel on Women Leaders in Vaccinology. April 26, 2021.
121. Invited speaker, University of Alabama Birmingham’s Sexually Transmitted Infections Clinical Trials Group 2021 Programmatic meeting – Conducting Sexually Transmitted Infection Research in Women of Reproductive Age. An Interdisciplinary Discussion of Experience, Strategies & Policies to Advance the Field. Her lecture was on COVID-19 Vaccine Studies in Pregnant and Lactating Women: A Timeline. April 28, 2021.
122. Invited Speaker, at the National Academies of Scient Engineering and Medicine (NASEM) Committee for Vaccine R & D for Advancing Pandemic & Seasonal Influenza Preparedness Learning from the COVID-19 Vaccine Experience. Presentation was on Influenza Vaccines in LMICS: Manufacturing & Feasibility Considerations. April 28, 2021.
123. Invited speaker, Genetic Vaccine Development for Infectious Diseases Summit, “Clinical Studies with Pregnant Women with COVID-19 Vaccines”. May 18, 2021.
124. Invited speaker, 2021 Penn Medicine HIV/COVID-19 Grand Rounds, “COVID-19 and Vaccine Research: Designing and Implementing Clinical Trials During a Pandemic”. June 3, 2021.
125. Invited speaker, AARP National Tele-Town Hall Conversation on “Coronavirus Vaccines & Staying Safe. June 17, 2021.
126. Session Co-Chair for Johns Hopkins University & University of Washington symposium on COVID-19 Immunization in Children & Adolescents as part of COVID-19 and Kids: Impacts, Uncertainties & the Role of Vaccines. June 30, 2021.
127. Invited speaker, National Academies of Sciences, Engineering and Medicine (NASEM) Workshop on The Utility, Feasibility, Security, and Ethics of Verifiable COVID-19 Credentials for International Travel. “Public Health Impact of Requiring Vaccination or Testing for Travel.” August 3, 2021.
128. Moderated a panel discussion on *Global Health Security – Combating Infectious Diseases* at the World Trade center Institute in Baltimore International Delegation. August 17, 2021.
129. Moderated at IDWeek 2021 for the sessions “Science of COVID Vaccines” and “COVID Vaccines Real Life Experience.” September 30, 2021.
130. Moderated at IDWeek 2021 on “Potpourri: the Vaccines I did not hear about during the Pandemic.” October 1, 2021.
131. Moderated at IDWeek 2021 for a session on “COVID-19 Vaccines in Special Populations.” October 1, 2021.
132. Co-Author IDWeek 2021 symposium session “Late Breaker Abstracts: COVID-19 Vaccines, Epidemilogy, and Clinical,” presentation title “Asymptomatic Infection and Duration of Viral Shedding in Symptomatic Breakthrough Infections in Phase 3 Study of AZD1222 (CAdOx1nCoV019). October 1, 2021.
133. Moderated at IDWeek 2021 presentation on “COVID-19 Vaccine Challenges.” October 1, 2021.
134. Session chair and presenter at the HIV Vaccine Trials/CoVPN Conference on “Boosting- variants vs ancestral as part of the plenary session titled “CoVPN- Boosters & Special Populations.” October 18, 2021.
135. Panelist for the NFID webinar “Coadministration of Influenza, COVID-19, and other Routine Vaccines”. October 19, 2021.
136. Keynote speaker at Emory University on “COVID Vaccine Boosters: Why, What, & When”, “Overview of Boosters for COVID.” October 29, 2021.
137. Invited speaker “TyVAC Update 2021: Typhoid conjugate vaccine in endemic settings” at Gavi TCV Subteam meeting. October 26, 2021.
138. Keynote address at the Baltimore Vaccines Research & Development event on “COVID-19 Vaccines: Past, Present, & Future. November 1, 2021.
139. Invited speaker at 2021 NFID Clinical Vaccinology Virtual Course: “Influenza Vaccines to Help #fightflu” session. “Influenza Vaccination Recommendations Across the Lifespan.” November 16, 2021.
140. Invited speaker at the 2021 NFID Clinical Vaccinology Virtual Course: “Rapid Response to a Pandemic” session. “COVID-19 Vaccines: From Scientific Discovery to Monitoring Safety.” November 16, 2021.
141. Invited speaker at the UW COVID Symposium XXIV Harborview Medical Center Seattle Area Chest Grand Rounds on COVID-19 Vaccine Development and Global Health. January 27, 2022.
142. Invited speaker at the VA/MD Health Care System COVID-19 Grand Rounds: COVID-19 Vaccines: The Evolving Policy Questions. February 4, 2022.
143. Invited speaker at the American Thoracic Society (ATS) webinar series on COVID-19 Vaccines: The Evolving Policy Questions. February 24, 2022.
144. Invited speaker at the Columbia University PCRI Symposium-Rigor and Research Integrity in a Public Health Crisis on “Designing and Implementing Vaccine Trials During a Pandemic.” March 11, 2022.
145. Moderated at the NFID Annual Conference on Vaccinology Research (ACVR) for a panel discussion on “Women Leaders in Vaccinology”. April 12, 2022.
146. Keynote speaker at the Nashville Surgical Society on COVID-19 Vaccines: How will the story end?” Nashville, TN April 12, 2022.
147. Invited speaker at the HVTN/CoVPN Fall Group Meeting Session on COVID-19 Our Experience with Vaccines and Therapeutics. “New Developments in the COVID-19 Vaccine Field.” Seattle, WA May 6, 2022.
148. Keynote speaker at the 2022 VIDD/Fred Hutch Faculty Retreat on “A Career in Vaccinology: From Academics to an NGO and Back Again.” Seattle, WA June 23, 2022.
149. Invited presenter and panelist at the Michigan Center for Respiratory Virus Research and Response and the Dept. of Epidemiology at the University of Michigan School of Public Health event on “Antimicrobial resistance, health equity and vaccines: The example of typhoid” Ann Arbor, MI, September 8, 2022.
150. Guest on Infectious IDeas, a podcast series presented by the National Foundation for Infectious Diseases (NFID) [https://www.nfid.org/about-nfid/infectious-ideas-podcast/](https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.nfid.org%2Fabout-nfid%2Finfectious-ideas-podcast%2F&data=05%7C01%7CBethanne.Smith%40som.umaryland.edu%7Ca3a726f5f3f84319aa1008daa8456ec7%7C717009a620de461a88940312a395cac9%7C0%7C0%7C638007313409115442%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=lYa72d9tFsmzJJyPuUuD%2BcyYLg44nPZbKM7b3E0eGKc%3D&reserved=0). October 5, 2022.
151. Invited moderator, “Late Breaking Vaccine Studies” at ID Week. October 20, 2022, Washington DC.
152. Invited moderator, NIAID Workshop on Mucosal Vaccines for SARS-CoV-2 as part of the Clinical Trial Designs and Endpoints, virtual. November 8, 2022.
153. Invited panelist and presenter at the 2022 NFID Online Clinical Vaccinology Course (CVC) on “Influenza Vaccination Recommendations Across the Lifespan”. November 16, 2022.
154. Invited panelist for the Vaccines Against Shigella and ETEC (VASE) workshop on “The Full Value of Vaccines Against Enteric Pathogens: How to Translate Evidence into Policy*”* at the 2022 VASE conference. Washington DC, November 29, 2022.
155. Invited keynote speaker for “The Urgency of Vaccine Development for Enteric Pathogens: Lessons Learned from Salmonella typhi*”* at the 2022 Vaccines Against Shigella and ETEC (VASE) conference. Washington DC. November 30, 2022.
156. Invited Headliner speaker for the FHI VIP dinner on “Vaccine Challenges and Response.” April 5, 2023. Washington DC.
157. Invited panelist, 2023 Women in Medicine Breakfast for Edwards Vaccinology and Infectious Diseases Symposium at Vanderbilt University. April 18, 2023. Nashville, TN.
158. Invited presenter on “Influenza”, 2023 Edwards Vaccinology and Infectious Diseases Symposium at Vanderbilt University. April 18, 2023. Nashville, TN.
159. Invited presenter on “IDCRC: State of the Network”, 2023 IDCRC Annual Meeting. April 25, 2023. Bethesda, MD.
160. Invited moderator for the 2023 NFID ACVR “Women Leaders in Vaccinology” Virtual Panel. June 6, 2023.
161. Invited moderator for the virtual 2023 NFID ACVR “Symposium 4 – Human Challenge Models in Vaccine Development” panel. June 7, 2023.
162. Invited presenter on “A Career in Science and Global Health: Persistence, Partnership, Passion, and a Sense of Humor” as part of the IDCRC Mentoring and Career Development virtual event. October 10, 2023.
163. Invited presenter on “The Impact of Bacterial Vaccines on Antimicrobial Resistance” at the Infectious Disease Week Session “Hit me with Your Best Shot” in Boston, Massachusetts, October 11, 2023.
164. Invited presenter on the “IDSA Foundation 2022-2023 US Respiratory Season Overview” as part of the “Respiratory Vaccines: Separating Fact from Fiction” webinar series on October 19, 2023.
165. Invited presenter on “Generating data on typhoid conjugate vaccines: Clinical Studies to Country Introduction” at the ASTMH Annual Meeting in Chicago, Illinois on October 21, 2023.
166. Invited presenter at the virtual Thomas Jefferson Health Department of Obstetrics & Gynecology RSV Vaccine in Pregnancy Grand Rounds on “Maternal Immunization: Influenza, pertussis, COVID-19 and …RSV” on October 26, 2023.
167. Invited speaker at the CHIVM Studies: Current Status & Future Directions for Innovation Workshop as part of the CHIVIM Networks and Standardization session. “Challenge Studies: Capacity and Results.” Rockville, MD. November 14, 2023.
168. Invited presenter at the 2023 NFID Clinical Vaccinology Course. Virtual presentation on “Influenza Vaccination Recommendations Across the Lifespan*”.* November 15, 2023.
169. Invited speaker at the virtual VaxCo Science Seminar Series. Presented on “Can Influenza challenge models accelerate vaccine development?” January 31, 2024.
170. Invited presenter at the virtual Stanford MED232. Presented on “Vaccines as tools for health equity.” January 31, 2024.
171. Invited speaker at the Johns Hopkins Bloomberg School of Public Health’s Vaccine Policy Issues course. Presented on “Typhoid Vaccine Policy.” Feb. 7, 2024.

**International**

1. Invited Speaker. “Clinical aspects of influenza and immunization against influenza in pregnant women.” XIII European Meetings on Influenza and Its Prevention, Nice, France, September 23, 1999.
2. Plenary speaker. “Influenza or RSV?” and “Is it time for universal immunization with influenza vaccine?” First Symposium on Respiratory Diseases, VigiGrip, University of San Paolo, San Paolo, Brazil, March 9 and 10, 2001.
3. Invited speaker: “Should healthy children receive influenza vaccine?” Annual Beijing Symposium on Influenza, Beijing, China, September 12, 2001.
4. Invited speaker. “Should healthy children receive influenza vaccine?” Third World Congress of Pediatric Infectious Diseases, Santiago, Chile, November 20, 2002.
5. Invited Speaker, “Influenza vaccine for children and pregnant women”, Asian-Pacific Committee on Influenza, Manila, Philippines, April 25, 2004.
6. Invited Speaker, “Burden of influenza illness in children”, Annual Philippine Pediatric Congress, Manila, Philippines, April 27, 2004.
7. Lecturer, “Influenza: Vaccines and Vaccination Strategies.” Advanced Course on Vaccinology, Annecy, France, May 24, 2004.
8. Invited speaker “Influenza vaccination programs for children and adults.” Mexico City, Mexico, October 4, 2004.
9. Lecturer, “Influenza: Evaluating Influenza Vaccine Strategies for Low Resource Countries.” Advanced Course on Vaccinology, Annecy, France, May 24, 2005.
10. Invited speaker, “Influenza in Pregnancy”, University of Toronto OB-Gyn Grand Rounds, Toronto, CA, October 14, 2005.
11. Invited speaker, “Influenza vaccination programs: who, why and how?” University of Toronto Infectious Disease Forum, Toronto, CA, October 14, 2005.
12. Invited presenter, “Building the evidence base for rotavirus vaccine introduction,” WHO Strategic Advisory Group of Experts on Immunization (SAGE) Meeting, Geneva, Switzerland, November 10, 2005.
13. Lecturer, “Influenza: Virus, Vaccines and Vaccination Strategies.” Advanced Course on Vaccinology, Annecy, France, May 23, 2006.
14. Invited Speaker, “Building the evidence base for rotavirus vaccine introduction”, 5th Asian Rotavirus Surveillance Workshop, Pattaya, Thailand, July 18, 2006.
15. Invited Speaker, “Future directions for rotavirus vaccines: Focus on developing countries,” 5th Asian Rotavirus Surveillance Workshop, Pattaya, Thailand, July 19, 2006.
16. Lecturer, “Seasonal and Pandemic Influenza.” Advanced Course on Vaccinology, Annecy, France, May 22, 2007.
17. Invited Speaker, “Rotavirus Vaccine as a Case Study,” Global Vaccine Safety Data Net Meeting, Annecy, France, September 13, 2007.
18. Invited Presenter, “Vaccines”, WHO Strategic Advisory Group of Experts on Immunization (SAGE) Meeting, Geneva, April 8, 2008.
19. Lecturer, “Influenza: Virus, Vaccines and Vaccination Strategies.” Advanced Course on Vaccinology, Annecy, France, May 27, 2008.
20. Invited Speaker, “Potential Impact of Rotavirus Vaccines in the Developing World,” WHO Global Vaccine Research Forum, Paris, France, June 29 - July 2, 2008.
21. Invited Presenter, WHO Strategic Advisory Group of Experts on Immunization (SAGE) Meeting, “Rotavirus Vaccines in the Developing World: Evidence for Impact,” Geneva, Switzerland, November 5, 2008.
22. Invited Presenter, “Update on Rotavirus Vaccines for the Developing World”, WHO Strategic Advisory Group of Experts on Immunization (SAGE) Meeting, Geneva, April 6-8, 2009.
23. Lecturer, “Influenza: Virus, Vaccines and Vaccination Strategies.” Advanced Course on Vaccinology, Annecy, France, May 26, 2009.
24. Invited Presenter, 27th Annual Meeting of the European Society for Paediatric Infectious Diseases, “RIX4414 is Protective Against Severe RVGE Caused by Diverse Rotavirus Serotypes During the First Year of Life in African Infants,” June 9-13, 2009, Brussels, Belgium.
25. Invited Presenter, 5th International Conference on Vaccines for Enteric Diseases, “A Global Perspective of Rotavirus Vaccines for Children in Developing Countries,” September 9, 2009, Malaga, Spain.
26. Invited Speaker, “Regional Perspectives on the Burden of Influenza, Including School-Aged Children,” 6th World Congress of the World Society for Pediatric Infectious Diseases, Buenos Aires, Argentina, November 18, 2009.
27. Moderator for session on “Seasonal and Pandemic Influenza Vaccines Research and Development,” and Invited Speaker “Rotavirus vaccine clinical trials’ results” WHO Global Vaccine Research Forum, Bamako, Mali, December 7, 2009.
28. Invited Presenter, “An Update on Rotavirus Vaccines and the WHO Recommendation,” 5th Annual Global Immunization Meeting, Geneva, Switzerland, February 2, 2010.
29. Invited Speaker, “Influenza Vaccines in the Developing World,” Annual Meeting of the Pediatric Academic Societies, Vancouver, Canada, May 3, 2010.
30. Lecturer, “Influenza: Seasonal and Pandemic Vaccines and Vaccination Strategies.” Advanced Course on Vaccinology, Annecy, France, May 28, 2010.
31. Invited Speaker and Moderator, “Update on Rotavirus Vaccines,” 9th International Rotavirus Symposium, Johannesburg, South Africa, August 2, 2010.
32. Moderator “Epidemiology, Disease Burden and Health Economics,” Options for the Control of Influenza VII Conference in Hong Kong, China, September 3, 2010.
33. Invited Speaker “Rotavirus vaccines for low resource countries”, “Epidemiology and Disease Burden of Respiratory Viruses” and “The 2009 Influenza Pandemic: Lessons Learned,” First Advanced Vaccinology Course in India, Vellore, India, September 22-24, 2010.
34. Plenary speaker, The Joseph E. Smadel Lecture, “The Global Impact of Vaccines,” Infectious Diseases Society of America (IDSA) 48th Annual Meeting, Vancouver, Canada, October 23, 2010.
35. Lecturer, “Influenza: Virus, Vaccines and Vaccination Strategies.” Advanced Course on Vaccinology, Annecy, France, May 24, 2011.
36. Invited speaker, Maternal immunization: results of a landscape analysis”, Bill and Melinda Gates Foundation Maternal immunization meeting, London, UK, June 1, 2011.
37. Invited speaker, “Improving clinical trial design & capacity and harnessing clinical trials to identify then validate correlates of risk or protection. Case study: Rotavirus vaccines”. Second global Health Research Congress, Seattle, WA, June 21, 2011.
38. ICAAC Meet-the-Experts, Progress and Promise in Perinatal Vaccination: Maternal and Neonatal, ICAAC Annual Meeting, Chicago, IL September 18, 2011.
39. Invited speaker, Global Threats to Child Health Symposium: “Diarrheal Disease and Impact of Rotavirus Vaccines”, ICAAC Annual Meeting, Chicago, IL, September 20, 2011.
40. Invited speaker, “Live attenuated influenza vaccines for low resource countries”, Influenza Technical Advisory Meeting on Developing country Influenza Vaccine Manufacturers, Belgrade, Serbia March 28, 2012.
41. Lecturer, “Influenza biology, new vaccines and vaccination strategies for different age groups” Advanced Course on Vaccinology, Annecy, France, May 21, 2012.
42. Invited speaker, “Hot topics in Vaccines: Malaria Vaccines”, ICAAC Annual meeting, San Francisco, CA. September 10, 2012.
43. Lecturer, “Influenza vaccines for children, adults and elderly”. Advanced Course on Vaccinology, Annecy, France, May 13, 2013.
44. Invited presenter, “Japanese Encephalitis Vaccine Global Usage and Safety Profile.” WHO Global Advisory Committee on Vaccine Safety, Geneva, Switzerland, June 13, 2013.
45. Invited speaker, “Efficacy of commercially available rotavirus vaccines in low resource countries.” International symposium on rotavirus vaccines for India. Delhi, India, May 14, 2013.
46. Speaker and moderator “Developing next generation rotavirus vaccines”, Global Vaccine and Immunization Research Forum, Bethesda, Md. March 4, 2014.
47. Plenary speaker, “Influenza vaccines: Novel vaccines and vaccination strategies.” International Congress on Infectious Diseases, Cape Town, South Africa, April 5, 2014.
48. Invited speaker, “Clinical evaluation of live attenuated seasonal influenza vaccine in Bangladesh and Senegal” Second WHO Integrated Meeting on development and clinical trials of Influenza vaccines that induce broadly protective and long-lasting immune responses, Geneva, Switzerland, May 6, 2014.
49. Lecturer, “Influenza: Virus, Vaccines and Vaccination Strategies”. Advanced Course on Vaccinology, Annecy, France, May 20, 2014.
50. Invited speaker, “The case for influenza vaccine: A debate.” ADVAC Alumni meeting, Philadelphia, PA, October 9, 2014.
51. Invited speaker. “Clinical evaluation of seasonal, live attenuated influenza vaccines in Bangladesh and Senegal”. WHO meeting to assess live-attenuated influenza vaccines, Geneva, Switzerland, December 16, 2014.
52. Invited speaker, “Influenza vaccines for children”. WHO meeting to assess live-attenuated influenza vaccines, Geneva, Switzerland, December 16, 2014.
53. Plenary speaker, “Global burden of rotavirus disease and the potential role of immunization to control rotavirus.” World Congress on Public Health – Rotavirus: priorities for control Kolkata, India, February 13, 2015.
54. Invited speaker, “Influenza in the developing world: prospects for disease control”. International Symposium on Respiratory Virus Infections, Vancouver, Canada, March 6, 2015.
55. Invited speaker, “Influenza vaccine for pregnant women: How far have we come in the past decade?” WHO Maternal Immunization Technical Consultation, Geneva, Switzerland, March 25, 2015.
56. Lecturer, “Influenza: Virus, Vaccines and Vaccination Strategies.” Advanced Course on Vaccinology, Annecy, France, May 19, 2015.
57. Plenary speaker, “Introduction & lessons learned from GVIRF 2014.” Global Vaccine and Immunization Research Forum (GVIRF), Johannesburg, South Africa, March 15, 2016.
58. Session chair, “Evolving Global Vaccine Markets,” Global Vaccine and Immunization Research Forum (GVIRF), Johannesburg, South Africa, March 15, 2016.
59. Invited Speaker, “Immunisation and Pregnancy: Past Present and Perspectives.” SOMAGO 5th Congress of the Malian Society of Gynecologists and Obstetricians, Bamako, Mali, March 30, 2016.
60. Lecturer, “Influenza biology, new vaccines and vaccination strategies for different age groups.” Advanced Course on Vaccinology, Annecy, France, May 31, 2016.
61. Invited Speaker, “Sustainability and Financing for GAVI and GAVI-graduating countries.” 10th African Rotavirus Symposium, Bamako, Mali, June 2, 2016.
62. Co-moderator, Session VI, “Sustainability and Control of Diarrhea in African Children: Looking to the Future,” 10th African Rotavirus Symposium, Bamako, Mali, June 2, 2016.
63. Invited Speaker, “Preferred product characteristics (PPC) of next-generation influenza vaccines.” 8th WHO Meeting on Development of Influenza Vaccines that Induce Broadly Protective and Long-lasting Immune Responses, Chicago, IL, August 23, 2016.
64. Panelist, “Discussion of PPC an integrated influenza vaccine development in low resource settings.” 8th WHO Meeting on Development of Influenza Vaccines that Induce Broadly Protective and Long-lasting Immune Responses, Chicago, IL, August 23, 2016.
65. Moderator, “Industry panel discussion.” 8th WHO Meeting on Development of Influenza Vaccines that Induce Broadly Protective and Long-lasting Immune Responses, Chicago, IL, August 24, 2016.
66. Moderator, “Public Health Featured Symposia: Influenza Vaccines.” ISIRV Options IX for the Control of Influenza, August 26, 2016.
67. Moderator, “The road ahead: Issue landscape, opportunities, and challenges for advocacy.” ROTA Council Strategy Meeting, Melbourne, Australia, September 6, 2016.
68. Moderator, “Session III: Poster Session”, Twelfth International Rotavirus Symposium, Melbourne Australia, September 7, 2016.
69. Participant, Roundtable Discussion, “Session IV: Women Leaders in the Scientific Advancement of Rotavirus – Tribute to Ruth Bishop”, Twelfth International Rotavirus Symposium, Melbourne Australia, September 7, 2016.
70. Invited Speaker, “The Expanding Rotavirus Vaccine Landscape: Lessons learns from influenza vaccines,” Session VII: Policy Session, Twelfth International Rotavirus Symposium, Melbourne Australia, September 8, 2016.
71. Session Chair, “Session C: Emerging Viruses and the Global Virus Network”, 18th Annual International Meeting of the Institute of Human Virology, Baltimore, MD, September 19, 2016.
72. Session Chair, “Session 4: Progress under Objective 3: R&D for Influenza Vaccines”, Third WHO Consultation on Global Action Plan for Influenza Vaccines (GAP III), Geneva, Switzerland, November 16, 2016.
73. Invited speaker, “New broad-spectrum influenza vaccines”, Third WHO Consultation on Global Action Plan for Influenza Vaccines (GAP III), Geneva, Switzerland, November 16, 2016.
74. Session Chair, “Session 1: The Public Health Value of Vaccines: Socio-economic Aspects”, Estimating the Full Public Health Value of Vaccines, Annecy, France, December 6, 2016.
75. Invited Speaker, “Unique considerations of public health value of vaccines given to pregnant women”, Estimating the Full Public Health Value of Vaccines, Annecy, France, December 6, 2016.
76. Session Chair, “Global Trends in Typhoid Fever: Determinants and Implications for Policy”, 10th International Conference on Typhoid and Other Invasive Salmonelloses, Kampala, Uganda, April 6, 2017.
77. Invited Speaker, “Introduction of Typhoid Conjugate Vaccines: Opportunities and Challenges”, 10th International Conference on Typhoid and Other Invasive Salmonelloses, Kampala, Uganda, April 6, 2017.
78. Lecturer, “Influenza biology, new vaccines and vaccination strategies for different age groups.” Advanced Course on Vaccinology, Annecy, France, May 16, 2017.
79. Small group facilitator, “Decision-making for the evaluation and impact assessment of new vaccines introduced in selected countries: safety and effectiveness.” Advanced Course on Vaccinology, Annecy, France, May 16, 2017.
80. Invited Speaker, “Global disease burden of influenza and RSV”, XIX International Symposium on Respiratory Viral Infections, Berlin, Germany, June 24, 2017.
81. Session Chair, “Session III: Vaccination Programs for Preventions of Respiratory Infections,” XIX International Symposium on Respiratory Viral Infections, Berlin, Germany, June 24, 2017.
82. Roundtable discussion, “Current Vaccines and Future Vaccine Development,” XIX International Symposium on Respiratory Viral Infections, Berlin, Germany, June 24, 2017.
83. United Nations Medical Expert on Typhoid Webinar. “Typhoid, AMR and new Vaccines”. May 9, 2018.
84. Invited Speaker. “Human Controlled Infection Models for Influenza: Lessons Learned from Cholera and Typhoid.” Bill and Melinda Gates Foundation Convening on Human Challenge Models, London, UK, May 31, 2018.
85. Moderator, “Session VI: Current rotavirus vaccines in routine immunization”, 13th International Rotavirus 2018 Symposium, Minisk, Belarus, August 30, 2018.
86. Invited Speaker. “Influenza in Low Resource Countries: Virus, Vaccines and Vaccination.” African Advanced Vaccinology Course 2018, Johannesburg, South Africa, September 10, 2018.
87. Session Chair. “Influenza”, 12th Vaccine Congress, Budapest, Hungary, September 17, 2018.
88. Session Chair. “Typhoid Conjugate Vaccine”, 12 Vaccine Congress, Budapest, Hungary, September 18, 2018.
89. Invited keynote speaker, “From Global Action to Local Impact: Typhoid Vaccines “, 11th International Conference on Typhoid & Other Invasive Salmonelloses, Hanoi, Vietnam, March 26, 2019.
90. Session Chair, STRATAA/TyVAC Symposium, 11th International Conference on Typhoid & Other Invasive Salmonelloses, Hanoi, Vietnam, March 27, 2019.
91. Debate, “Does a vaccine have to protect against a VPD that kills to matter to politicians and parents?”, 20th Advanced Course of Vaccinology, Annecy, France, May 20, 2019.
92. Invited Speaker, “Influenza biology, new vaccines and vaccination strategies for different age groups”, 20th Advanced Course of Vaccinology, Annecy, France, May 21, 2019.
93. Facilitator, “Decision-making for the evaluation and impact assessment of new vaccines introduced in selected countries: safety and effectiveness”, 20th Advanced Course of Vaccinology, Annecy, France, May 21, 2019.
94. Invited Speaker, “Typhoid Conjugate Vaccines”, 7th Annual Asian Vaccine Conference, Yangon, Myanmar, September 15, 2019.
95. Invited presenter, “COVID-19 and mRNA Vaccine Research”, WHO SAGE WG, July 23, 2020.
96. Invited panelist, “COVID-19 Correlation of Protections”, COVAX. November 19, 2020. Seattle, Washington.
97. Chaired two GVIRF workshop sessions on New and Improved Vaccines on the Horizon. February 24, 2021.
98. Invited speaker, 2021 WHO consultation on enteric disease burden on Strategic Typhoid Alliance Across Africa & Asia (STRATAA). April 21, 2021.
99. Invited speaker, 2021 BactiVac Network Online conference on the Results from the TyVAC study. April 27, 2021.
100. Invited speaker, GlaxoSmithKline Vaccine Virtual Days Symposium “COVID-19 Vaccines: Using New Technologies.” April 28, 2021.
101. Facilitator, Interactive Virtual Advanced Course of Vaccinology 2021 (ADVAC) for a discussion on Decision-making for the Evaluation and Impact Assessment of New Vaccines Introduced in Selected Countries: Safety and Effectiveness. May 18, 2021.
102. Invited speaker, Interactive Virtual Advanced Course of Vaccinology 2021 (ADVAC). “Influenza Biology, New Vaccines & Vaccination Strategies for Different Age Groups”. May 20, 2021.
103. Invited panelist, WHO Stakeholder Consultation on Enteric Fever Disease Burden for session on “Translating Burden Data to Policy”. July 2, 2021.
104. Invited speaker, International Aids Society (IAS) 2021 – COVID Vaccines & Antibodies: Where are we now, and where are we headed? Presentation “COVID Vaccines: State of the Art.” July 21, 2021.
105. Invited Plenary speaker, 12th International Conference on Typhoid & Other Invasive Salmonelloses conference, Plenary Session – *Typhoid Conjugate Vaccines in High-Burden Countries: where are we and where do we need to go?* December 6, 2021.
106. Invited moderator, 12th International Conference on Typhoid & Other Invasive Salmonelloses conference, *Typhoid conjugate vaccine safety and efficacy: Results from clinical studies in Africa and Asia Symposium.* December 6, 2021.
107. Invited moderator, 12th International Conference on Typhoid & Other Invasive Salmonelloses conference, *Typhoid intestinal perforations in Africa: What do we know? What can we learn?* December 8, 2021.
108. Invited speaker at the Global Vaccinology class at GWU where she talked about vaccine safety and development. February 4, 2022.
109. Invited speaker at the Malawi-Liverpool Wellcome Trust on COVID-19 Vaccine: A Global Perspective. February 24, 2022.
110. Invited speaker at the Merck Vaccinology Conference, Veyrier-du-Lac, France, on “Assessing Vaccines in Emerging Situations: SARS-CoV-2. March 31, 2022.
111. Invited speaker at the Merck Vaccinology Conference, Veyrier-du-Lac, France, on “What will be Game Changers for the Vaccine World in the Future?”. April 1, 2022.
112. Invited speaker at the SAGE Typhoid Update Session 5 on TCV Evidence Emerging from TyVAC and Other Studies on “Post-Licensure Data on TCV”. April 6, 2022.
113. Invited speaker at the World Vaccine Congress, Washington DC, as part of the COVID-19 Vaccines and the Elderly session on “COVID-19 Vaccines and Older Adults: Vaccine Development and Policy”. April 20, 2022.
114. Panelist at the World Vaccine Congress, Washington DC – “What Challenges must be addressed to accelerate adoption and funding for new vaccines?” April 20, 2022.
115. Facilitator at the 22nd Annual ADVAC Conference, Geneva, Switzerland, on the session “The Evaluation and Impact Assessment of New Malaria Vaccines Introduced in Selected Countries: Safety & Effectiveness”. May 16, 2022.
116. Invited speaker at the 22nd Annual ADVAC Conference, Geneva, Switzerland, on “Influenza Biology, New Vaccines, and Vaccination Strategies for Different Age Groups”. May 18, 2022.
117. Keynote speaker at JPIMR-BactiVac webinar “Vaccinations as a Strategy to Combat Antimicrobial Resistance”. June 17, 2022.
118. Invited speaker and panelist, 2022 International Conference on Emerging Infectious Diseases (ICEID) on “Beyond COVID-19: The Promise of mRNA Vaccines” in session “The Promise of mRNA Vaccines for Infectious Diseases Beyond COVID-19.” August 9, 2022.
119. Guest lecturer, Galmi Hospital Grand Rounds, Galmi, Niger on “Typhoid Fever, Antimicrobial Resistance, and Vaccines” September 13, 2022.
120. Invited virtual speaker at 25th year Anniversary Showcase of the National Centre for Immunisation Research and Surveillance (NCIRS) of Sidney, Australia, on “COVID-19: A Tale of Two Pandemics”. September 14, 2022.
121. Invited speaker at the Options for Control of Influenza XI Conference, Belfast, Ireland on “Can Human Challenge Models Accelerate Respiratory Virus Vaccine Development? September 29, 2022.
122. Panelist, at the ADVAC webinar on “Industry and Vaccine Development – Dispelling Some Myths” Washington DC October 20, 2022.
123. Invited presenter at the 2022 Virtual International Workshop on COVID-19 Vaccines. Presentation on “Newly Approved and Rolled Out Vaccines”. December 14, 2022.
124. Invited speaker at the Institut Pasteur Symposium. Presented on COVID-19 Vaccines. February 28, 2023. Paris, France.
125. Invited panelist for the Decision-making for the “Evaluation and Impact Assessment of New Vaccines Introduced in Selected Countries: Safety & Effectiveness”. ADVAC, May 15, 2023. Annecy, France.
126. Invited speaker on “Influenza Biology, New Vaccines and Vaccination Strategies for Different Age Groups as Part of Selecting Appropriate Vaccination Strategies”. ADVAC. May 17, 2023. Annecy, France.
127. Invited presenter for the 2023 Alumni Refresher Vaccinology Course (ARVAC) virtual lecture “Update on Typhoid Vaccines”. June 7 & 14, 2023.
128. Invited speaker, Surgery Grand Rounds, Galmi Hospital, Galmi, Niger. “Typhoid conjugate vaccines”. July 21, 2023
129. Keynote speaker, National Scientific Day on surgical complications of typhoid fever and advocacy for the introduction of typhoid conjugate vaccine, “The role of typhoid conjugate vaccines in preventing typhoid fever and its complications”. Niamey, Niger, July 22, 2023.
130. Keynote speaker at the 2023 Aotearoa New Zealand Immunisation Conference. Virtual presentation on “What’s new with respiratory viruses? Influenza, COVID-19 and …RSV” at the plenary session on *New Vaccines from Development to Immunsation*. New Zealand, November 15, 2023.
131. Invited speaker at the 13th International Conference on Typhoid and other Invasive Salmonelloses “Confronting the Challenge of Date Inequity.” Kigali, Rwanda. December 5, 2023.
132. Invited moderator at the TyVAC CaT International Conference for the session “Maximizing learnings from clinical trials and public sector use – the full public health value of typhoid conjugate vaccines.” Kigali, Rwanda. December 5, 2023.
133. Invited panelist at the 13th International Conference on Typhoid and other Invasive Salmonelloses, “Bridging the Gap: Environmental and Sero-surveillance for Estimating Typhoid Burden and Supporting Vaccine Introductions”. Kigali, Rwanda. December 5, 2023.
134. Invited speaker, “Data inequity and the need for low cost surveillance tools: The example of typhoid fever” at the Gates Foundation Environmental Surveillance: Progress and Path Forward Convening.” Kigali, Rwanda, December 8, 2023.